<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SPIROS DEVELOPMENT CORPORATION II, INC.
- - - - --------------------------------------------------------------------------------
(NAME OF ISSUER)
CALLABLE COMMON STOCK, PAR VALUE $0.001 PER SHARE
- - - - --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
848 936 100
- - - - --------------------------------------------------------------------------------
(CUSIP NUMBER)
CAM L. GARNER
CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER
DURA PHARMACEUTICALS, INC.
7475 LUSK BOULEVARD
SAN DIEGO, CALIFORNIA 92121
(619) 457-2553
- - - - --------------------------------------------------------------------------------
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON
AUTHORIZED TO RECEIVE NOTICES AND COMMUNICATIONS)
DECEMBER 22, 1997
- - - - --------------------------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
(Continued on following pages)
<PAGE>
- - - - --------------------------------------------------------------------------------
CUSIP NO. 848 936 100 13D Page 2 of 7 Pages
- - - - --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
DURA PHARMACEUTICALS, INC.
IRS Employer Identification No.: 95-3645543
- - - - --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / / (b) / /
- - - - --------------------------------------------------------------------------------
3 SEC USE ONLY
- - - - --------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
- - - - --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) OR 2(e) / /
- - - - --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
- - - - --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER 6,325,000(1)
OF ---------------------------------------------------------------
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY ---------------------------------------------------------------
REPORTING 9 SOLE DISPOSITIVE POWER
PERSON 6,325,000(1)
WITH ---------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- - - - --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,325,000(1)
- - - - --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES
CERTAIN SHARES*
/ /
- - - - --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
100%
- - - - --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- - - - --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
(1) Represents the total number of shares of Callable Common Stock of
Spiros Development Corporation II, Inc. ("SDCII Common Stock") currently
outstanding. Such shares are currently traded as units, each unit consisting of
one Share of SDCII Common Stock and one warrant to purchase one-fourth of one
share of Common Stock of Dura Pharmaceuticals, Inc. ("Dura"). However, pursuant
to Dura's option, upon exercise Dura shall purchase all of the outstanding
shares of SDCII Common Stock outstanding at the time of exercise of Dura's
option. As a result, the above reported number of shares of SDCII Common Stock
is subject to change, based upon the total number of SDCII Common Stock
outstanding at the time of exercise.
PAGE 2 OF 7 PAGES
<PAGE>
Item 1. SECURITY AND ISSUER
The class of securities to which this Statement relates is the Callable
Common Stock (the "SDCII Common Stock") of Spiros Development Corporation
II, Inc., a Delaware corporation, ("SDCII") whose principal executive offices
are at 7475 Lusk Blvd., San Diego, California 92121.
ITEM 2. IDENTITY AND BACKGROUND
Dura Pharmaceuticals, Inc., a Delaware corporation ("Dura") is the party
filing this Statement. Dura's principal executive offices are located at 7475
Lusk Boulevard, San Diego, CA 92121, and its principal business is the
development and marketing of respiratory pharmaceutical products and the
development of a pulmonary drug delivery system.
During the last five years, Dura has not been convicted in a criminal
proceeding and has not been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction which resulted in a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities, subject to, Federal or State securities laws or finding
any violation with respect to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
If Dura exercises its option to purchase all of the SDCII Common Stock
(the "Purchase Option" or "Transaction"), the purchase price calculated on a
per share basis (the "Purchase Option Exercise Price") will be as follows:
IF THE SPIROS CORP. II COMMON STOCK IS ACQUIRED PURCHASE OPTION
PURSUANT TO THE PURCHASE OPTION: EXERCISE PRICE
- - - - -------------------------------- --------------
Before January 1, 2000 . . . . . . . . . . . . . . . . . . . . $24.01
On or after January 1, 2000 and on or before March 31, 2000. . 25.26
On or after April 1, 2000 and on or before June 30, 2000 . . . 26.57
On or after July 1, 2000 and on or before September 30, 2000 . 27.96
On or after October 1, 2000 and on or before December 31, 2000 29.41
On or after January 1, 2001 and on or before March 31, 2001. . 31.10
On or after April 1, 2001 and on or before June 30, 2001 . . . 32.88
On or after July 1, 2001 and on or before September 30, 2001 . 34.77
On or after October 1, 2001 and on or before December 31, 2001 36.76
On or after January 1, 2002 and on or before March 31, 2002. . 38.87
On or after April 1, 2002 and on or before June 30, 2002 . . . 41.10
On or after July 1, 2002 and on or before September 30, 2002 . 43.46
On or after October 1, 2002 and on or before December 31, 2002 45.95
The Purchase Option Exercise Price may be paid in cash or shares of Dura
Common Stock, or any combination of the foregoing, at Dura's sole discretion.
Any such shares of Dura Common Stock will be valued based upon the average of
the closing price for Dura Common Stock on the Nasdaq National Market for ten
trading days immediately preceding the date of the Exercise Notice. Management
currently expects that any cash payments will be derived from Dura's existing
cash and cash equivalents.
PAGE 3 OF 7 PAGES
<PAGE>
ITEM 4. PURPOSE OF TRANSACTION
The purpose of the Transaction is to acquire the rights to all products and
product candidates developed or under development by SDCII pursuant to a certain
Development Agreement dated December 22, 1997 between Dura and SDCII.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) Dura beneficially owns an interest in 100% of the SDCII Common Stock
outstanding at the time of Dura's exercise of the Purchase Option.
Currently there are 6,325,000 shares of SDCII Common Stock
outstanding, all of which are currently trading as a component of
units (the "Units"), each Unit consisting of one share of SDCII
Common Stock and one warrant (the "Warrants") to purchase
one-fourth of one share of Dura Common Stock.
(b) Upon the closing of the Transaction, Dura shall have sole power to
vote and dispose of all of the outstanding shares of SDCII Common
Stock at the time of exercise. Currently there are 6,325,000 shares
of SDCII Common Stock outstanding, all of which are trading as Units.
(c) Not applicable.
(d) No other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale
of, the securities.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER
Pursuant to SDCII's Amended and Restated Certificate of Incorporation (the
"SDCII Certificate"), Dura, as the holder of all of the issued and outstanding
special shares, par value $1.00 per share, of Spiros Corp. II (the "Special
Shares"), has the right to purchase all, but not less than all, of the SDCII
Common Stock outstanding at the time the Purchase Option is exercised. The
Purchase Option will be exercisable by notice (the "Exercise Notice") given at
any time beginning on December 22, 1997, the closing of the initial public U.S.
and international offerings of the Units (the "Offerings") and ending on the
earlier of (i) December 31, 2002 or (ii) the 90th day after the date SDCII
provides Dura (as such holder) with quarterly financial statements of SDCII
showing cash or cash equivalents of less than $5 million (the "Financial
Notice"), although, following the receipt of the Financial Notice, Dura may
elect to extend such period by providing additional funding for the continued
development of certain products (the "Spiros Products") (but in no event beyond
December 31, 2002). If the Purchase Option is exercised, the purchase price
calculated on a per share basis (the "Purchase Option Exercise Price") will be
as follows:
PAGE 4 OF 7 PAGES
<PAGE>
IF THE SPIROS CORP. II COMMON STOCK IS ACQUIRED PURCHASE OPTION
PURSUANT TO THE PURCHASE OPTION: EXERCISE PRICE
- - - - -------------------------------- --------------
Before January 1, 2000 . . . . . . . . . . . . . . . . . . . . $24.01
On or after January 1, 2000 and on or before March 31, 2000. . 25.26
On or after April 1, 2000 and on or before June 30, 2000 . . . 26.57
On or after July 1, 2000 and on or before September 30, 2000 . 27.96
On or after October 1, 2000 and on or before December 31, 2000 29.41
On or after January 1, 2001 and on or before March 31, 2001. . 31.10
On or after April 1, 2001 and on or before June 30, 2001 . . . 32.88
On or after July 1, 2001 and on or before September 30, 2001 . 34.77
On or after October 1, 2001 and on or before December 31, 2001 36.76
On or after January 1, 2002 and on or before March 31, 2002. . 38.87
On or after April 1, 2002 and on or before June 30, 2002 . . . 41.10
On or after July 1, 2002 and on or before September 30, 2002 . 43.46
On or after October 1, 2002 and on or before December 31, 2002 45.95
The Purchase Option Exercise Price may be paid in cash or shares of Dura
Common Stock, or any combination of the foregoing, at Dura's sole discretion.
Any such shares of Dura Common Stock will be valued based upon the average of
the closing price for Dura Common Stock on the Nasdaq National Market for ten
trading days immediately preceding the date of the Exercise Notice.
Dura owns all of the issued and outstanding Special Shares, which grants
Dura the Purchase Option and confers certain voting and other rights, including
the right to elect two of the five directors of SDCII. Under SDCII's Amended
and Restated Certificate of Incorporation, SDCII will be prohibited, until the
expiration of the Purchase Option, from taking or permitting certain actions
inconsistent with Dura's rights under the Purchase Option. For example, until
the expiration of the Purchase Option, SDCII will not be able to, among other
things, without the consent of Dura, pay any dividends, issue additional shares
of capital stock, have outstanding borrowings in excess of an aggregate of $1
million, or merge, liquidate or sell all or substantially all of its assets or
alter the Purchase Option.
On December 22, 1995 the Offerings closed pursuant to certain underwriting
agreements dated December 16, 1997 by and between SDCII, Dura and the U.S. and
International Underwriters (as hereinafter defined). The Offerings resulted in
an issuance and sale of 6,325,000 Units (including the Units sold to the
international and U.S. underwriters of the Offerings (the "Underwriters") as a
result of the full exercise of their respective over allotment options) and net
proceeds for SDCII of $94,156,000. The Units are listed on the Nasdaq National
Market. The SDCII Common Stock and the Warrants comprising the Units will trade
only as units through December 31, 1999 or such earlier date as the Purchase
Option is exercised or expires unexercised (the "Separation Date"). It is
expected that the SDCII Common Stock and the Warrants will be eligible for
quotation after the Separation Date on the Nasdaq National Market. There can be
no assurance that there will be an active trading market for the Units or that,
after the Separation Date, there will be active trading markets for the SDCII
Common Stock or the Warrants. The Dura Common Stock is quoted on the Nasdaq
National Market.
PAGE 5 OF 7 PAGES
<PAGE>
In accordance with the terms of the SDCII Certificate, the holders of
the SDCII Common Stock will be obligated to sell such shares to Dura upon
exercise of the Purchase Option. These stockholders have no investment
discretion in connection with Dura's purchase of such outstanding shares of
SDCII Common Stock, and title to the SDCII Common Stock automatically vests
in Dura on the closing of the Transaction.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
99.1 Amended and Restated Certificate of Incorporation of SDCII as filed
with the Secretary of State of Delaware on December 18, 1997.
99.2 U.S. Purchase Agreement dated December 16, 1997 by and between Dura,
SDCII and the U.S. Underwriter.
99.3 International Purchase Agreement dated December 16, 1997 by and
between Dura, SDCII and the international Underwriters.
PAGE 6 OF 7 PAGES
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
December 31, 1997 DURA PHARMACEUTICALS, INC.
By: /s/ Mitchell R. Woodbury
-----------------------------------------
Title: Senior Vice President
ATTENTION: Intentional misstatements or omissions of fact constitute Federal
criminal violations (SEE 18 U.S.C. 1001).13
PAGE 7 OF 7 PAGES
<PAGE>
EXHIBIT 99.(a)
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
SPIROS DEVELOPMENT CORPORATION II, INC.
Spiros Development Corporation II, Inc., a corporation organized and
existing under the laws of the State of Delaware (the "Corporation"), hereby
certifies as follows:
1. The name of the Corporation is Spiros Development Corporation II, Inc.
The Corporation's original Certificate of Incorporation was filed with the
Secretary of State of the State of Delaware on September 23, 1997 under the name
of SDC II, Inc., and was amended pursuant to a Certificate of Amendment of
Certificate of Incorporation filed with the Secretary of State of the State of
Delaware on October 8, 1997.
2. Pursuant to Sections 242 and 245 of the General Corporation Law of the
State of Delaware, this Amended and Restated Certificate of Incorporation was
adopted by the Corporation's Board of Directors and its sole stockholder, the
holder of one hundred percent (100%) of the Corporation's capital stock, in
accordance with Section 228 thereof. The Amended and Restated Certificate of
Incorporation restates, integrates and amends the provisions of the Certificate
of Incorporation of this Corporation.
3. The text of the Corporation's Certificate of Incorporation as
heretofore amended is hereby restated and further amended to read in its
entirety as follows:
ARTICLE I
NAME
The name of the Corporation is Spiros Development Corporation II, Inc.
ARTICLE II
REGISTERED OFFICE AND REGISTERED AGENT
The address of the Corporation's registered office in the State of Delaware
is 30 Old Rudnick Lane, City of Dover, County of Kent 19901. The name of its
registered agent at such address is CorpAmerica, Inc.
<PAGE>
ARTICLE III
CORPORATE PURPOSE
The purpose of the Corporation is to engage in any lawful act or activity
for which corporations may now or hereafter be organized under the General
Corporation Law of Delaware.
ARTICLE IV
CAPITAL STOCK
Section 4.1. AUTHORIZED STOCK. The Corporation is authorized to issue
two classes of stock, one of which shall be known as Callable Common Stock and
the other of which shall be known as Special Common Stock. The total number of
shares of all classes of stock the Corporation shall have authority to issue is
7,501,000. The total number of shares of Callable Common Stock which the
Corporation is authorized to issue is 7,500,000. The par value of each share of
Callable Common Stock shall be $.001. The total number of shares of Special
Common Stock which the Corporation is authorized to issue is 1,000. The par
value of each share of Special Common Stock shall be $1.00. The authorized and
outstanding shares of the Corporation's capital stock as of the date of this
Amended and Restated Certificate of Incorporation are hereby renamed Special
Common Stock.
SECTION 4.2. DIVIDENDS. Subject to Section 4.4(c) hereof, the holders of
Callable Common Stock are entitled to receive dividends when, as and if declared
by the Board of Directors of the Corporation (the "Board") out of funds legally
available therefore. No dividends are payable on or with respect to the Special
Common Stock and, other than as set forth in Section 4.3, the holder of Special
Common Stock is not entitled to participate in any way in the profits or assets
of the Corporation.
SECTION 4.3. LIQUIDATION. In the event of the liquidation, dissolution
or winding-up of the Corporation, the holders of Callable Common Stock have
priority over the holder of Special Common Stock with respect to a return of
capital.
SECTION 4.4. VOTING RIGHTS OF STOCKHOLDERS.
(a) Each holder of Callable Common Stock shall have one vote, either
in person or by proxy, for each share standing in his, her or its name on all
matters submitted to a vote of the stockholders of the Corporation. The holder
of Special Common Stock shall be entitled to vote only as required by law or as
set forth in this Section 4.4. In such instances, the holder of Special Common
Stock shall have one vote for each share standing in his, her or its name.
-2-
<PAGE>
(b) In any election of directors of the Corporation, the holder of
Special Common Stock, voting as a separate class, shall be entitled to elect two
directors (each a "Special Common Stock Director"). This right of the holder of
Special Common Stock shall continue until the earliest of (i) the exercise of
the Purchase Option (as defined in Article V), (ii) the Purchase Option
Expiration Date (as defined in Article V) or (iii) the date of termination of
the Purchase Option pursuant to Section 5.10 hereof, at which time such right
shall terminate.
(c) The Corporation shall not, without the affirmative vote of the
holder of the then issued and outstanding shares of Special Common Stock, voting
separately as a class, authorize or permit: (i) the allotment or issue of shares
of capital stock of the Corporation or the creation of any right to such an
allotment or issue; (ii) the reduction of the Corporation's authorized capital
stock; (ii) the alteration of or any change to the rights, powers, preferences
and restrictions of the Special Common Stock; (iii) outstanding borrowings of an
aggregate of more than $1 million at any one time; (iv) the sale or other
disposition of or the creation of any lien or liens on the whole or a material
part of the Corporation's business or assets; (v) the declaration or payment of
dividends or the making of any other distributions to the Corporation's
stockholders; (vi) the merger, consolidation or reorganization of the
Corporation with or into any other corporation; (vii) the sale, liquidation or
other disposition of all or substantially all of the assets of the Corporation;
(viii) the alteration or amendment of Articles IV or VII of this Amended and
Restated Certificate of Incorporation; and (ix) the adoption, amendment or
repeal of the Bylaws of the Corporation. The affirmative vote of a majority of
the issued and outstanding shares of Special Common Stock required by this
Section 4.4(c) shall continue until the earliest of (i) the exercise of the
Purchase Option; (ii) the Purchase Option Expiration Date or (iii) the date of
termination of the Purchase Option pursuant to Section 5.10 hereof, at which
time such requirement shall terminate.
(d) No holder of Special Common Stock may transfer or sell less than
all of the shares of Special Common Stock held by such holder. In the event of
any sale, assignment, delegation or transfer of the Special Common Stock, the
holder thereof shall provide written notice to the record holders of shares of
Callable Common Stock and to the Corporation of any such assignment, delegation,
transfer or sale not later than thirty (30) days after such assignment,
delegation, transfer or sale setting forth the identity and address of the
assignee and summarizing the terms of the assignment, delegation, transfer or
sale.
SECTION 4.5. REDEMPTION OF SPECIAL COMMON STOCK.
(a) The Corporation may, from time to time on and after the earliest
of (i) the exercise of the Purchase Option, (ii) the Purchase Option Expiration
Date or (iii) the date of termination of the Purchase Option pursuant to Section
5.10 hereof, redeem all of the outstanding shares of Special Common Stock by
paying in cash $1.00 per share on each redeemed share (the "Redemption Price").
At least 15 days before the date of redemption, a written redemption notice (the
"Redemption Notice") shall be given to the holder of Special
-3-
<PAGE>
Common Stock by first-class mail, postage prepaid, at the holder's address as
shown on the Corporation's records, stating that: (i) all the shares of
Special Common Stock are to be redeemed; (ii) the date fixed for redemption
(the "Redemption Date"); (iii) the Redemption Price; and (iv) the place of
payment of the Redemption Price.
(b) On or before the Redemption Date, the holder of shares of Special
Common Stock to be redeemed shall surrender the certificates representing these
shares to the Corporation at the place designated for payment in the redemption
notice and shall then be entitled to receive payment of the Redemption Price.
(c) If the Redemption Notice is given in the manner provided in this
Article IV, and if on the Redemption Date the Redemption Price is available for
payment, whether or not the certificates covering these shares are surrendered,
all rights with respect to the redeemable Special Common Stock shall terminate,
except the right of the holder thereof to receive the Redemption Price without
interest on the surrender of the certificates.
ARTICLE V
STOCK PURCHASE OPTION
Section 5.1. TERMS OF OPTION.
(a) The holder of the Special Common Stock has the right to purchase
all, but not less than all, of the issued and outstanding shares of Callable
Common Stock of the Corporation at the time such right is exercised on the terms
and conditions set forth herein (the "Purchase Option").
(b) Subject to Section 5.13 hereof, the Purchase Option may be
exercised at any time beginning on the closing date of the underwritten offering
(the "Offering") of units (the "Units"), each Unit consisting of one share of
the Corporation's Callable Common Stock and a warrant to purchase one-fourth of
one share of the common stock of Dura Pharmaceuticals, Inc. ("Dura"), and ending
on the earliest of (i) December 31, 2002, (ii) the 90th day after the date the
Corporation delivers quarterly financial statements of the Corporation to the
holder of the Special Common Stock showing cash or cash equivalents of less than
$5 million (the "Financial Notice"), and (iii) the date of termination by the
Corporation of the Technology License Agreement among the Corporation, Dura,
Spiros Development Corporation and Dura Delivery Systems, Inc. pursuant to
Section 8.4 thereof, the Development Agreement between the Corporation and Dura
pursuant to Section 10.4 thereof or the Manufacturing and Marketing Agreement
between the Corporation and Dura pursuant to Section 9.4 thereof, each such
agreement being dated on or about December 22, 1997 (such date of expiration
being the "Purchase Option Expiration Date"); PROVIDED, that the delivery of
Financial Notice will be deemed not to have occurred with respect to any one
-4-
<PAGE>
or more quarterly financial statements delivered if within 15 days of
receipt, the Corporation receives a written commitment from the holder of the
Special Common Stock, in form and substance reasonably satisfactory to a
majority of the Board members elected by the holders of the Callable Common
Stock, to make a cash contribution in an amount considered sufficient by the
Board, and consistent with the budget and workplans then in effect, to allow
the Corporation to continue research and development under the Development
Agreement between the Corporation and Dura executed on the date of the
closing of the Offering, as may be amended from time to time (the
"Development Agreement"), for at least three months subsequent to such
quarterly financial statements, and in such case the holder of the Special
Common Stock funds such cash contribution within fifteen (15) days after such
written commitment is received by the Corporation.
(c) If the Purchase Option Expiration Date is not a Business Day (as
defined below), then the Purchase Option Expiration Date shall be 11:59 p.m.,
San Diego time, on the next succeeding Business Day. "Business Day" shall mean
any day, other than a Saturday, Sunday or any other day on which banking
institutions in San Diego, California are authorized or required by law,
regulation or executive order to be closed.
SECTION 5.2. PURCHASE OPTION EXERCISE PRICE. Upon exercise of the
Purchase Option, the holder of the Special Common Stock shall make a payment for
each outstanding share of Callable Common Stock (the "Purchase Option Exercise
Price") in accordance with the following schedule:
<TABLE>
<CAPTION>
PURCHASE
OPTION
IF THE PURCHASE OPTION IS EXERCISED EXERCISE PRICE
- - - - ----------------------------------- ------------
<S> <C>
Before January 1, 2000......................................... $24.01
On or after January 1, 2000 and before March 31, 2000.......... $25.26
On or after April 1, 2000 and before June 30, 2000............. $26.57
On or after July 1, 2000 and before September 30, 2000......... $27.96
On or after October 1, 2000 and before December 31, 2000....... $29.41
On or after January 1, 2001 before March 31, 2001.............. $31.10
On or after April 1, 2001 and before June 30, 2001............. $32.88
On or after July 1, 2001 and before December 31, 2001.......... $34.77
On or after October 1, 2001 and before December 31, 2001....... $36.76
On or after January 1, 2002 and before March 31, 2002.......... $38.87
On or after April 1, 2002 and before June 30, 2002............. $41.10
On or after July 1, 2002 and before September 30, 2002......... $43.46
On or after October 1, 2002 and before December 31, 2002....... $45.95
</TABLE>
-5-
<PAGE>
SECTION 5.3. FORM OF PAYMENT.
(a) If the holder of the Special Common Stock exercises the Purchase
Option, subject to Section 5.6 hereof, the Purchase Option Exercise Price may be
paid in cash, in shares of Dura common stock, or the Common Equity Securities
(as defined below) of the holder of the Special Common Stock, if other than Dura
(provided that such Common Equity Securities must be listed on a national
securities exchange or listed on the Nasdaq National Market), or in any
combination thereof at the sole discretion of the holder of the Special Common
Stock. The number of shares of Common Equity Securities, if any, to be
delivered in payment of all or a portion of the Purchase Option Exercise Price
shall be determined by dividing the portion of the Purchase Option Exercise
Price to be paid in shares of Common Equity Securities by the average of the
closing prices of such Common Equity Securities on the principal national
securities exchange on which such Common Equity Securities are then traded or,
if not traded on any national securities exchange, the average of the closing
prices of such Common Equity Securities on the Nasdaq National Market (in each
case the "Closing Price") for the ten (10) trading days immediately preceding
the date the holder of the Special Common Stock gives written notice of its
exercise of the Purchase Option as provided in this Article. No fractional
shares of Common Equity Securities shall be issued in payment of all or a
portion of the Purchase Option Exercise Price. Instead of any fractional shares
of Common Equity Securities that would otherwise be issuable in payment of all
or a portion of the Option Exercise Price, the holder of the Special Common
Stock shall pay a cash adjustment in respect of such fractional interest in an
amount equal to that fractional interest multiplied by the average of the
Closing Price on each of the ten (10) trading days immediately preceding the
exercise of the Purchase Option.
(b) "Common Equity Securities" shall mean, with respect to any
corporation (the "Acquiror"), common stock having the right under ordinary
circumstances to elect a majority of directors of the Acquiror, and that is
registered under the Securities Act and (i) listed on the principal national
securities exchange on which such common stock of the Acquiror is then listed or
(ii) if not listed on national securities exchange, listed on the Nasdaq
National Market if such stock is traded thereon or, if such stock is neither
listed as provided in either (i) or (ii), qualified for inclusion on the Nasdaq
over-the-counter system.
SECTION 5.4. MANNER OF EXERCISE.
(a) The holder of the Special Common Stock shall exercise the
Purchase Option by delivery of a Purchase Exercise Notice (as defined in clause
(c) of this Section 5.4) to the Corporation and to each holder of record of
Callable Common Stock on the Record Date (as defined below). The Purchase
Exercise Notice sent pursuant to this Section 5.4 shall be sent via first class
mail.
-6-
<PAGE>
(b) "Record Date" shall mean the record date fixed by the Purchase
Exercise Notice which shall be a date no earlier than 10 days after, and no
later than 20 days after, the date of such notice.
(c) The "Purchase Exercise Notice" shall be a written notice signed
by the holder of the Special Common Stock given in accordance with the
provisions of this Article V and stating that such party intends to exercise the
Purchase Option and setting forth: (i) the Purchase Option Exercise Price as
determined in accordance with Section 5.2 hereof; (ii) the portion, if any, of
the Purchase Option Exercise Price to be paid in cash, (iii) the portion, if
any, of the Purchase Option Exercise Price to be paid in shares of Common Equity
Securities; (v) the Record Date; (vi) the Purchase Option Closing Date (as
defined in clause (d) of this Section 5.4); and (vii) the place at which the
holders of the shares of Callable Common Stock may obtain payment of the
Purchase Option Exercise Price for their shares of Callable Common Stock and any
instructions for obtaining such payment; PROVIDED, HOWEVER, that at any time
prior to the Purchase Option Closing Date, the holder of the Special Common
Stock may determine to make payment of a greater amount of the Purchase Option
Exercise Price in cash than was set forth in the Purchase Exercise Notice. The
exercise of the Purchase Option is irrevocable upon delivery of the Purchase
Exercise Notice, and such action shall not require another notice to be given in
accordance with this Section 5.4. If the holder of the Special Common Stock
elects to exercise the Purchase Option by delivering solely shares of Common
Equity Securities, such exercise may occur by means of a merger of either a
subsidiary of the holder of the Special Common Stock with and into the
Corporation or the Corporation with and into a subsidiary of the holder of the
Special Common Stock, pursuant to which Callable Common Stock shall be cancelled
in exchange for the shares of Common Equity Securities.
(d) The "Purchase Option Closing Date" shall be a date, not less than
20 days nor more than 40 days, after the date of the Purchase Option Exercise
Notice on which all of the issued and outstanding shares of Callable Common
Stock will be purchased; PROVIDED, HOWEVER, that the Purchase Option Closing
Date will be such later date as provided by (i) the last sentence of Section 5.6
hereof in the event that the conditions described therein are satisfied or (ii)
Section 5.12 hereof in the event that the conditions described therein are
satisfied.
SECTION 5.5. CLOSING. On or before the Purchase Option Closing Date, the
holder of the Special Common Stock shall deposit the full amount of the Purchase
Option Exercise Price for all of the issued and outstanding shares of Callable
Common Stock with a bank, transfer agent or similar entity (the "Payment Agent")
designated by the holder of the Special Common Stock to pay, on the holder's
behalf, the Purchase Option Exercise Price. Cash, if any, and shares of Common
Equity Securities, if any, deposited with the Payment Agent shall be delivered
in trust for the benefit of the holders of record of the Callable Common Stock
on the Record Date. The holder of the Special Common Stock shall provide the
Payment Agent with irrevocable instructions to pay, on or within 5 days after
the Purchase
-7-
<PAGE>
Option Closing Date, the Purchase Option Exercise Price for the Callable
Common Stock to such record holders upon surrender of their certificates
representing shares of Callable Common Stock. Payment for shares of Callable
Common Stock shall be mailed to each such record holder at the address set
forth in the Corporation's records or at the address provided by each such
holder or, if no address is set forth in the Corporation's records for any
such holder or provided by such holder, to such holder at the address of the
Corporation, but only upon receipt from such holder of certificates
evidencing shares of Callable Common Stock. Any cash or shares of Common
Equity Securities deposited with the Payment Agent pursuant to this Section
5.5 remaining unclaimed for two years following the Purchase Option Closing
Date shall be returned to the holder of the Special Common Stock at its
request. At the request of the holder of the Special Common Stock, the
Corporation shall provide, or shall cause its transfer agent to provide, to
the holder of the Special Common Stock or to the Payment Agent, free of
charge, a complete list of the record holders of the shares of Callable
Common Stock, including the number of shares of Callable Common Stock held of
record and the address of each record holder.
SECTION 5.6. REGISTRATION OF COMMON EQUITY SECURITIES. If the holder of
the Special Common Stock fails by the Purchase Option Closing Date set forth in
the Purchase Option Exercise Notice, with respect to any shares of Common Equity
Securities to be delivered as payment of the Purchase Option Exercise Price on
such date, to have (i) a registration statement declared effective under the
Securities Act or (ii) such shares of Common Equity Securities to be issued in
connection therewith (A) listed on the principal national securities exchange on
which the Common Equity Securities are then listed or (B) if the Common Equity
Securities are not then listed on a national securities exchange, listed on the
Nasdaq National Market if the Common Equity Securities are traded thereon, then
in either of such cases the holder of the Special Common Stock shall be
obligated to make such payment in cash on the Purchase Option Closing Date.
Notwithstanding any other provision herein to the contrary, the holder of the
Special Common Stock shall not be in breach or violation of this Article V for
any failure to timely pay any amount due and payable to the record holders of
Callable Common Stock hereunder in shares of the Common Equity Securities if
such failure to timely pay such amount arises from a delay in satisfying any of
the provisions of this Section 5.6, so long as the holder of the Special Common
Stock shall continue to diligently seek the satisfaction thereof; PROVIDED,
HOWEVER, that such delay may not exceed sixty (60) days from the original due
date of such payment (such original due date being not less than 20 days, nor
more than 40 days, after the date of the Purchase Option Exercise Notice).
SECTION 5.7. TRANSFER OF TITLE. Transfer of title to the holder of the
Special Common Stock of all of the issued and outstanding shares of Callable
Common Stock shall be deemed to occur automatically on the Purchase Option
Closing Date subject to the payment by the holder of the Special Common Stock to
the Payment Agent on or before such date of the amount owing to the record
holders of Callable Common Stock as determined in accordance with Section 5.2
hereof, and thereafter the Corporation shall be entitled to treat the
-8-
<PAGE>
holder of the Special Common Stock as the sole holder of all issued and
outstanding shares of Callable Common Stock, notwithstanding the failure of
any holder of shares of Callable Common Stock to tender the certificates
representing such shares to the Payment Agent for payment therefor in
accordance with Section 5.5 hereof. The Corporation shall instruct its
transfer agent not to accept any shares of Callable Common Stock for transfer
on and after the Purchase Option Closing Date, except for the shares of
Callable Common Stock transferred by the holder of the Special Common Stock.
The Corporation shall take all actions reasonably requested by the holder of
the Special Common Stock to assist in effectuating the transfer of shares of
Callable Common Stock in accordance with this Article V. After the Purchase
Option Closing Date, the record holders of the Callable Common Stock as
determined in accordance with Section 5.6 above shall have no rights in
connection with such Callable Common Stock other than the right to receive
the Purchase Option Exercise Price.
SECTION 5.8. ASSIGNMENT. Upon the assignment, delegation, transfer or
sale by any record holder of Callable Common Stock, such shares of Callable
Common Stock shall continue to be subject to the Purchase Option and the other
terms and conditions of this Article V.
SECTION 5.9. LEGEND.
(a) Any certificates evidencing shares of Callable Common Stock
issued by or on behalf of the Corporation shall bear a legend in substantially
the following form:
THE SECURITIES OF SPIROS DEVELOPMENT CORPORATION II, INC., A
DELAWARE CORPORATION ("SPIROS CORP. II"), EVIDENCED HEREBY
ARE SUBJECT TO AN OPTION AS DESCRIBED IN THE AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION OF SPIROS CORP. II, AS
AMENDED FROM TIME TO TIME, TO PURCHASE SUCH SECURITIES AT A
PURCHASE PRICE DETERMINED IN ACCORDANCE WITH ARTICLE V
THEREOF, EXERCISABLE BY WRITTEN NOTICE AT ANY TIME DURING
THE PERIOD SET FORTH THEREIN. COPIES OF THE AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION ARE AVAILABLE AT THE
PRINCIPAL PLACE OF BUSINESS OF SPIROS CORP. II AT 7475 LUSK
BOULEVARD, SAN DIEGO, CALIFORNIA 92121, AND WILL BE
FURNISHED TO ANY SPIROS CORP. II STOCKHOLDER ON REQUEST AND
WITHOUT COST.
(b) Upon the termination or expiration (other than by exercise) of
the Purchase Option, the Corporation shall, at the request of any holder of
shares of Callable Common Stock bearing the legend described in this Section
5.9(a), take such steps as are necessary to remove such legend from such shares
of Callable Common Stock.
-9-
<PAGE>
SECTION 5.10. TERMINATION. The Purchase Option and the provisions of this
Article V shall terminate on the earliest to occur of: (1) the Purchase Option
Closing Date; (2) if the Purchase Option is not exercised, 11:59 p.m., San Diego
time, the Purchase Option Expiration Date; or (3) receipt by the Corporation of
written notice of the occurrence of any of the following events, which notice
shall be provided by the holder of the Special Common Stock promptly after the
occurrence of any such event: (a) the holder of the Special Common Stock fails
to make the payment described in Section 5.3 of this Article V on the Purchase
Option Closing Date; (b) the holder of the Special Common Stock (i) seeks the
liquidation, reorganization, dissolution or winding-up of itself or the
composition or readjustment of all or substantially all of its debts, (ii)
applies for or consents to the appointment of, or the taking of possession by, a
receiver, custodian, trustee or liquidator of itself or of all or substantially
all of its assets, (iii) makes a general assignment for the benefit of its
creditors, (iv) commences a voluntary case under Title 11 of the United States
Code, (v) files a petition seeking to take advantage of any other law relating
to bankruptcy, insolvency, reorganization, winding-up or composition or
readjustment of debt or (vi) adopts any resolution of its Board or shareholders
for the purpose of effecting any of the foregoing; (c) a proceeding or case is
commenced without the application or consent of the holder of the Special Common
Stock and such proceeding or case continues undismissed, or an order, judgment
or decree approving or ordering any of the following is entered and continues
unstayed and in effect for a period of sixty (60) days from and after the date
service of process is effected upon the holder of the Special Common Stock,
seeking (i) the liquidation, reorganization, dissolution or winding up, or the
composition or readjustment of all or substantially all of its debts, (ii) the
appointment of a trustee, receiver, custodian, liquidator or the like of the
holder of the Special Common Stock or of all or substantially all of its assets
or (iii) similar relief in respect of the holder of the Special Common Stock
under any law relating to bankruptcy, insolvency, reorganization, winding up or
the composition or readjustment of debt; or (d) material default by the holder
of the Special Common Stock on any material loan agreement which default is not
cured in accordance with such loan agreement. The Corporation shall promptly
notify each holder of record of Callable Common Stock in writing upon the
occurrence of an event specified herein.
SECTION 5.11 AMENDMENT. This Article may not be released, discharged,
amended or modified in any manner except by an instrument approved by the holder
of the outstanding shares of Special Common Stock and the holders of record of
two-thirds (2/3) of the outstanding shares of Callable Common Stock of the
Corporation; provided, however, that, except as expressly provided herein,
without the approval of the holders of record of ninety percent (90%) of the
Callable Common Stock, this Article V may not be amended to change (a) the
amounts of the Purchase Option Exercise Price, (b) the relevant periods during
which and the conditions under which the Purchase Option may be exercised and
the Purchase Option Exercise Price may be paid, (c) the type of securities or
method of calculating the number of securities to be issued upon the payment of
the Purchase Option Exercise Price or (d) the provisions of this Section 5.11.
-10-
<PAGE>
SECTION 5.12. NO CONFLICTING ACTION. The Corporation shall not take, or
permit any other person or entity within its control to take, any action
inconsistent with the rights of the holder of the Special Common Stock under
this Article V. The Corporation shall not enter into any arrangement, agreement
or understanding, either oral or in writing, that is inconsistent with the
rights of the holder of the Special Common Stock and the obligations of the
Corporation hereunder.
ARTICLE VI
CORPORATE EXISTENCE
The Corporation shall have a perpetual existence.
ARTICLE VII
DIRECTORS
SECTION 7.1. SIZE OF BOARD.
(a) The number of directors shall be as specified in the Bylaws of
the Corporation, except that until the earliest of (i) the exercise of the
Purchase Option, (ii) the Purchase Option Expiration Date or (iii) the date of
termination of the Purchase Option pursuant to Section 5.10 hereof, there shall
be five directors. In no event will the number of directors be less than five.
Directors need not be stockholders of the Corporation.
(b) Upon termination of the right of the holder of Special Common
Stock, as a class, to vote for directors pursuant to Article IV hereof, the term
of office of all Special Common Stock Directors then in office shall terminate
immediately.
SECTION 7.2. ELECTIONS. Elections of directors need not be by written
ballot except and to the extent provided in the bylaws of the Corporation.
ARTICLE VIII
EXCULPATION AND INDEMNIFICATION OF DIRECTORS, OFFICERS AND OTHERS
SECTION 8.1. EXCULPATION.
(a) DELAWARE. A director or officer of the Corporation shall not be
personally liable to the Corporation or its stockholders for monetary damages
for breach of
-11-
<PAGE>
fiduciary duty as a director or officer, except for liability (i) for any
breach of the director's or officer's duty of loyalty to the Corporation or
its stockholders, (ii) for acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii) under
Section 174 of the Delaware General Corporation Law or (iv) for any
transaction from which the director or officer derived any improper personal
benefit. If the Delaware General Corporation Law is hereafter amended to
further reduce or to authorize, with the approval of the Corporation's
stockholders, further reductions in the liability of the Corporation's
directors or officers for breach of fiduciary duty, then a director or
officer of the Corporation shall not be liable for any such breach to the
fullest extent permitted by the Delaware General Corporation Law as so
amended.
(b) CALIFORNIA. The liability of each and every director or officer
of the Corporation for monetary damages shall be eliminated to the fullest
extent permissible under California law.
(c) CONSISTENCY. In the event of any inconsistency between
Paragraphs (a) and (b) of this Section 8.1, the controlling Paragraph, as to any
particular issue with regard to any particular matter, shall be the one which
provides to the director or officer in question the greatest protection from
liability.
SECTION 8.2. INDEMNIFICATION.
(a) DELAWARE. To the extent permitted by applicable law, the
Corporation is also authorized to provide indemnification of (and advancement of
expenses to) such agents (and any other persons to which Delaware law permits
the corporation to provide indemnification) through bylaw provisions, agreements
with such agents or other persons, vote of stockholders or disinterested
directors or otherwise, in excess of the indemnification and advancement
otherwise permitted by Section 145 of the Delaware General Corporation Law,
subject only to limits created by applicable Delaware law (statutory or
nonstatutory), with respect to actions for breach of duty to the Corporation,
its stockholders, and others.
(b) CALIFORNIA. The Corporation is authorized to indemnify the
directors and officers of the Corporation to the fullest extent permissible
under California law. Moreover, the Corporation is authorized to provide
indemnification of (and advancement of expenses to) agents (as defined in
Section 317 of the California Corporations Code) through bylaw provisions,
agreements with agents, vote of shareholders or disinterested directors or
otherwise, in excess of the indemnification and advancement otherwise permitted
by Section 317 of the California Corporations Code, subject only to applicable
limits set forth in Section 204 of the California Corporations Code, with
respect to actions for breach of duty to the corporation and its shareholders.
(c) CONSISTENCY. In the event of any inconsistency between
Paragraphs (a) and (b) of this Section 8.2, the controlling Paragraph, as to any
particular issue with
-12-
<PAGE>
regard to any particular matter, shall be the one which authorizes for the
benefit of the agent or other person in question the provision of the
fullest, promptest, most certain or otherwise most favorable indemnification
and/or advancement.
SECTION 8.3. EFFECT OF REPEAL OR MODIFICATION. Any repeal or modification
of any of the foregoing provisions of this Article VIII shall not adversely
affect any right or protection of a director, officer, agent or other person
existing at the time of, or increase the liability of any director or officer of
the Corporation with respect to any acts or omissions of such director or
officer occurring prior to, such repeal or modification.
ARTICLE IX
PREEMPTIVE RIGHTS
No holder of shares of stock of the Corporation shall have any preemptive
or other right, except as such rights are expressly provided by contract, to
purchase or subscribe for or receive any shares of any class, or series thereof,
of stock of the Corporation, whether now or hereafter authorized, or any
warrants, options, bonds, debentures or other securities convertible into,
exchangeable for or carrying any right to purchase any share of any class, or
series thereof, of stock; but such additional shares of stock and such warrants,
options, bonds, debentures or other securities convertible into, exchangeable
for or carrying any right to purchase any shares of any class, or series
thereof, of stock may be issued or disposed of by the Board to such persons, and
on such terms and for such lawful consideration as in its discretion it shall
deem advisable or as the Corporation shall have by contract agreed.
ARTICLE X
AMENDMENTS TO CERTIFICATE
Except as set forth in Section 4.4 and 5.11, the Corporation reserves the
right to repeal, alter, amend or rescind any provision contained in this Amended
and Restated Certificate of Incorporation and/or any provision contained in any
amendment to or any restatement of this Amended and Restated Certificate of
Incorporation, in the manner now or hereafter prescribed by statute, and all
rights conferred on stockholders herein are granted subject to this reservation.
-13-
<PAGE>
ARTICLE XI
BYLAWS
The Board may from time to time make, amend, supplement or repeal the
Bylaws by the requisite affirmative vote of the Board as set forth in the
Bylaws; provided, however, that the stockholders may change or repeal any bylaw
adopted by the Board by the requisite affirmative vote of stockholders as set
forth in the Bylaws; and, provided further, that no amendment or supplement to
the Bylaws adopted by the Board shall vary or conflict with any amendment or
supplement thus adopted by the stockholders.
ARTICLE XII
STOCKHOLDER APPROVAL
No action shall be taken by the stockholders of the Corporation except at
an annual or special meeting of stockholders called in accordance with the
Bylaws, and no action shall be taken by the stockholders by written consent.
ARTICLE XIII
NOTICE
Advance notice of stockholder nominations for the election of directors and
of business to be brought by stockholders before any meeting of the stockholders
of the Corporation shall be given in the manner provided in the Bylaws of the
Corporation.
[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
-14-
<PAGE>
IN WITNESS WHEREOF, the Amended and Restated Certificate of Incorporation
has been executed by the Corporation's President and Chief Executive Officer as
of this 17 day of December, 1997.
SPIROS DEVELOPMENT CORPORATION II, INC.
By: /s/ David S. Kabakoff
------------------------------------
David S. Kabakoff,
President and Chief Executive Officer
ATTEST:
/s/ Mitchell R. Woodbury
- - - - ---------------------------------
Mitchell R. Woodbury,
Secretary
[SIGNATURE PAGE TO AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION]
-15-
<PAGE>
- - - - --------------------------------------------------------------------------------
- - - - --------------------------------------------------------------------------------
SPIROS DEVELOPMENT CORPORATION II, INC.
(a Delaware corporation)
DURA PHARMACEUTICALS, INC.
(a Delaware corporation)
4,400,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
U.S. PURCHASE AGREEMENT
Dated: December 16, 1997
- - - - --------------------------------------------------------------------------------
- - - - --------------------------------------------------------------------------------
<PAGE>
TABLE OF CONTENTS
SECTION 1. Representations and Warranties . . . . . . . . . . . . . . . . 5
(a) Representations and Warranties by the Companies . . . . . . . 5
(i) Compliance with Registration Requirements . . . . . . 5
(ii) Incorporated Documents. . . . . . . . . . . . . . . . 6
(iii) Independent Accountants . . . . . . . . . . . . . . . 6
(iv) Financial Statements. . . . . . . . . . . . . . . . . 6
(v) No Material Adverse Change in Business. . . . . . . . 7
(vi) Good Standing of the Companies. . . . . . . . . . . . 8
(vii) Good Standing of Subsidiaries . . . . . . . . . . . . 8
(viii) Capitalization. . . . . . . . . . . . . . . . . . . . 9
(ix) Authorization of Agreements . . . . . . . . . . . . . 9
(x) Authorization and Description of Units. . . . . . . . 10
(xi) Registration or Similar Rights Waived . . . . . . . . 11
(xii) Absence of Defaults and Conflicts . . . . . . . . . . 11
(xiii) Compliance with Laws. . . . . . . . . . . . . . . . . 13
(xiv) Absence of Labor Dispute. . . . . . . . . . . . . . . 13
(xv) Absence of Proceedings. . . . . . . . . . . . . . . . 13
(xvi) Accuracy of Exhibits. . . . . . . . . . . . . . . . . 13
(xvii) Possession of Intellectual Property . . . . . . . . . 14
(xviii) Absence of Further Requirements . . . . . . . . . . . 14
(xix) Possession of Licenses and Permits. . . . . . . . . . 15
(xx) Title to Property . . . . . . . . . . . . . . . . . . 15
(xxi) Compliance with Cuba Act. . . . . . . . . . . . . . . 15
(xxii) Investment Company Act. . . . . . . . . . . . . . . . 16
(xxiii) Environmental Laws. . . . . . . . . . . . . . . . . . 16
(xxiv) Taxes . . . . . . . . . . . . . . . . . . . . . . . . 16
(xxv) Insurance . . . . . . . . . . . . . . . . . . . . . . 16
(xxvi) Accounting Controls . . . . . . . . . . . . . . . . . 17
(xxvii) Lock-up Agreements . . . . . . . . . . . . . . . . . 17
(xxviii) Affiliate Transactions . . . . . . . . . . . . . . . 17
(xxix) Distribution of Prospectuses. . . . . . . . . . . . 17
(b) Officer's Certificates. . . . . . . . . . . . . . . . . . . . 17
SECTION 2. Sale and Delivery to U.S. Underwriters; Closing. . . . . . . . 18
(a) Initial U.S. Units. . . . . . . . . . . . . . . . . . . . . . 18
(b) U.S. Option Units . . . . . . . . . . . . . . . . . . . . . . 18
(c) Payment . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
(d) Denominations; Registration . . . . . . . . . . . . . . . . . 19
SECTION 3. Covenants of the Companies . . . . . . . . . . . . . . . . . . 19
(a) Compliance with Securities Regulations and Commission
Requests. . . . . . . . . . . . . . . . . . . . . . . . . . . 19
(b) Filing of Amendments. . . . . . . . . . . . . . . . . . . . . 20
i
<PAGE>
(c) Delivery of Registration Statement. . . . . . . . . . . . . . 20
(d) Delivery of Prospectuses. . . . . . . . . . . . . . . . . . . 20
(e) Continued Compliance with Securities Laws . . . . . . . . . . 20
(f) Rule 158. . . . . . . . . . . . . . . . . . . . . . . . . . . 21
(g) Use of Proceeds . . . . . . . . . . . . . . . . . . . . . . . 21
(h) Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
(i) Restriction on Sale of Dura Common Stock. . . . . . . . . . . 21
(j) Reporting Requirements. . . . . . . . . . . . . . . . . . . . 22
(k) Compliance with NASD Rules. . . . . . . . . . . . . . . . . . 22
(l) Lock-up Agreements. . . . . . . . . . . . . . . . . . . . . . 22
SECTION 4. Payment of Expenses. . . . . . . . . . . . . . . . . . . . . . 22
(a) Expenses. . . . . . . . . . . . . . . . . . . . . . . . . . . 22
(b) Termination of Agreement. . . . . . . . . . . . . . . . . . . 23
SECTION 5. Conditions of U.S. Underwriters' Obligations . . . . . . . . . 23
(a) Effectiveness of Registration Statement . . . . . . . . . . . 23
(b) Opinion of Counsel for the Companies. . . . . . . . . . . . . 23
(c) Opinion of Patent Counsel for the Companies . . . . . . . . . 24
(d) Opinion of Regulatory Counsel for the Companies . . . . . . . 24
(e) Opinion of Counsel for the U.S. Underwriters. . . . . . . . . 24
(f) Officers' Certificate . . . . . . . . . . . . . . . . . . . . 24
(g) Accountants' Comfort Letter . . . . . . . . . . . . . . . . . 25
(h) Bring-down Comfort Letter . . . . . . . . . . . . . . . . . . 25
(i) Approval of Listing . . . . . . . . . . . . . . . . . . . . . 25
(j) No Objection. . . . . . . . . . . . . . . . . . . . . . . . . 25
(k) Lock-up Agreements. . . . . . . . . . . . . . . . . . . . . . 25
(l) Purchase of Initial International Units . . . . . . . . . . . 25
(m) Conditions to Purchase of U.S. Option Units . . . . . . . . . 25
(i) Officers' Certificate. . . . . . . . . . . . . . . . . 26
(ii) Opinions of Counsel for the Companies. . . . . . . . . 26
(iii) Opinion of Counsel for the U.S. Underwriters . . . . . 26
(iv) Bring-down Comfort Letter. . . . . . . . . . . . . . . 26
(n) Additional Documents. . . . . . . . . . . . . . . . . . . . . 26
(o) Termination of Agreement. . . . . . . . . . . . . . . . . . . 26
SECTION 6. Indemnification. . . . . . . . . . . . . . . . . . . . . . . . 27
(a) Indemnification of U.S. Underwriters. . . . . . . . . . . . . 27
(b) Indemnification of the Companies, Directors and Officers. . . 28
(c) Actions against Parties; Notification . . . . . . . . . . . . 28
(d) Settlement without Consent if Failure to Reimburse. . . . . . 29
SECTION 7. Contribution . . . . . . . . . . . . . . . . . . . . . . . . . 29
SECTION 8. Representations, Warranties and Agreements to Survive
Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
SECTION 9. Termination of Agreement . . . . . . . . . . . . . . . . . . . 31
(a) Termination; General . . . . . . . . . . . . . . . . . 31
ii
<PAGE>
(b) Liabilities. . . . . . . . . . . . . . . . . . . . . . 31
SECTION 10. Default by One or More of the U.S. Underwriters. . . . . . . 31
SECTION 11. Default by the Companies . . . . . . . . . . . . . . . . . . 32
SECTION 12. Notices. . . . . . . . . . . . . . . . . . . . . . . . . . . 32
SECTION 13. Parties. . . . . . . . . . . . . . . . . . . . . . . . . . . 33
SECTION 14. Governing Law and Time. . . . . . . . . . . . . . . . . . . 33
SECTION 15. Effect of Headings. . . . . . . . . . . . . . . . . . . . . 33
iii
<PAGE>
SPIROS DEVELOPMENT CORPORATION II, INC.
(a Delaware corporation)
DURA PHARMACEUTICALS, INC.
(a Delaware corporation)
4,400,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
U.S. PURCHASE AGREEMENT
December 16, 1997
MERRILL LYNCH & CO.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
as U.S. Representatives of the several U.S. Underwriters
c/o Merrill Lynch & Co.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
North Tower
World Financial Center
New York, New York 10281-1209
Ladies and Gentlemen:
Spiros Development Corporation II, Inc., a Delaware corporation ("SDC II"),
and Dura Pharmaceuticals, Inc., a Delaware corporation ("Dura" and, together
with SDC II, the "Companies"), confirm their respective agreements with Merrill
Lynch & Co., Merrill Lynch,
<PAGE>
Pierce, Fenner & Smith ("Merrill Lynch") and each of the other U.S. Underwriters
named in Schedule A hereto (collectively, the "U.S. Underwriters", which term
shall also include any underwriter substituted as hereinafter provided in
Section 10 hereof), for whom Merrill Lynch and Donaldson, Lufkin & Jenrette
Securities Corporation are acting as representatives (in such capacity, the
"U.S. Representatives"), with respect to the issue and sale by the Companies,
and the purchase by the U.S. Underwriters, acting severally and not jointly, of
the respective number of units set forth in said Schedule A, each unit composed
of one share of callable common stock, par value $.001 per share, of SDC II
("SDC II Common Stock") and one warrant (each a "Warrant") that will entitle the
registered owner thereof to purchase one-fourth of one share of common stock,
par value $.001 per share, of Dura ("Dura Common Stock") at a per share exercise
price as set forth in Schedule B hereto, pursuant to and subject to certain
adjustments as set forth in the Warrant certificate to be issued as part of the
Unit Certificate (as hereinafter defined), and with respect to the grant by SDC
II and Dura to the U.S. Underwriters, acting severally and not jointly, of the
option described in Section 2(b) hereof to purchase all or any part of 660,000
additional units to cover over-allotments, if any. The SDC II Common Stock and
the Warrants will be paired for sale as units by SDC II and Dura and then sold
to the U.S. Underwriters. The aforesaid 4,400,000 units (the "Initial U.S.
Units") to be purchased by the U.S. Underwriters and all or any part of the
660,000 units subject to the option described in Section 2(b) (the "U.S. Option
Units") are hereinafter called, collectively, the "U.S. Units".
It is understood that the Companies concurrently are entering into an
agreement dated the date hereof (the "International Purchase Agreement")
providing for the offering by the Companies of an aggregate of 1,100,000 units
composed of one share of SDC II Common Stock and one Warrant (the "Initial
International Units") through arrangements with certain underwriters outside the
United States and Canada (the "Managers") for whom Merrill Lynch International
is acting as lead manager (the "Lead Manager") and the grant by the Companies to
the Managers, acting severally and not jointly, of an option to purchase all or
any part of the Managers' pro rata portion of up to 165,000 additional units
composed of one share of SDC II Common Stock and one Warrant solely to cover
over-allotments, if any (the "International Option Units" and, together with the
U.S. Option Units, the "Option Units"). The Initial International Units and the
International Option Units are hereinafter called the "International Units". It
is understood that the Companies are not obligated to sell and the U.S.
Underwriters are not obligated to purchase, any Initial U.S. Units unless all of
the Initial International Units are contemporaneously purchased by the Managers.
The U.S. Underwriters and the Managers are hereinafter collectively called
the "Underwriters", the Initial U.S. Units and the Initial International Units
are hereinafter collectively called the "Initial Units", and the U.S. Units and
the International Units are hereinafter collectively called the "Units".
The Underwriters concurrently will enter into an Intersyndicate Agreement
of even date herewith (the "Intersyndicate Agreement") providing for the
coordination of certain transactions
2
<PAGE>
among the Underwriters under the direction of Merrill Lynch & Co., Merrill
Lynch, Pierce, Fenner & Smith Incorporated (in such capacity, the "Global
Coordinator").
The Companies understand that the U.S. Underwriters propose to make a
public offering of the U.S. Units as soon as the U.S. Representatives deem
advisable after this Agreement has been executed and delivered.
Each Unit initially will be represented by a certificate representing one
or more Warrants and one or more shares of SDC II Common Stock (a "Unit
Certificate"). Each Unit will be transferable only as a whole and as described
in the Prospectuses (as hereinafter defined) through December 31, 1999 or such
earlier date on which the Purchase Option (as defined in the Prospectuses) is
exercised or expires unexercised, after which date the Warrants and the SDC II
Common Stock will trade separately; PROVIDED, HOWEVER, that such separation date
will be accelerated upon the occurrence of an Acceleration Event (as defined in
the Prospectuses) with respect to Dura. The SDC II Common Stock, the Warrants
and the U.S. Units are more fully described in the Registration Statement (as
hereinafter defined) and the Prospectuses.
The Companies and the U.S. Underwriters agree that up to 552,200 shares of
the Initial U.S. Units to be purchased by the U.S. Underwriters (the "Reserved
Units") shall be reserved for sale by the U.S. Underwriters to certain eligible
employees and persons having business relationships with the Companies, as part
of the distribution of the U.S. Units by the U.S. Underwriters, subject to the
terms of this Agreement, the applicable rules, regulations and interpretations
of the National Association of Securities Dealers, Inc. and all other applicable
laws, rules and regulations. To the extent that such Reserved Units are not
orally confirmed for purchase by such eligible employees and persons having
business relationships with the Companies by the end of the first business day
after the date of this Agreement, such Reserved Units may be offered to the
public as part of the public offering contemplated hereby.
The Companies have filed with the Securities and Exchange Commission (the
"Commission") a combined registration statement (Nos. 333-37673 and
333-37673-01) covering the registration of the U.S. Units under the Securities
Act of 1933, as amended (the "1933 Act"), including the related preliminary
prospectus or prospectuses, (a) with respect to SDC II, on Form S-1, relating to
the SDC II Common Stock comprising a portion of the U.S. Units, and (b) with
respect to Dura, on Form S-3, relating to the Warrants comprising a portion of
the U.S. Units, the Dura Common Stock underlying the Warrants and the Dura
Common Stock issuable upon exercise of the Purchase Option. Promptly after
execution and delivery of this Agreement, the Companies will either (i) prepare
and file a prospectus in accordance with the provisions of Rule 430A ("Rule
430A") of the rules and regulations of the Commission under the 1933 Act (the
"1933 Act Regulations") and paragraph (b) of Rule 424 ("Rule 424(b)") of the
1933 Act Regulations or (ii) if the Companies have elected to rely upon Rule 434
("Rule 434") of the 1933 Act Regulations, prepare and file a term sheet (a "Term
Sheet") in accordance with the provisions of Rule 434 and Rule 424(b). Two
forms of prospectus are to be used in connection with the offering and sale of
the Units: one relating to the U.S. Units (the "Form of U.S.
3
<PAGE>
Prospectus") and one relating to the International Units (the "Form of
International Prospectus"). The Form of International Prospectus is identical
to the Form of U.S. Prospectus, except for the front cover and back cover pages,
the information under the caption "Underwriting", the inclusion in the
"Prospectus Summary" section of the Form of International Prospectus of a
paragraph under the caption "United States Taxation of Non-U.S. Persons" and the
exclusion in the Form of International Prospectus of a section under the caption
"United States Federal Income Tax Consequences." The information included in
any such prospectus or in any such Term Sheet, as the case may be, that was
omitted from such registration statement at the time it became effective but
that is deemed to be part of such registration statement at the time it became
effective (A) pursuant to paragraph (b) of Rule 430A is referred to as "Rule
430A Information" or (B) pursuant to paragraph (d) of Rule 434 is referred to as
"Rule 434 Information". Each Form of U.S. Prospectus and Form of International
Prospectus used before such registration statement became effective, and any
prospectus that omitted, as applicable, the Rule 430A Information or the Rule
434 Information, that was used after such effectiveness and prior to the
execution and delivery of this Agreement, is herein called a "preliminary
prospectus". Such registration statement, including the exhibits thereto,
schedules thereto, if any, and the documents incorporated by reference therein
pursuant to Item 12 of Form S-3 under the 1933 Act, at the time it became
effective and including the Rule 430A Information and the Rule 434 Information,
as applicable, is herein called the "Registration Statement". Any registration
statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein
referred to as the "Rule 462(b) Registration Statement", and after such filing
the term "Registration Statement" shall include the Rule 462(b) Registration
Statement. The final Form of U.S. Prospectus and the final Form of
International Prospectus, including the documents incorporated by reference
therein pursuant to Item 12 of Form S-3 under the 1933 Act, in the forms first
furnished to the Underwriters for use in connection with the offering of the
Units (the "Unit Offering") are herein called the "U.S. Prospectus" and the
"International Prospectus", respectively, and, collectively, the "Prospectuses".
If Rule 434 is relied on, the term "U.S. Prospectus" and "International
Prospectus" shall refer to the preliminary U.S. Prospectus dated December 1,
1997 and the preliminary International Prospectus dated December 1, 1997,
respectively, each together with the applicable Term Sheet and all references in
this Agreement to the date of such Prospectuses shall mean the date of the
applicable Term Sheet. For purposes of this Agreement, all references to the
Registration Statement, any preliminary prospectus, the U.S. Prospectus, the
International Prospectus or any Term Sheet or any amendment or supplement to any
of the foregoing shall be deemed to include the copy filed with the Commission
pursuant to its Electronic Data Gathering, Analysis and Retrieval system
("EDGAR").
Prior to the Closing Time (as defined), Dura intends to acquire all of the
outstanding capital stock of Spiros Development Corporation ("SDC") for an
aggregate purchase price of approximately $45.7 million, payable in cash, shares
of Dura Common Stock, or any combination thereof (the "SDC Purchase").
4
<PAGE>
All references in this Agreement to financial statements and schedules and
other information which is "contained", "included" or "stated" in the
Registration Statement, any preliminary prospectus (including the Form of U.S.
Prospectus and the Form of International Prospectus) or the Prospectuses (or
other references of like import) shall be deemed to mean and include all such
financial statements and schedules and other information which is incorporated
by reference in the Registration Statement, any preliminary prospectus
(including the Form of U.S. Prospectus and the Form of International Prospectus)
or the Prospectuses, as the case may be; and all references in this Agreement to
amendments or supplements to the Registration Statement, any preliminary
prospectus or the Prospectuses shall be deemed to mean and include the filing of
any document under the Securities Exchange Act of 1934 (the "1934 Act") which is
incorporated by reference in the Registration Statement, such preliminary
prospectus or the Prospectuses, as the case may be.
SECTION 1. REPRESENTATIONS AND WARRANTIES.
(a) REPRESENTATIONS AND WARRANTIES BY THE COMPANIES. The Companies
jointly and severally represent and warrant to each U.S. Underwriter as of the
date hereof, as of the Closing Time referred to in Section 2(c) hereof, and as
of each Date of Delivery (if any) referred to in Section 2(b) hereof, and agree
with each U.S. Underwriter, as follows:
(i) COMPLIANCE WITH REGISTRATION REQUIREMENTS. Dura meets the
requirements for use of Form S-3 under the 1933 Act. Each of the
Registration Statement and any Rule 462(b) Registration Statement has
become effective under the 1933 Act and no stop order suspending the
effectiveness of the Registration Statement or any Rule 462(b) Registration
Statement has been issued under the 1933 Act and no proceedings for that
purpose have been instituted or are pending or, to the knowledge of the
Companies, are contemplated by the Commission, and any request on the part
of the Commission for additional information has been complied with.
At the respective times the Registration Statement, any Rule 462(b)
Registration Statement and any post-effective amendments thereto become
effective and at the Closing Time (and, if any U.S. Option Units are
purchased, at the Date of Delivery), the Registration Statement, the Rule
462(b) Registration Statement and any amendments and supplements thereto
complied and will comply in all material respects with the requirements of
the 1933 Act and the 1933 Act Regulations and did not and will not contain
an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein
not misleading. Neither of the Prospectuses nor any amendments or
supplements thereto, at the time the Prospectuses or any amendments or
supplements were issued and at the Closing Time (and, if any U.S. Option
Units are purchased, at the Date of Delivery), included or will include an
untrue statement of a material fact or omitted or will omit to state a
material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. If
Rule 434 is used, the Companies will
5
<PAGE>
comply with the requirements of Rule 434. The representations and
warranties in this subsection shall not apply to statements in or omissions
from the Registration Statement or the U.S. Prospectus made in reliance
upon and in conformity with information furnished to the Companies in
writing by any U.S. Underwriter through Merrill Lynch expressly for use in
the Registration Statement or the U.S. Prospectus.
Each preliminary prospectus and the prospectuses filed as part of the
Registration Statement as originally filed or as part of any amendment
thereto, or filed pursuant to Rule 424 under the 1933 Act, complied when so
filed in all material respects with the 1933 Act Regulations and each
preliminary prospectus and the Prospectuses delivered to the Underwriters
for use in connection with this offering was identical to the
electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(ii) INCORPORATED DOCUMENTS. The documents incorporated or
deemed to be incorporated by reference in the Registration Statement and
the Prospectuses, when they became effective or at the time they were or
hereafter are filed with the Commission, complied and will comply in all
material respects with the requirements of the 1933 Act and the 1933 Act
Regulations or the Securities Exchange Act of 1934 (the "1934 Act") and the
rules and regulations of the Commission thereunder (the "1934 Act
Regulations"), as applicable, and, when read together with the other
information in the Prospectuses, at the time the Registration Statement
became effective, at the time the Prospectuses were issued and at the
Closing Time (and, if any U.S. Option Units are purchased, at the Date of
Delivery), did not and will not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.
(iii) INDEPENDENT ACCOUNTANTS. Deloitte & Touche LLP, which are
reporting upon the audited financial statements and supporting schedules
with respect to Dura, Spiros Development Corporation ("SDC") and SDC II
incorporated by reference or included in the Registration Statement, are
independent accountants as required by the 1933 Act and the 1933 Act
Regulations.
(iv) FINANCIAL STATEMENTS. (A) The financial statements of Dura
incorporated by reference or included in the Registration Statement and the
Prospectuses, together with the related schedules and notes, present fairly
the financial position of Dura (and, for relevant periods consistent with
the Commission's rules and regulations, Dura's Subsidiaries (as defined in
clause (vii) below)) at the dates indicated and the statements of
operations, shareholders' equity and cash flows of Dura (and, for relevant
periods consistent with the Commission's rules and regulations, each of the
Subsidiaries) for the periods specified; except as otherwise stated in the
Registration Statement, said financial statements have been prepared in
conformity with generally accepted accounting
6
<PAGE>
principles ("GAAP") applied on a consistent basis throughout the periods
involved. The supporting schedules, if any, included in the Registration
Statement present fairly in accordance with GAAP the information required
to be stated therein. The selected financial data and summary financial
information for Dura and the Subsidiaries included in the Prospectuses
present fairly in accordance with GAAP the information shown therein and
have been compiled on a basis consistent with that of the audited financial
statements of Dura and the Subsidiaries included in the Registration
Statement. Other than the financial statements and schedules referred to
in this paragraph (iv), no other financial statements or schedules are
required to be included in the Registration Statement or incorporated
therein by reference.
(B) The financial statements of SDC included in the Registration
Statement and the Prospectuses, together with the related schedules and
notes, present fairly the financial position of SDC at the dates indicated
and the statements of operations, shareholders' equity and cash flows of
SDC for the periods specified; except as otherwise stated in the
Registration Statement, said financial statements have been prepared in
conformity with GAAP applied on a consistent basis throughout the periods
involved.
(C) The financial statements of SDC II included in the Registration
Statement and the Prospectuses, together with the related schedules and
notes, present fairly the financial position of SDC II at the date
indicated; except as otherwise stated in the Registration Statement, said
financial statements have been prepared in conformity with GAAP.
(D) The pro forma financial statements and the related notes thereto
included in the Registration Statement and the Prospectuses or incorporated
therein by reference present fairly in accordance with GAAP the information
shown therein, have been prepared in accordance with the Commission's rules
and guidelines with respect to pro forma financial statements and have been
properly compiled on the bases described therein, and the assumptions used
in the preparation thereof are reasonable and the adjustments used therein
are appropriate to give effect to the transactions and circumstances
referred to therein.
(v) NO MATERIAL ADVERSE CHANGE IN BUSINESS. Since the
respective dates as of which information is given in the Registration
Statement and the Prospectuses, except as otherwise stated therein, (A)
there has been no material adverse change in the condition, financial or
otherwise, or in the earnings, business affairs or business prospects of
Dura and the Subsidiaries (as defined below), considered as one enterprise,
whether or not arising in the ordinary course of business (a "Dura Material
Adverse Effect"), (B) there has been no material adverse change in the
condition, financial or otherwise, or in the earnings, business affairs or
business prospects of SDC, whether or not arising in the ordinary course
of business (an "SDC Material Adverse Effect"), (C) there has been no
material adverse change in the condition, financial or otherwise, or in
the earnings,
7
<PAGE>
business affairs or business prospects of SDC II, whether or not arising
in the ordinary course of business (an "SDC II Material Adverse Effect"),
(D) there have been no transactions entered into by Dura or any Subsidiary,
SDC or SDC II, other than in the ordinary course of business, which are
material with respect to Dura and the Subsidiaries, considered as one
enterprise, SDC or SDC II, respectively, and (D) there has been no dividend
or distribution of any kind declared, paid or made by each of SDC, SDC II
or Dura, on any class of its respective capital stock. As used in this
Agreement on the date hereof, a "Material Adverse Effect" shall mean both a
Dura Material Adverse Effect and an SDC Material Adverse Effect.
(vi) GOOD STANDING OF THE COMPANIES. (A) Dura has been duly
organized and is validly existing as a corporation in good standing under
the laws of the State of Delaware and has corporate power and authority to
own, lease and operate its properties and to conduct its business as
described in the Prospectuses and to enter into and perform its obligations
under this Agreement; and Dura is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction in
which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure to
so qualify or to be in good standing would not result in a Dura Material
Adverse Effect.
(B) SDC II has been duly organized and is validly existing as a
corporation in good standing under the laws of the State of Delaware and
has corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Prospectuses and to enter
into and perform its obligations under this Agreement; and SDC II is duly
qualified as a foreign corporation to transact business and is in good
standing in each jurisdiction in which such qualification is required,
whether by reason of the ownership or leasing of property or the conduct of
business, except where the failure to so qualify or to be in good standing
would not result in an SDC II Material Adverse Effect.
(vii) GOOD STANDING OF SUBSIDIARIES. Dura Delivery Systems,
Inc., a Delaware corporation ("DDSI"), Health Script Pharmacy Services,
Inc., a Colorado corporation ("Health Script"), Healthco Solutions, Inc., a
Colorado corporation ("Healthco"), HS Wholesaler, Inc., a Colorado
corporation ("HS Wholesaler"), Scandi Acquisition Corp., a Delaware
corporation ("Scandi"), DCI, Ltd., a corporation organized under the laws
of the Cayman Islands ("DCI"), Dura (Bermuda) Trading Company Ltd., a
corporation organized under the laws of Bermuda ("Dura (Bermuda)"), Dura
(Barbados) Ltd., a corporation organized under the laws of Barbados ("Dura
(Barbados)"), Dura (Barbados) Holding Company Ltd., a corporation organized
under the laws of Barbados ("Dura (Barbados) Holding"), Dura USA Holdings,
Inc., a Delaware corporation ("Dura USA") and SDC Acquisition Corp., a
Delaware corproation ("SDC Acquiisition") are the only subsidiaries of Dura
(DDSI, Health Script, Healthco, HS Wholesaler, Scandi, DCI, Dura (Bermuda),
Dura (Barbados), Dura (Barbados) Holding, Dura USA, SDC Acquisition
8
<PAGE>
and, unless otherwise indicated, SDC, are hereinafter referred to as the
"Subsidiaries"). Except for the Subsidiaries, neither Dura nor any
Subsidiary owns any shares of stock or any other equity securities of any
corporation or has any equity interests in any firm, partnership,
association or other entity other than 775,193 shares of Common Stock of
Trega Biosciences, Inc. and 754,799 shares of Common Stock of Cosmederm
Technologies, Inc., each held by Dura. Each Subsidiary has been duly
organized and is validly existing as a corporation in good standing under
the laws of the jurisdiction of its incorporation, has corporate power and
authority to own, lease and operate its properties and conduct its business
as described in the Prospectuses and is duly qualified as a foreign
corporation to transact business and is in good standing in each
jurisdiction in which such qualification is required, whether by reason of
the ownership or leasing of property or the conduct of business, except
where the failure so to qualify or to be in good standing would not result
in a Material Adverse Effect; all of the issued and outstanding capital
stock of each Subsidiary has been duly authorized and validly issued, is
fully paid and non-assessable and (other than with respect to SDC) is owned
solely by Dura or another Subsidiary free and clear of any security
interest, mortgage, pledge, lien, encumbrance, claim or equity; none of the
outstanding shares of capital stock of any Subsidiary was issued in
violation of the preemptive or similar rights of any securityholder of such
Subsidiary arising by operation of law, under the charter or by-laws of
such Subsidiary or under any agreement to which Dura or such Subsidiary is
a party.
(B) Upon the consummation of the SDC Purchase, all of the outstanding
shares of capital stock of SDC will be owned by Dura free and clear of any
security interest, mortgage, pledge, lien, encumbrance, claim or equity.
(viii) CAPITALIZATION. The authorized, issued and outstanding
capital stock of each of Dura and SDC II is as set forth in the
Prospectuses under the column "Actual" under the captions "Dura
Capitalization" and "Spiros Corp. II Capitalization", respectively (except,
in the case of Dura, for subsequent issuances, if any, pursuant to
reservations, agreements or employee benefit plans referred to in the
Prospectuses or incorporated by reference therein or pursuant to the
exercise of convertible securities, warrants or options referred to in the
Prospectuses or incorporated by reference therein). The shares of issued
and outstanding capital stock of each of Dura and SDC II have been duly
authorized and validly issued and are fully paid and non-assessable; none
of the outstanding shares of capital stock of Dura or SDC II was issued in
violation of the preemptive or other similar rights of any securityholder
of Dura or SDC II, respectively, arising by operation of law, under the
charter or by-laws of Dura or SDC II, as the case may be, or under any
agreement to which Dura or SDC II is a party. Except as disclosed in the
Prospectuses or incorporated by reference therein, there are no outstanding
options, warrants or other rights calling for the issuance of, and no
commitments, plans or arrangements to issue, any shares of capital stock of
Dura, SDC
9
<PAGE>
II or any Subsidiary or any security convertible into or exchangeable for
capital stock of Dura, SDC II or any Subsidiary.
(ix) AUTHORIZATION OF AGREEMENTS. (A) This Agreement and the
International Purchase Agreement have been duly authorized, executed and
delivered by each of Dura and SDC II.
(B) The Warrant Agreement (as hereinafter defined) has been duly
authorized by Dura, and when executed and delivered by Dura and the Warrant
Agent thereunder, will constitute a valid and binding agreement of Dura,
enforceable against Dura in accordance with its terms, except as
enforcement thereof may be limited by bankruptcy, insolvency (including,
without limitation, all laws relating to fraudulent transfers),
reorganization, moratorium or similar laws affecting enforcement of
creditors' rights generally and except as enforcement thereof is subject to
general principles of equity (regardless of whether enforcement is
considered in a proceeding in equity or at law).
(C) Each of the Development Agreement, the Technology Agreement, the
Albuterol and Product Option Agreement, the Manufacturing and Marketing
Agreement and the Services Agreement (each as defined in the Prospectuses,
and collectively referred to herein as the "Transaction Agreements") has
been duly authorized by Dura and SDC II and, in the case of the Technology
Agreement, Dura, SDC II, SDC and DDSI, and when executed and delivered by
Dura and SDC II, and, in the case of the Technology Agreement, Dura, SDC
II, SDC and DDSI, will constitute valid and binding agreements of each of
Dura, SDC II, SDC and DDSI, as the case may be, enforceable against Dura,
SDC II, SDC and DDSI in accordance with their terms, except as the
enforcement thereof may be limited by bankruptcy, insolvency (including,
without limitation, all laws relating to fraudulent transfers),
reorganization, moratorium or similar laws affecting enforcement of
creditors' rights generally and except as enforcement thereof is subject to
general principles of equity (regardless of whether enforcement is
considered in a proceeding in equity or at law).
(x) AUTHORIZATION AND DESCRIPTION OF UNITS. (A) The SDC II
Common Stock to be issued by SDC II as a component of the Units has been
duly authorized for issuance and sale to the U.S. Underwriters pursuant
to this Agreement and to the Managers pursuant to the International
Purchase Agreement, respectively, and, when issued and delivered by SDC
II against payment of the purchase price therefor as provided in this
Agreement and the International Purchase Agreement, respectively, will
be validly issued, fully paid and non-assessable; the SDC II Common
Stock conforms in all material respects to the statements relating
thereto contained in the Prospectuses and such description conforms to
the rights set forth in the instruments defining the same; no holder of
SDC II Common Stock will be subject to personal liability by reason of
being such a holder; and the issuance of the SDC II Common Stock is not
subject to the preemptive or other similar rights of any securityholder
of SDC II.
10
<PAGE>
(B) The Warrants to be issued as a component of the Units have been
duly authorized by Dura for issuance and sale to the U.S. Underwriters
pursuant to this Agreement and to the Managers pursuant to the
International Purchase Agreement, respectively, and, when duly executed,
issued and delivered by Dura and duly countersigned by the Warrant Agent
(as hereinafter defined) in the manner provided for in the Warrant
Agreement (the "Warrant Agreement") to be entered into between Dura and
ChaseMellon Shareholder Services, as warrant agent (the "Warrant Agent"),
and, when issued and delivered by Dura against payment of the purchase
price therefor as provided in this Agreement and the International Purchase
Agreement, respectively, will constitute valid and binding obligations of
Dura, entitled to the benefits of the Warrant Agreement, and will be
enforceable in accordance with its terms, except as the enforcement thereof
may be limited by bankruptcy, insolvency (including, without limitation,
all laws relating to fraudulent transfers), reorganization, moratorium or
similar laws affecting enforcement of creditors' rights generally and
except as enforcement thereof is subject to general principles of equity
(regardless of whether enforcement is considered in a proceeding in equity
or at law); such Warrants are not subject to the preemptive rights of any
stockholder of Dura.
(C) Dura shall have available such number of shares of Dura Common
Stock deliverable upon exercise of the Warrants as is sufficient to permit
the exercise in full of the Warrants. All shares of Dura Common Stock
issued upon exercise of the Warrants, when issued and paid for in
accordance with the terms of the Warrant Agreement, will be duly
authorized, validly issued, fully paid and nonassessable; shares of Dura
Common Stock are not subject to the preemptive rights of any stockholder of
Dura; and all corporate action required to be taken for such authorization,
issue and sale of the Dura Common Stock will have been validly and
sufficiently taken upon the issuance of the Warrants; such shares of Dura
Common Stock conform in all material respects to the descriptions thereof
contained or incorporated by reference in the Prospectuses and all
corporate action required to be taken for the authorization, issue and sale
of such shares of Dura Common Stock has been validly and sufficiently
taken.
(xi) REGISTRATION OR SIMILAR RIGHTS WAIVED. Except as set
forth in the Prospectus, there are no persons with registration or other
similar rights to have any securities registered pursuant to the
Registration Statement or otherwise registered by the Companies under
the 1933 Act who have not waived such rights.
(xii) ABSENCE OF DEFAULTS AND CONFLICTS. (A) Neither Dura nor
any Subsidiary is in violation of its charter or by-laws or in default in
the performance or observance of any obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, deed of trust,
loan or credit agreement, note, lease or other agreement or instrument to
which Dura or any Subsidiary is a party or by which it or any of them may
be bound, or to which any of the property or assets of Dura or any
Subsidiary is subject (collectively, "Agreements and Instruments") except
for such defaults that would not
11
<PAGE>
result in a Material Adverse Effect; and the execution, delivery and
performance of each of this Agreement, the International Purchase
Agreement, the Warrant Agreement and the Transaction Agreements by Dura,
SDC and DDSI, as the case may by, the issuance and delivery of the Warrants
and the issuance of shares of Dura Common Stock upon the exercise of the
Warrants and the consummation by Dura, SDC and DDSI, as the case may be, of
the transactions contemplated in this Agreement, the International Purchase
Agreement, the Warrant Agreement and the Transaction Agreements and in the
Registration Statement (including the issuance and sale of the Warrants as
part of the Units) and compliance by Dura, SDC and DDSI, as the case may
be, with their respective obligations under this Agreement, the
International Purchase Agreement, the Warrant Agreement and each of the
Transaction Agreements to which they are a party have been duly authorized
by all necessary corporate action and do not and will not, whether with or
without the giving of notice or passage of time or both, conflict with or
constitute a breach of, or default or Repayment Event (as defined below)
under, or result in the creation or imposition of any lien, charge or
encumbrance upon any property or assets of Dura or any Subsidiary pursuant
to, the Agreements and Instruments (except for such conflicts, breaches or
defaults or liens, charges or encumbrances that would not result in a
Material Adverse Effect), nor will such action result in any violation of
the provisions of the charter or by-laws of Dura or any Subsidiary or any
applicable material law, statute, rule, regulation, judgment, order, writ
or decree of any government, government instrumentality or court, domestic
or foreign, having jurisdiction over Dura or any Subsidiary or any of their
assets, properties or operations. As used herein, a "Repayment Event"
means any event or condition which gives the holder of any note, debenture
or other evidence of indebtedness (or any person acting on such holder's
behalf) the right to require the repurchase, redemption or repayment of all
or a portion of such indebtedness by Dura or any Subsidiary.
(B) SDC II is not in violation of its charter or by-laws or in
default in the performance or observance of any obligation, agreement,
covenant or condition contained in any contract, indenture, mortgage, deed
of trust, loan or credit agreement, note, lease or other agreement or
instrument to which SDC II is a party or by which it may be bound, or to
which any of the property or assets of SDC II is subject (collectively,
"SDC II Agreements and Instruments") except for such defaults that would
not result in an SDC II Material Adverse Effect; and the execution,
delivery and performance of each of this Agreement, the International
Purchase Agreement and the Transaction Agreements by SDC II and the
consummation by SDC II of the transactions contemplated herein, therein and
in the Registration Statement (including the issuance and sale of the SDC
II Common Stock as part of the Units and the use of the proceeds from the
sale of the Units as described in the Prospectuses under the caption "Use
of Proceeds") and compliance by SDC II with its obligations under this
Agreement, the International Purchase Agreement and each of the Transaction
Agreements have been duly authorized by all necessary corporate action and
do not and will not, whether with or without the giving of notice or
passage of time or both, conflict with or constitute a breach of, or
default
12
<PAGE>
or SDC II Repayment Event (as defined below) under, or result in the
creation or imposition of any lien, charge or encumbrance upon any property
or assets of SDC II pursuant to, the SDC II Agreements and Instruments
(except for such conflicts, breaches or defaults or liens, charges or
encumbrances that would not result in an SDC II Material Adverse Effect),
nor will such action result in any violation of the provisions of the
charter or by-laws of SDC II or any applicable material law, statute, rule,
regulation, judgment, order, writ or decree of any government, government
instrumentality or court, domestic or foreign, having jurisdiction over SDC
II or any of its assets, properties or operations. As used herein, an "SDC
II Repayment Event" means any event or condition which gives the holder of
any note, debenture or other evidence of indebtedness (or any person acting
on such holder's behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by SDC II.
(xiii) COMPLIANCE WITH LAWS. Except as set forth in the
Prospectuses, Dura and the Subsidiaries and SDC II are in compliance in all
material respects with all applicable laws, statutes, ordinances, rules or
regulations, the enforcement of which, individually or in the aggregate,
would be reasonably expected to have a Material Adverse Effect or an SDC II
Material Adverse Effect, as the case may be.
(xiv) ABSENCE OF LABOR DISPUTE. No labor dispute with the
employees of Dura or any Subsidiary exists or, to the knowledge of Dura, is
imminent, and Dura is not aware of any existing or imminent labor
disturbance by the employees of any of its or any Subsidiary's principal
suppliers, manufacturers, customers or contractors, which, in either case,
may reasonably be expected to result in a Dura Material Adverse Effect or
an SDC II Material Adverse Effect.
(xv) ABSENCE OF PROCEEDINGS. There is no action, suit, proceeding,
inquiry or investigation (except applications for regulatory approval for
marketing of pharmaceutical products) before or brought by any court or
governmental agency or body, domestic or foreign, now pending or, to the
knowledge of either Dura or SDC II, threatened against or affecting Dura or
any Subsidiary or SDC II that is required to be disclosed in the
Registration Statement or that might reasonably be expected to have a
Material Adverse Effect, or an SDC II Material Adverse Effect, or which
might reasonably be expected to materially and adversely affect the
properties or assets of either Dura and the Subsidiaries (other than SDC),
considered as one enterprise, or SDC II or SDC, as the case may be, or the
consummation of the transactions contemplated in this Agreement, the
International Purchase Agreement, the Warrant Agreement and the Transaction
Agreements or the performance by Dura or SDC II of its obligations
hereunder or thereunder; the aggregate of all pending legal or governmental
proceedings to which Dura or any Subsidiary or SDC II, as the case may be,
is a party or which affect any of their respective property or assets is
subject which are not described in the Registration Statement, including
ordinary routine litigation incidental to its business, could not
13
<PAGE>
reasonably be expected to result in a Material Adverse Effect or an SDC II
Material Adverse Effect, as the case may be.
(xvi) ACCURACY OF EXHIBITS. There are no contracts or documents
which are required to be described in the Registration Statement, the
Prospectuses or the documents incorporated by reference therein or to be
filed as exhibits thereto which have not been described and filed as
required.
(xvii) POSSESSION OF INTELLECTUAL PROPERTY. (A) Except as set
forth in the Prospectuses, each of Dura and the Subsidiaries owns or
possesses adequate licenses or other rights to use the patents, patent
rights, licenses, inventions, copyrights, know how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), which are necessary for the operation
of their businesses as presently conducted except where the failure to so
own or have the right to use would not have a Material Adverse Effect.
Except as disclosed in the Prospectuses, nothing has come to the attention
of Dura or the Subsidiaries to the effect that (1) any product, process,
method, substance, part or other material presently contemplated to be sold
by or employed by Dura or any of the Subsidiaries in connection with Dura's
or such Subsidiary's business may infringe any patent, trademark, service
mark, trade name, copyright, license or other right owned by others,
(2) there is pending or threatened any claim or litigation against or
affecting Dura and the Subsidiaries contesting their right to sell or use
any such product, process, method, substance, part or other material or
(3) there is, or there is pending, any patent, invention, device,
application or any applicable statute, law, rule, regulation, standard or
code, in the case of each of clause (1), (2) or (3) above, which could have
Material Adverse Effect.
(B) SDC II will, to the extent provided for in the Technology
Agreement, have the right to use all patents, patent rights, licenses,
inventions, copyrights, know how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information,
systems or procedures) owned or controlled by Dura or the Subsidiaries,
which are necessary for the operation of its business as described in the
Prospectuses. SDC II has not received any notice of proceedings relating
to revocation or modification of any such licenses, permits, certificates,
consents, orders, approvals or authorizations which singularly or in the
aggregate, if the subject of an unfavorable ruling or finding, could have a
SDC II Material Adverse Effect.
(xviii) ABSENCE OF FURTHER REQUIREMENTS. (A) No filing with, or
authorization, approval, consent, license, order, registration,
qualification or decree of, any court or governmental authority or agency
is necessary or required for the performance by the Companies of their
obligations under this Agreement, the International Purchase Agreement, the
Warrant Agreement and the Transaction Agreements, in connection with the
offering, issuance, sale and delivery of the shares of SDC II Common Stock,
the Warrants or the shares of Dura Common Stock deliverable upon exercise
of the Warrants
14
<PAGE>
or the consummation of the transactions contemplated by this Agreement, the
International Purchase Agreement, the Warrant Agreement and the Transaction
Agreements, except such as have been already obtained or as may be required
under the 1933 Act or the 1933 Act Regulations and foreign or state
securities or blue sky laws.
(B) No filing with, or authorization, approval, consent, license,
order, registration, qualification or decree of, any court or governmental
authority or agency is necessary or required for the consummation by SDC
and DDSI of the transactions contemplated by this Agreement, except such as
have already been obtained.
(xix) POSSESSION OF LICENSES AND PERMITS. Dura and the
Subsidiaries and SDC II possess such permits, licenses, approvals, consents
and other authorizations (collectively, "Governmental Licenses") issued by
the appropriate federal, state, local or foreign regulatory agencies or
bodies material to the conduct of the business now operated by Dura, the
Subsidiaries and SDC II, respectively; Dura and the Subsidiaries and SDC II
are in compliance with the terms and conditions of all such Governmental
Licenses, except where the failure so to comply would not, singly or in the
aggregate, have a Material Adverse Effect or a SDC II Material Adverse
Effect, as the case may be; all of the Governmental Licenses are valid and
in full force and effect, except when the invalidity of such Governmental
Licenses or the failure of such Governmental Licenses to be in full force
and effect would not have a Material Adverse Effect or a SDC II Material
Adverse Effect, as the case may be; and neither Dura nor any Subsidiary nor
SDC II has received any notice of proceedings relating to the revocation or
modification of any such Governmental Licenses which, singly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding,
would result in a Material Adverse Effect or an SDC II Material Adverse
Effect; provided, however, that no FDA approval has been received with
respect to products that Dura, the Subsidiaries or SDC II currently are not
permitted to market.
(xx) TITLE TO PROPERTY. Dura and the Subsidiaries have good and
marketable title to all material properties and assets owned by Dura and
the Subsidiaries, in each case, free and clear of all mortgages, pledges,
liens, security interests, claims, restrictions or encumbrances of any kind
except such as (a) are described or incorporated by reference in the
Prospectuses or (b) do not, singly or in the aggregate, materially affect
the value of such property and do not interfere with the use made and
proposed to be made of such property by Dura or the affected Subsidiaries,
as the case may be; and all properties held under lease by Dura or any
Subsidiary are held under valid, subsisting and enforceable leases.
(B) SDC II has good and marketable title to all material properties
and assets described in the Prospectuses as owned by it, free and clear of
all mortgages, pledges, liens, security interests, claims, restrictions or
encumbrances of any kind except such as (a) are described in the
Prospectuses or (b) do not, singly or in the aggregate, materially
15
<PAGE>
affect the value of such property and do not interfere with the use made
and proposed to be made of such property by SDC II.
(xxi) COMPLIANCE WITH CUBA ACT. Dura has complied with, and is
and will be in compliance with, the provisions of that certain Florida act
relating to disclosure of doing business with Cuba, codified as Section
517.075 of the Florida statutes, and the rules and regulations thereunder
(collectively, the "Cuba Act") or is exempt therefrom.
(xxii) INVESTMENT COMPANY ACT. Neither of the Companies is and,
upon the issuance and sale of the Units as herein contemplated and the
application of the net proceeds therefrom as described in the Prospectuses,
will not be an "investment company" or an entity "controlled" by an
"investment company" as such terms are defined in the Investment Company
Act of 1940, as amended (the "1940 Act").
(xxiii) ENVIRONMENTAL LAWS. Except as described in the Registration
Statement and except as would not, singly or in the aggregate, result in a
Dura Material Adverse Effect, (A) neither Dura nor any Subsidiary is in
material violation of any federal, state, local or foreign law, rule,
regulation, ordinance or any judicial or administrative interpretation
thereof, including any judicial or administrative order, consent, decree or
judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including,
without limitation, laws and regulations relating to the release or
threatened release of chemicals, pollutants, contaminants, wastes, toxic
substances, hazardous substances, petroleum or petroleum products
(collectively, "Hazardous Materials") or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials (collectively, "Environmental Laws"), (B) Dura and the
Subsidiaries have all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their
requirements, (C) there are no pending or, to the best knowledge of Dura,
threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against Dura
or any of the Subsidiaries and (iv) to the best knowledge of Dura, there
are no events or circumstances that could form the basis of an order for
clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting Dura or any
Subsidiary relating to Hazardous Materials or any Environmental Laws.
(xxiv) TAXES. Dura and the Subsidiaries have filed all federal,
state, local and foreign tax returns that are required to be filed or have
duly requested extensions thereof and have paid all taxes required to be
paid by any of them and any related assessments, fines or penalties, except
for any such tax, assessment, fine or penalty that is being contested in
good faith and by appropriate proceedings; and adequate charges, accruals
and reserves have been provided for in the financial statements referred to
in Section
16
<PAGE>
1(a)(iv)(A) above in respect of all federal, state, local and foreign taxes
for all periods as to which the tax liability of Dura or any Subsidiary has
not been finally determined or remains open to examination by applicable
taxing authorities.
(xxv) INSURANCE. Dura and the Subsidiaries carry or are entitled
to the benefits of insurance in such amounts and covering such risks as is
generally maintained by companies of established repute engaged in the same
or similar business and all such insurance is in full force and effect.
(xxvi) ACCOUNTING CONTROLS. Dura and the Subsidiaries maintain a
system of internal accounting controls sufficient to provide reasonable
assurance that (A) transactions are executed in accordance with
management's general and specific authorizations; (B) transactions are
recorded as necessary to permit preparations of financial statements in
conformity with GAAP and to maintain accountability for assets; (C) access
to assets is permitted only in accordance with management's general or
specific authorizations; and (D) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.
(xxvii) LOCK-UP AGREEMENTS. The Companies have obtained and
delivered to the U.S. Underwriters the agreements, in the form of Exhibit D
hereto, of the persons and entities named in Schedule C annexed hereto to
the effect that each such person will not, for a period of 90 days from the
date of this Agreement and except as otherwise provided in their respective
agreement, without the prior written consent of Merrill Lynch, directly or
indirectly, offer to sell, grant any option for the sale of, or otherwise
dispose of any shares of Dura Common Stock or any securities convertible
into or exercisable for shares of Dura Common Stock owned by such person or
entity or with respect to which such person has the power of disposition.
(xxviii) AFFILIATE TRANSACTIONS. No relationship, direct or
indirect, exists between or among any of Dura or any affiliate of Dura, on
the one hand, and any director, officer, shareholder, customer or supplier
of any of them, on the other hand, which is required by the 1933 Act or by
the 1933 Act Regulations to be described in the Registration Statement or
the Prospectuses and which is not so described or is not described as
required or is not incorporated by reference therein.
(xxix) DISTRIBUTION OF PROSPECTUSES. The Companies have not
distributed and, prior to the later to occur of (A) Closing Time and (B)
completion of the distribution of the Units, will not distribute any
prospectus (as such term is defined in the 1933 Act and the 1933 Act
Regulations) in connection with the offering and sale of the Units other
than the Registration Statement, any preliminary prospectus, the
Prospectuses or other materials, if any, permitted by the 1933 Act or by
the 1933 Act Regulations and approved by the U.S. Representatives.
17
<PAGE>
(b) OFFICER'S CERTIFICATES. Any certificate signed by any officer of Dura
or any Subsidiary or SDC II, delivered to the Global Coordinator, the U.S.
Representatives or to counsel for the U.S. Underwriters shall be deemed a
representation and warranty by Dura or SDC II, as the case may be, to each U.S.
Underwriter as to the matters covered thereby.
SECTION 2. SALE AND DELIVERY TO U.S. UNDERWRITERS; CLOSING.
(a) INITIAL U.S. UNITS. On the basis of the representations and
warranties herein contained and subject to the terms and conditions herein set
forth, the Companies, severally and not jointly, agree to sell to each U.S.
Underwriter, and each U.S. Underwriter, severally and not jointly, agrees to
purchase from the Companies, at the price per Unit set forth in Schedule B, the
number of Initial U.S. Units set forth in Schedule A opposite the name of such
U.S. Underwriter, plus any additional number of Initial U.S. Units that such
U.S. Underwriter may become obligated to purchase pursuant to the provisions of
Section 10 hereof.
(b) U.S. OPTION UNITS. In addition, on the basis of the representations
and warranties herein contained and subject to the terms and conditions herein
set forth, the Companies, acting severally and not jointly, hereby grant an
option to the U.S. Underwriters, severally and not jointly, to purchase up to an
additional 660,000 Units at the same price per Unit set forth in Schedule B for
the Initial U.S. Units. The option hereby granted will expire 30 days after the
date hereof and may be exercised in whole or in part from time to time only for
the purpose of covering over-allotments which may be made in connection with the
offering and distribution of the Initial U.S. Units upon notice by the Global
Coordinator to the Companies setting forth the number of U.S. Option Units as to
which the several U.S. Underwriters are then exercising the option and the time
and date of payment and delivery for such U.S. Option Units. Any such time and
date of delivery (a "Date of Delivery") shall be determined by the Global
Coordinator, but shall not be later than seven full business days after the
exercise of said option, nor in any event prior to the Closing Time, as
hereinafter defined. If the option is exercised as to all or any portion of the
U.S. Option Units, each of the U.S. Underwriters, acting severally and not
jointly, will purchase that proportion of the total number of U.S. Option Units
then being purchased which the number of Initial U.S. Units set forth in
Schedule A opposite the name of such U.S. Underwriter bears to the total number
of Initial U.S. Units, subject in each case to such adjustments as the Global
Coordinator in its discretion shall make to eliminate any sales or purchases of
fractional Units.
(c) PAYMENT. Payment of the purchase price for, and delivery of
certificates for, the Initial U.S. Units shall be made at the offices of
Brobeck, Phleger & Harrison LLP, 550 West C Street, Suite 1300, San Diego,
California 92101, or at such other place as shall be agreed upon by the Global
Coordinator and the Companies, at 7:00 A.M. (California time) on the third
(fourth, if the pricing occurs after 4:30 P.M. (Eastern time) on any given day)
business day after the date hereof (unless postponed in accordance with the
provisions of Section 10), or such other time not later than ten business days
after such date as shall be agreed upon by the Global
18
<PAGE>
Coordinator and the Companies (such time and date of payment and delivery being
herein called "Closing Time").
In addition, in the event that any or all of the U.S. Option Units are
purchased by the U.S. Underwriters, payment of the purchase price for, and
delivery of certificates for, such U.S. Option Units shall be made at the
above-mentioned offices, or at such other place as shall be agreed upon by the
Global Coordinator and the Companies, on each Date of Delivery as specified in
the notice from the Global Coordinator to the Companies.
Payment shall be made to the Companies by wire transfer of immediately
available funds to a bank account designated by the Companies against delivery
to the U.S. Representatives of certificates for the respective accounts of the
U.S. Underwriters of certificates for the U.S. Units to be purchased by them.
It is understood that each U.S. Underwriter has authorized the U.S.
Representatives, for its account, to accept delivery of, receipt for, and make
payment of the purchase price for, the Initial U.S. Units and the U.S. Option
Units, if any, that it has agreed to purchase. Merrill Lynch, individually and
not as representative of the U.S. Underwriters, may (but shall not be obligated
to) make payment of the purchase price for the Initial U.S. Units or the U.S.
Option Units, if any, to be purchased by any U.S. Underwriter whose funds have
not been received by the Closing Time or the relevant Date of Delivery, as the
case may be, but such payment shall not relieve such U.S. Underwriter from its
obligations hereunder.
(d) DENOMINATIONS; REGISTRATION. Certificates for the Initial U.S. Units
and the U.S. Option Units, if any, shall be in such denominations and registered
in such names as the U.S. Representatives may request in writing at least one
full business day before the Closing Time or the relevant Date of Delivery, as
the case may be. The certificates for the Initial U.S. Units and the U.S.
Option Units, if any, will be made available for examination and packaging by
the U.S. Underwriters in The City of New York not later than 10:00 A.M. (Eastern
time) on the business day prior to the Closing Time or the relevant Date of
Delivery, as the case may be.
SECTION 3. COVENANTS OF THE COMPANIES. Each of the Companies covenants
with each U.S. Underwriter as follows:
(a) COMPLIANCE WITH SECURITIES REGULATIONS AND COMMISSION REQUESTS.
The Companies, subject to Section 3(b), will comply with the requirements
of Rule 430A or Rule 434, as applicable, and will notify the Global
Coordinator immediately, and confirm the notice in writing, (i) when any
post-effective amendment to the Registration Statement shall become
effective, or any supplement to the Prospectuses or any amended
Prospectuses shall have been filed, (ii) of the receipt of any comments
from the Commission, (iii) of any request by the Commission for any
amendment to the Registration Statement or any amendment or supplement to
the Prospectuses or for additional information and (iv) of the issuance by
the Commission of any stop order suspending the effectiveness of the
Registration Statement or of any order preventing or suspending the use of
any preliminary prospectus, or of the suspension of the
19
<PAGE>
qualification of the Units for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes.
The Companies will promptly effect the filings necessary pursuant to Rule
424(b) and will take such steps as they deem necessary to ascertain
promptly whether the form of prospectus transmitted for filing under Rule
424(b) was received for filing by the Commission and, in the event that it
was not, will promptly file such prospectus. The Companies will make every
reasonable effort to prevent the issuance of any stop order and, if any
stop order is issued, to obtain the lifting thereof at the earliest
possible moment.
(b) FILING OF AMENDMENTS. The Companies will give the Global
Coordinator notice of their intention to file or prepare any amendment to
the Registration Statement (including any filing under Rule 462(b)), any
Term Sheet or any amendment, supplement or revision to either the
prospectus included in the Registration Statement at the time it became
effective or to the Prospectuses, whether pursuant to the 1933 Act, the
1934 Act or otherwise, will furnish the Global Coordinator with copies of
any such documents a reasonable amount of time prior to such proposed
filing or use, as the case may be, and will not file or use any such
document to which the Global Coordinator or counsel for the U.S.
Underwriters shall object.
(c) DELIVERY OF REGISTRATION STATEMENT. The Companies have furnished
or will deliver to the U.S. Representatives and counsel for the U.S.
Underwriters, without charge, signed copies of the Registration Statement
as originally filed and of each amendment thereto (including exhibits filed
therewith or incorporated by reference therein and documents incorporated
or deemed to be incorporated by reference therein) and signed copies of all
consents and certificates of experts, and will also deliver to the U.S.
Representatives, without charge, a conformed copy of the Registration
Statement as originally filed and of each amendment thereto (without
exhibits) for each of the U.S. Underwriters. The copies of the
Registration Statement and each amendment thereto furnished to the U.S.
Underwriters will be identical to the electronically transmitted copies
thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.
(d) DELIVERY OF PROSPECTUSES. The Companies have delivered to each
U.S. Underwriter, without charge, as many copies of each preliminary
prospectus as such U.S. Underwriter reasonably requested, and the Companies
hereby consent to the use of such copies for purposes permitted by the 1933
Act. The Companies will furnish to each U.S. Underwriter, without charge,
during the period when the U.S. Prospectus is required to be delivered
under the 1933 Act or the 1934 Act, such number of copies of the U.S.
Prospectus (as amended or supplemented) as such U.S. Underwriter may
reasonably request. The U.S. Prospectus and any amendments or supplements
thereto furnished to the U.S. Underwriters will be identical to the
electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.
20
<PAGE>
(e) CONTINUED COMPLIANCE WITH SECURITIES LAWS. The Companies will
comply with the 1933 Act and the 1933 Act Regulations and the 1934 Act and
the 1934 Act Regulations so as to permit the completion of the distribution
of the Units as contemplated in this Agreement, the International Purchase
Agreement and in the Prospectuses. If at any time when a prospectus is
required by the 1933 Act to be delivered in connection with sales of the
Units, any event shall occur or condition shall exist as a result of which
it is necessary, in the opinion of counsel for the U.S. Underwriters or for
the Companies, to amend the Registration Statement or amend or supplement
any Prospectus in order that the Prospectuses will not include any untrue
statements of a material fact or omit to state a material fact necessary in
order to make the statements therein not misleading in the light of the
circumstances existing at the time any such Prospectus is delivered to a
purchaser, or if it shall be necessary, in the opinion of such counsel, at
any such time to amend the Registration Statement or amend or supplement
any Prospectus in order to comply with the requirements of the 1933 Act or
the 1933 Act Regulations, the Companies will promptly prepare and file with
the Commission, subject to Section 3(b), such amendment or supplement as
may be necessary to correct such statement or omission or to make the
Registration Statement or the Prospectuses comply with such requirements,
and the Companies will furnish to the U.S. Underwriters such number of
copies of such amendment or supplement as the U.S. Underwriters may
reasonably request.
(f) RULE 158. The Companies will timely file such reports pursuant
to the 1934 Act as are necessary in order to make generally available to
their securityholders as soon as practicable an earnings statement for the
purposes of, and to provide the benefits contemplated by, the last
paragraph of Section 11(a) of the 1933 Act.
(g) USE OF PROCEEDS. SDC II will use the net proceeds received by it
from the sale of the Units in the manner specified in the Prospectuses
under "Use of Proceeds".
(h) LISTING. The Companies will use their best efforts to effect and
maintain the quotation of the Units on the Nasdaq National Market and will
file with the Nasdaq National Market all documents and notices required by
the Nasdaq National Market of companies that have securities that are
traded in the over-the-counter market and quotations for which are reported
by the Nasdaq National Market.
(i) RESTRICTION ON SALE OF DURA COMMON STOCK. During a period of 90
days from the date of the Prospectuses, Dura will not, without the prior
written consent of the Global Coordinator, (i) directly or indirectly,
offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase or otherwise transfer or dispose of any shares of
Dura Common Stock or any securities convertible into or exercisable or
exchangeable for shares of Dura Common Stock or file any registration
statement under the 1933 Act with respect to any of the foregoing or
(ii) enter into any swap or any other agreement or any
21
<PAGE>
transaction that transfers, in whole or in part, directly or indirectly,
the economic consequence of ownership of Dura Common Stock whether any such
swap or transaction described in clause (i) or (ii) above is to be settled
by delivery of shares of Dura Common Stock or such other securities, in
cash or otherwise. The foregoing sentence shall not apply to (A) the Units
to be sold hereunder or under the International Purchase Agreement, (B) any
shares of Dura Common Stock issued by Dura upon the exercise of an option
or warrant or the conversion of a security outstanding on the date hereof
and referred to in, or incorporated by reference into, the Prospectuses,
(C) any shares of Dura Common Stock issued or options to purchase Dura
Common Stock granted pursuant to existing employee benefit plans of Dura
referred to in, or incorporated by reference into, the Prospectuses or (D)
any shares of Dura Common Stock issued to stockholders of SDC in connection
with the acquisition of all of the outstanding stock of SDC pursuant to a
registration statement on Form S-3 filed with the Commission on October 15,
1997, as amended (No. 333-37955).
(j) REPORTING REQUIREMENTS. The Companies, during the period when the
Prospectuses are required to be delivered under the 1933 Act or the 1934
Act, will file all documents required to be filed with the Commission
pursuant to the 1934 Act within the time periods required by the 1934 Act
and the 1934 Act Regulations.
(k) COMPLIANCE WITH NASD RULES. The Companies hereby agree to
cooperate with the U.S. Underwriters to ensure that the Reserved Units will
be restricted as required by the National Association of Securities
Dealers, Inc. (the "NASD") or the NASD rules from sale, transfer,
assignment, pledge or hypothecation for a period of three months following
the date of this Agreement. After such time as they have been notified in
writing by the U.S. Underwriters as to which persons will need to be so
restricted, the Companies will use their best efforts to direct the
transfer agent or such other applicable person to place a stop transfer
restriction upon such securities for such period of time. Should the
Companies release, or seek to release, from such restrictions any of the
Reserved Units, the Companies agree to reimburse the U.S. Underwriters for
any reasonable expenses (including, without limitation, legal expenses)
they incur in connection with such release.
(l) LOCK-UP AGREEMENTS. SDC II will cause each person that becomes a
director or officer within 90 days of the date hereof to deliver an
agreement substantially in the form of Exhibit D hereto.
SECTION 4. PAYMENT OF EXPENSES.
(a) EXPENSES. SDC II will pay or cause to be paid all expenses incident to
the performance of the Companies' obligations under this Agreement, including
(i) the preparation, printing and filing of the Registration Statement
(including financial statements and exhibits) as originally filed and of each
amendment thereto, (ii) the preparation, printing and delivery to the
Underwriters of this Agreement, any Agreement among Underwriters, the Warrant
Agreement
22
<PAGE>
and such other documents as may be required in connection with the offering,
purchase, sale, issuance or delivery of the Units, (iii) the preparation,
issuance and delivery of the certificates for the Units to the Underwriters,
including any stock or other transfer taxes and any stamp or other duties
payable upon the sale, issuance or delivery of the Units to the Underwriters and
the transfer of the Units between the U.S. Underwriters and the Managers,
(iv) the fees and disbursements of the Companies' counsel, accountants and other
advisors, (v) the fees and disbursements of SDC's counsel, accountants and other
advisors, (vi) the printing and delivery to the Underwriters of copies of each
preliminary prospectus, any Term Sheets and of the Prospectuses and any
amendments or supplements thereto, (vii) the preparation, printing and delivery
to the Underwriters of copies of the Blue Sky Survey and any supplement thereto,
(viii) the fees and expenses of any transfer agent or registrar for the Units,
(ix) all charges of the Warrant Agent, (x) the filing fees incident to, and the
reasonable fees and disbursements of counsel to the Underwriters in connection
with, the review by the NASD of the terms of the sale of the Units, (xi) the
fees and expenses incurred in connection with the listing of the Units, the
SDC II Common Stock and the Warrants on the Nasdaq National Market and (xii) all
costs and expenses of the U.S. Underwriters, including the fees and
disbursements of counsel for the U.S. Underwriters, in connection with matters
related to the Reserved Units that are designated by the Companies for sale to
employees and others having a business relationship with the Companies; PROVIDED
that the Underwriters will reimburse SDC II for up to $1,140,000 of expenses
incurred in connection with the Offerings.
(b) TERMINATION OF AGREEMENT. If this Agreement is terminated by the U.S.
Representatives in accordance with the provisions of Section 5, Section 9(a)(i)
or Section 11, the Companies shall reimburse the U.S. Representatives for all of
their out-of-pocket expenses, including the reasonable fees and disbursements of
counsel for the U.S. Underwriters.
SECTION 5. CONDITIONS OF U.S. UNDERWRITERS' OBLIGATIONS. The
obligations of the several U.S. Underwriters hereunder are subject to the
accuracy of the representations and warranties of the Companies contained in
Section 1 hereof or in certificates of any officer of the Companies or any
Subsidiary delivered pursuant to the provisions hereof, to the performance by
the Companies of their covenants and other obligations hereunder, and to the
following further conditions:
(a) EFFECTIVENESS OF REGISTRATION STATEMENT. The Registration
Statement, including any Rule 462(b) Registration Statement has become
effective and at Closing Time no stop order suspending the effectiveness of
the Registration Statement shall have been issued under the 1933 Act or
proceedings therefor initiated or threatened by the Commission, and any
request on the part of the Commission for additional information shall have
been complied with to the reasonable satisfaction of counsel to the U.S.
Underwriters. A prospectus containing the Rule 430A Information shall have
been filed with the Commission in accordance with Rule 424(b) (or a
post-effective amendment providing such information shall have been filed
and declared effective in accordance with the requirements of Rule 430A)
or, if the Companies have elected to rely upon Rule
23
<PAGE>
434, a Term Sheet shall have been filed with the Commission in accordance
with Rule 424(b).
(b) OPINION OF COUNSEL FOR THE COMPANIES. At Closing Time, the U.S.
Representatives shall have received the favorable opinion, dated as of
Closing Time, of Brobeck, Phleger & Harrison LLP, counsel for Dura and SDC
II, in form and substance satisfactory to counsel for the U.S.
Underwriters, and, to the extent provided in Exhibit A hereto, Mitchell R.
Woodbury, General Counsel for Dura, together with signed or reproduced
copies of such letters for each of the other U.S. Underwriters, to the
effect set forth in Exhibit A hereto.
(c) OPINION OF PATENT COUNSEL FOR THE COMPANIES. At Closing Time,
the U.S. Representatives shall have received the favorable opinion, dated
as of Closing Time, of Lyon & Lyon LLP (solely with respect to patents
concerning the Spiros products), patent counsel for the Companies, in form
and substance satisfactory to counsel for the U.S. Underwriters, together
with signed or reproduced copies of such letter for each of the other U.S.
Underwriters, to the effect set forth in Exhibit B hereto.
(d) OPINION OF REGULATORY COUNSEL FOR THE COMPANIES. At Closing
Time, the U.S. Representatives shall have received the favorable opinion,
dated as of Closing Time, of Kleinfeld, Kaplan and Becker, regulatory
counsel for the Companies, in form and substance satisfactory to counsel
for the U.S. Underwriters, together with signed or reproduced copies of
such letter for each of the other U.S. Underwriters, to the effect set
forth in Exhibit C hereto.
(e) OPINION OF COUNSEL FOR THE U.S. UNDERWRITERS. At Closing Time,
the U.S. Representatives shall have received the favorable opinion, dated
as of Closing Time, of Shearman & Sterling, counsel for the U.S.
Underwriters, together with signed or reproduced copies of such letter for
each of the other U.S. Underwriters, with respect to such matters as the
U.S. Underwriters may reasonably request. In giving such opinion, such
counsel may rely, as to all matters governed by the laws of jurisdictions
other than the law of the State of New York and the federal law of the
United States upon the opinions of counsel satisfactory to the U.S.
Representatives. Such counsel may also state that, insofar as such opinion
involves factual matters, they have relied, to the extent they deem proper,
upon certificates of officers of the Companies and the Subsidiaries and
certificates of public officials.
(f) OFFICERS' CERTIFICATE. At Closing Time, there shall not have
been, since the date hereof or since the respective dates as of which
information is given in the Prospectuses, any Dura Material Adverse Effect,
SDC Material Adverse Effect or SDC II Material Adverse Effect, whether or
not arising in the ordinary course of business, and the U.S.
Representatives shall have received a certificate of the President or a
Vice President of Dura and of the chief financial or chief accounting
officer of Dura, and the President or a Vice President of SDC II and of the
chief financial or chief accounting
24
<PAGE>
officer of SDC II, dated as of the Closing Time, to the effect that
(i) there has been no such material adverse effect, (ii) the
representations and warranties of Dura and SDC II set forth in Section 1(a)
hereof are true and correct with the same force and effect as though
expressly made at and as of the Closing Time, (iii) each of Dura and SDC II
shall have complied with all agreements and satisfied all conditions on its
part to be performed or satisfied at or prior to Closing Time, and (iv) no
stop order suspending the effectiveness of the Registration Statement has
been issued and no proceedings for that purpose have been instituted or are
pending or are contemplated by the Commission.
(g) ACCOUNTANTS' COMFORT LETTER. At the time of the execution of
this Agreement, the U.S. Representatives shall have received from Deloitte
& Touche LLP a letter, dated such date, in form and substance satisfactory
to the U.S. Representatives, together with signed or reproduced copies of
such letter for each of the other U.S. Underwriters, containing statements
and information of the type ordinarily included in accountants' "comfort
letters" to underwriters with respect to the financial statements and
certain financial information contained in the Registration Statement and
the Prospectuses.
(h) BRING-DOWN COMFORT LETTER. At Closing Time, the U.S.
Representatives shall have received from Deloitte & Touche LLP a letter,
dated as of Closing Time, to the effect that they reaffirm the statements
made in the letter furnished pursuant to subsection (g) of this Section 5,
except that the specified date referred to shall be a date not more than
three business days prior to Closing Time.
(i) APPROVAL OF LISTING. At Closing Time, the Units shall have been
approved for inclusion in the Nasdaq National Market, subject only to
official notice of issuance.
(j) NO OBJECTION. The NASD has confirmed that it has not raised any
objection with respect to the fairness and reasonableness of the
underwriting terms and arrangements.
(k) LOCK-UP AGREEMENTS. At the date of this Agreement, the U.S.
Underwriters shall have received an agreement substantially in the form of
Exhibit D hereto signed by the persons listed on Schedule C hereto.
(l) PURCHASE OF INITIAL INTERNATIONAL UNITS. Contemporaneously with
the purchase by the U.S. Underwriters of the Initial U.S. Units under this
Agreement, the Managers shall have purchased the Initial International
Units under the International Purchase Agreement.
(m) CONDITIONS TO PURCHASE OF U.S. OPTION UNITS. In the event that
the U.S. Underwriters exercise their option provided in Section 2(b) hereof
to purchase all or any portion of the U.S. Option Units, the
representations and warranties of the Companies contained herein and the
statements in any certificates furnished by the Companies and
25
<PAGE>
any Subsidiary hereunder shall be true and correct as of each Date of
Delivery and, at the relevant Date of Delivery, the U.S. Representatives
shall have received:
(i) OFFICERS' CERTIFICATE. A certificate, dated such Date
of Delivery, of the President or a Vice President of each of the
Companies and of the chief financial or chief accounting officer of
each of the Companies confirming that the certificate delivered at the
Closing Time pursuant to Section 5(f) remains true and correct as of
such Date of Delivery.
(ii) OPINIONS OF COUNSEL FOR THE COMPANIES. The favorable
opinions of Brobeck, Phleger & Harrison LLP, counsel for the
Companies, Lyon & Lyon, patent counsel for the Companies, and
Kleinfeld, Kaplan and Becker, regulatory counsel for the Companies,
each in form and substance satisfactory to counsel for the U.S.
Underwriters, dated such Date of Delivery, relating to the U.S. Option
Units to be purchased on such Date of Delivery and otherwise to the
same effect as the opinions required by Sections 5(b), 5(c) and 5(d).
(iii) OPINION OF COUNSEL FOR THE U.S. UNDERWRITERS. The
favorable opinion of Shearman & Sterling, counsel for the U.S.
Underwriters, dated such Date of Delivery, relating to the U.S. Option
Units to be purchased on such Date of Delivery and otherwise to the
same effect as the opinion required by Section 5(e).
(iv) BRING-DOWN COMFORT LETTER. A letter from Deloitte &
Touche LLP, in form and substance satisfactory to the U.S.
Representatives and dated such Date of Delivery, substantially in the
same form and substance as the letter furnished to the U.S.
Representatives pursuant to Section 5(h), except that the "specified
date" in the letter furnished pursuant to this paragraph shall be a
date not more than five days prior to such Date of Delivery.
(n) ADDITIONAL DOCUMENTS. At Closing Time and at each Date of
Delivery, counsel for the U.S. Underwriters shall have been furnished with
such documents and opinions as they may require for the purpose of enabling
them to pass upon the issuance and sale of the Units as herein
contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Companies in connection
with the issuance and sale of the Units as herein contemplated shall be
reasonably satisfactory in form and substance to the U.S. Representatives
and counsel for the U.S. Underwriters.
(o) TERMINATION OF AGREEMENT. If any condition specified in this
Section 5 shall not have been fulfilled when and as required to be
fulfilled, this Agreement, or, in the case of any condition to the purchase
of U.S. Option Units, on a Date of Delivery which is after the Closing
Time, the obligations of the U.S. Underwriters to purchase the relevant
U.S. Option Units, may be terminated by the U.S. Representatives by notice
to
26
<PAGE>
the Companies at any time at or prior to Closing Time or such Date of
Delivery, as the case may be, and such termination shall be without
liability of any party to any other party except as provided in Section 4
and except that Sections 1, 6, 7 and 8 shall survive any such termination
and remain in full force and effect.
SECTION 6. INDEMNIFICATION.
(a) INDEMNIFICATION OF U.S. UNDERWRITERS. The Companies, jointly and
severally, agree to indemnify and hold harmless each U.S. Underwriter and each
person, if any, who controls any U.S. Underwriter within the meaning of
Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows:
(i) against any and all loss, liability, claim, damage and expense
whatsoever, as incurred, arising out of any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement
(or any amendment thereto), including the Rule 430A Information and the
Rule 434 Information, if applicable, or the omission or alleged omission
therefrom of a material fact required to be stated therein or necessary to
make the statements therein not misleading or arising out of any untrue
statement or alleged untrue statement of a material fact included in any
preliminary prospectus or the Prospectuses (or any amendment or supplement
thereto), or the omission or alleged omission therefrom of a material fact
necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading;
(ii) against any and all loss, liability, claim, damage and expense
whatsoever, as incurred, to the extent of the aggregate amount paid in
settlement of any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission; provided that (subject to Section
6(d) below) any such settlement is effected with the written consent of the
Companies; and
(iii) against any and all expense whatsoever, as incurred (including
the fees and disbursements of counsel chosen by Merrill Lynch), reasonably
incurred in investigating, preparing or defending against any litigation,
or any investigation or proceeding by any governmental agency or body,
commenced or threatened, or any claim whatsoever based upon any such untrue
statement or omission, or any such alleged untrue statement or omission, to
the extent that any such expense is not paid under (i) or (ii) above;
PROVIDED, HOWEVER, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with written information furnished to the Companies by
any U.S. Underwriter through the U.S. Representatives expressly for use in the
Registration Statement (or any amendment thereto), including the Rule 430A
27
<PAGE>
Information and the Rule 434 Information, if applicable, or any preliminary
prospectus or the U.S. Prospectus (or any amendment or supplement thereto).
(b) INDEMNIFICATION OF THE COMPANIES, DIRECTORS AND OFFICERS. Each U.S.
Underwriter severally agrees to indemnify and hold harmless the Companies, their
directors, each of their officers who signed the Registration Statement, and
each person, if any, who controls either of the Companies within the meaning of
Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all
loss, liability, claim, damage and expense described in the indemnity contained
in subsection (a) of this Section 6, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made
in the Registration Statement (or any amendment thereto), including the Rule
430A Information and the Rule 434 Information, if applicable, or any preliminary
U.S. prospectus or the U.S. Prospectus (or any amendment or supplement thereto)
in reliance upon and in conformity with written information furnished to the
Companies by such U.S. Underwriter through the U.S. Representatives expressly
for use in the Registration Statement (or any amendment thereto) or such
preliminary prospectus or the U.S. Prospectus (or any amendment or supplement
thereto).
(c) ACTIONS AGAINST PARTIES; NOTIFICATION. Each indemnified party shall
give notice as promptly as reasonably practicable to each indemnifying party of
any action commenced against it in respect of which indemnity may be sought
hereunder, but failure to so notify an indemnifying party shall not relieve such
indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it
from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 6(a) above,
counsel to the indemnified parties shall be selected by Merrill Lynch, and, in
the case of parties indemnified pursuant to Section 6(b) above, counsel to the
indemnified parties shall be selected by the Companies. An indemnifying party
may participate at its own expense in the defense of any such action; PROVIDED,
HOWEVER, that counsel to the indemnifying party shall not (except with the
consent of the indemnified party) also be counsel to the indemnified party. In
no event shall the indemnifying parties be liable for fees and expenses of more
than one counsel (in addition to any local counsel) separate from their own
counsel for all indemnified parties in connection with any one action or
separate but similar or related actions in the same jurisdiction arising out of
the same general allegations or circumstances. No indemnifying party shall,
without the prior written consent of the indemnified parties, settle or
compromise or consent to the entry of any judgment with respect to any
litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever in respect of which
indemnification or contribution could be sought under this Section 6 or Section
7 hereof (whether or not the indemnified parties are actual or potential parties
thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party from all liability arising out
of such litigation, investigation, proceeding or claim and (ii) does not include
a statement as to or an admission of fault, culpability or a failure to act by
or on behalf of any indemnified party.
28
<PAGE>
(d) SETTLEMENT WITHOUT CONSENT IF FAILURE TO REIMBURSE. If at any time an
indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel, such indemnifying party
agrees that it shall be liable for any settlement of the nature contemplated by
Section 6(a) effected without its written consent if (i) such settlement is
entered into more than 45 days after receipt by such indemnifying party of the
aforesaid request, (ii) such indemnifying party shall have received notice of
the terms of such settlement at least 30 days prior to such settlement being
entered into and (iii) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such
settlement.
(e) INDEMNIFICATION FOR RESERVED UNITS. In connection with the offer and
sale of the Reserved Units, the Companies agree, promptly upon a request in
writing, to indemnify and hold harmless the U.S. Underwriters from and against
any and all losses, liabilities, claims, damages and expenses incurred by them
as a result of the failure of eligible directors, officers, employees, business
associates and related persons of the Companies to pay for and accept delivery
of Reserved Units which, by the end of the first business day following the date
of this Agreement, were subject to a properly confirmed agreement to purchase.
SECTION 7. CONTRIBUTION. If the indemnification provided for in
Section 6 hereof is for any reason unavailable to or insufficient to hold
harmless an indemnified party in respect of any losses, liabilities, claims,
damages or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate amount of such losses, liabilities, claims, damages
and expenses incurred by such indemnified party, as incurred, (i) in such
proportion as is appropriate to reflect the relative benefits received by the
Companies on the one hand and the U.S. Underwriters on the other hand from the
offering of the Units pursuant to this Agreement or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as
is appropriate to reflect not only the relative benefits referred to in clause
(i) above but also the relative fault of the Companies on the one hand and of
the U.S. Underwriters on the other hand in connection with the statements or
omissions that resulted in such losses, liabilities, claims, damages or
expenses, as well as any other relevant equitable considerations.
The relative benefits received by the Companies on the one hand and the
U.S. Underwriters on the other hand in connection with the offering of the Units
pursuant to this Agreement shall be deemed to be in the same respective
proportions as the total net proceeds from the offering of the Units pursuant to
this Agreement (before deducting expenses) received by the Companies and the
total underwriting discount received by the U.S. Underwriters, in each case as
set forth on the cover of the U.S. Prospectus, or, if Rule 434 is used, the
corresponding location on the Term Sheet, bear to the aggregate initial public
offering price of the Units as set forth on such cover.
The relative fault of the Companies on the one hand and the U.S.
Underwriters on the other hand shall be determined by reference to, among other
things, whether any such untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact relates to information
supplied by the Companies or by the U.S. Underwriters and the
29
<PAGE>
parties' relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission.
The Companies and the U.S. Underwriters agree that it would not be just and
equitable if contribution pursuant to this Section 7 were determined by pro rata
allocation (even if the U.S. Underwriters were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this Section 7. The aggregate
amount of losses, liabilities, claims, damages and expenses incurred by an
indemnified party and referred to above in this Section 7 shall be deemed to
include any legal or other expenses reasonably incurred by such indemnified
party in investigating, preparing or defending against any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no U.S. Underwriter shall
be required to contribute any amount in excess of the amount by which the total
price at which the Units underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages which such U.S.
Underwriter has otherwise been required to pay by reason of any such untrue or
alleged untrue statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the 1933 Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.
For purposes of this Section 7, each person, if any, who controls a U.S.
Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of
the 1934 Act shall have the same rights to contribution as such U.S.
Underwriter, and each director of each of the Companies, each officer of each of
the Companies who signed the Registration Statement, and each person, if any,
who controls the Companies within the meaning of Section 15 of the 1933 Act or
Section 20 of the 1934 Act shall have the same rights to contribution as the
Companies. The U.S. Underwriters' respective obligations to contribute pursuant
to this Section are several in proportion to the number of Initial U.S. Units
set forth opposite their respective names in Schedule A hereto and not joint.
SECTION 8. REPRESENTATIONS, WARRANTIES AND AGREEMENTS TO SURVIVE
DELIVERY. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Companies or any Subsidiary
submitted pursuant hereto, shall remain operative and in full force and effect,
regardless of any investigation made by or on behalf of any U.S. Underwriter or
controlling person, or by or on behalf of the Companies, and shall survive
delivery of the Units to the U.S. Underwriters.
30
<PAGE>
SECTION 9. TERMINATION OF AGREEMENT.
(a) TERMINATION; GENERAL. The U.S. Representatives may terminate this
Agreement, by notice to the Companies, at any time at or prior to Closing Time
(i) if there has been, since the time of execution of this Agreement or since
the respective dates as of which information is given in the U.S. Prospectus,
any Dura Material Adverse Effect or any SDC II Material Adverse Effect, whether
or not arising in the ordinary course of business, or (ii) if there has occurred
any material adverse change in the financial markets in the United States or the
international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a
prospective change in national or international political, financial or economic
conditions, in each case the effect of which is such as to make it, in the
judgment of the U.S. Representatives, impracticable to market the Units or to
enforce contracts for the sale of the Units, or (iii) if trading in any
securities of the Companies has been suspended or materially limited by the
Commission or the Nasdaq National Market, or if trading generally on the
American Stock Exchange or the New York Stock Exchange or in the Nasdaq National
Market has been suspended or materially limited, or minimum or maximum prices
for trading have been fixed, or maximum ranges for prices have been required, by
any of said exchanges or by such system or by order of the Commission, the NASD
or any other governmental authority, or (iv) if a banking moratorium has been
declared by either Federal or New York or California authorities.
(b) LIABILITIES. If this Agreement is terminated pursuant to this Section
9, such termination shall be without liability of any party to any other party
except as provided in Section 4 hereof, and provided further that Sections 1, 6,
7 and 8 shall survive such termination and remain in full force and effect.
SECTION 10. DEFAULT BY ONE OR MORE OF THE U.S. UNDERWRITERS. If one or
more of the U.S. Underwriters shall fail at Closing Time or a Date of Delivery
to purchase the Units which it or they are obligated to purchase under this
Agreement (the "Defaulted Units"), the U.S. Representatives shall have the
right, within 24 hours thereafter, to make arrangements for one or more of the
non-defaulting U.S. Underwriters, or any other underwriters, to purchase all,
but not less than all, of the Defaulted Units in such amounts as may be agreed
upon and upon the terms herein set forth; if, however, the U.S. Representatives
shall not have completed such arrangements within such 24-hour period, then:
(a) if the number of Defaulted Units does not exceed 10% of the
number of Units to be purchased on such date, the non-defaulting U.S.
Underwriters shall be obligated, each severally and not jointly, to
purchase the full amount thereof in the proportions that their respective
underwriting obligations hereunder bear to the underwriting obligations of
all non-defaulting U.S. Underwriters, or
(b) if the number of Defaulted Units exceeds 10% of the number of
Units to be purchased on such date, this Agreement or, with respect to any
Date of Delivery which occurs after Closing Time, the obligation of the
U.S. Underwriters to purchase
31
<PAGE>
and of the Companies to sell the U.S. Option Units to be purchased and sold
on such Date of Delivery shall terminate without liability on the part of
any non-defaulting U.S. Underwriter.
No action taken pursuant to this Section 10 shall relieve any defaulting
U.S. Underwriter from liability in respect of its default.
In the event of any such default which does not result in a termination of
this Agreement or, in the case of a Date of Delivery which is after Closing
Time, which does not result in a termination of the obligation of the U.S.
Underwriters to purchase and the Companies to sell the relevant U.S. Option
Units, as the case may be, either the U.S. Representatives or the Companies
shall have the right to postpone Closing Time or the relevant Date of Delivery,
as the case may be, for a period not exceeding seven days in order to effect any
required changes in the Registration Statement or Prospectuses or in any other
documents or arrangements. As used herein, the term "U.S. Underwriter" includes
any person substituted for a U.S. Underwriter under this Section.
SECTION 11. DEFAULT BY THE COMPANIES. If the Companies shall fail at
Closing Time or at the Date of Delivery to sell the number of Units that they
are obligated to sell hereunder, then this Agreement shall terminate without any
liability on the part of any nondefaulting party; PROVIDED, HOWEVER, that the
provisions of Sections 1, 4, 6, 7 and 8 shall remain in full force and effect.
No action taken pursuant to this Section 11 shall relieve the Companies from
liability, if any, in respect of such default.
SECTION 12. NOTICES. All notices and other communications hereunder shall
be in writing and shall be deemed to have been duly given if mailed or
transmitted by any standard form of telecommunication. Notices to the U.S.
Underwriters shall be directed to the U.S. Representatives at North Tower, World
Financial Center, New York, New York 10281, attention of Cara Londin; notices to
either of the Companies shall be directed to them at:
Dura Pharmaceuticals, Inc.
7475 Lusk Boulevard
San Diego, California 92121-4204
Attn: Mitchell R. Woodbury
with a copy to:
Brobeck, Phleger & Harrison LLP
550 West "C" Street, Suite 1300
San Diego, California 92101
Attn: Faye H. Russell
SECTION 13. PARTIES. This Agreement shall inure to the benefit of and be
binding upon the U.S. Underwriters and the Companies and their respective
successors. Nothing expressed
32
<PAGE>
or mentioned in this Agreement is intended or shall be construed to give any
person, firm or corporation, other than the U.S. Underwriters and the Companies
and their respective successors and the controlling persons and officers and
directors referred to in Sections 6 and 7 and their heirs and legal
representatives, any legal or equitable right, remedy or claim under or in
respect of this Agreement or any provision herein contained. This Agreement and
all conditions and provisions hereof are intended to be for the sole and
exclusive benefit of the U.S. Underwriters and the Companies and their
respective successors, and said controlling persons and officers and directors
and their heirs and legal representatives, and for the benefit of no other
person, firm or corporation. No purchaser of Units from any U.S. Underwriter
shall be deemed to be a successor by reason merely of such purchase.
SECTION 14. GOVERNING LAW AND TIME. THIS AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EXCEPT AS
OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 15. EFFECT OF HEADINGS. The Article and Section headings herein
and the Table of Contents are for convenience only and shall not affect the
construction hereof.
33
<PAGE>
If the foregoing is in accordance with your understanding of our agreement,
please sign and return to each of Dura and SDC II a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding
agreement among the U.S. Underwriters, Dura and SDC II in accordance with its
terms.
Very truly yours,
DURA PHARMACEUTICALS, INC.
By: /s/ Cam L. Garner
----------------------------------
Title: Chairman, President & CEO
SPIROS DEVELOPMENT CORPORATION II, INC.
By: /s/ David S. Kabakoff
----------------------------------
Title: Chairman, President & CEO
CONFIRMED AND ACCEPTED,
as of the date first above written:
MERRILL LYNCH & CO.
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
By: MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
By: /s/ James J. Jackson, Vice President
------------------------------------
Authorized Signatory
For themselves and as U.S. Representatives of the other U.S. Underwriters named
in Schedule A hereto.
34
<PAGE>
SCHEDULE A
Number of
Initial U.S.
Name of U.S. Underwriter Units
------------------------ -----
Merrill Lynch, Pierce, Fenner & Smith
Incorporated . . . . . . . . . . . . . . . . . . . . . 1,500,000
Donaldson, Lufkin & Jenrette Securities Corporation . . . . . 1,500,000
BT Alex. Brown Incorporated . . . . . . . . . . . . . . . . . 200,000
BancAmerica Robertson Stephens . . . . . . . . . . . . . . . 200,000
William Blair & Company . . . . . . . . . . . . . . . . . . . 200,000
CIBC Oppenheimer Corp. . . . . . . . . . . . . . . . . . . . 200,000
Hambrecht & Quist LLC . . . . . . . . . . . . . . . . . . . . 200,000
Nations Banc Montgomery Securities, Inc. . . . . . . . . . . 200,000
Piper Jaffrey, Inc. . . . . . . . . . . . . . . . . . . . . . 200,000
----------
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,400,000
----------
----------
Sch A - 1
<PAGE>
SCHEDULE B
SPIROS DEVELOPMENT CORPORATION II, INC.
DURA PHARMACEUTICALS, INC.
4,400,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
1. The initial public offering price per U.S. Unit, determined as
provided in Section 2, shall be $16.00.
2. The purchase price per U.S. Unit to be paid by the U.S. Underwriters
shall be $14.88, being an amount equal to the initial public offering price set
forth above less $1.12 per U.S. Unit.
3. The exercise price of the Warrants shall be $54.84 per share of Dura
Common Stock.
Sch B - 1
<PAGE>
SCHEDULE C
James C. Blair
Julia Brown
Herbert J. Conrad
Joseph C. Cook, Jr.
Chester Damecki
Cam L. Garner
David F. Hale
Malcolm Hill
David S. Kabakoff
Robert W. Keith
Erle T. Mast
James W. Newman
Charles W. Prettyman
Gordon V. Ramseier
Robert K. Schultz
Charles G. Smith
Walter F. Spath
David Sudolsky
Clyde Witham
Mitchell R. Woodbury
Sch C - 1
<PAGE>
EXHIBIT A
FORM OF OPINION OF COUNSEL FOR DURA, SDC II and SDC
TO BE DELIVERED PURSUANT TO
SECTION 5(b)
[For purposes of this opinion, to be delivered at the Closing Time, the
term "Subsidiaries" includes SDC.]
(i) Each of Dura and SDC II has been duly incorporated and is validly
existing as a corporation in good standing under the laws of the State of
Delaware.
(ii) Each of Dura and SDC II has full corporate power and authority to
own or lease its properties and conduct its business as described in the
Registration Statement and Prospectuses and, to enter into and perform its
obligations under the U.S. Purchase Agreement and the International Purchase
Agreement.
(iii) Each of Dura and SDC II is duly qualified as a foreign
corporation to transact business and is in good standing in each jurisdiction in
which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure so to
qualify or to be in good standing would not result in a Dura Material Adverse
Effect or a SDC II Material Adverse Effect, as the case may be (which opinion as
to Dura may be given by the General Counsel of Dura).
(iv) The authorized capital stock of Dura conforms as to legal matters
in all material respects to the description thereof contained in the
Registration Statement and Prospectuses. The authorized and outstanding shares
of capital stock of Dura are as set forth under the caption "Capitalization" and
have been duly and validly authorized and issued, are fully paid and
non-assessable, and are not subject to any preemptive rights (the opinion called
for by the last sentence of this paragraph (iv) may be given by the General
Counsel of Dura).
(v) The authorized, capital stock of SDC II conforms as to legal
matters in all material respects to the descriptions thereof contained in the
Registration Statement and Prospectuses under the caption "Spiros Corp. II
Capital Stock".
(vi) The outstanding shares of Special Common Stock of SDC II are as
set forth under the caption "Capitalization" have been duly and validly
authorized and issued, are, to our knowledge, fully paid and nonassessable, and
are not subject to any preemptive rights.
(vii) The Warrant Agreement has been duly authorized, executed and
delivered by Dura and constitutes a legal, valid and binding obligation of Dura,
enforceable against Dura in accordance to its terms.
A-1
<PAGE>
(viii) The issuance of the Warrants has been duly authorized by Dura
and, when duly executed, issued and delivered by Dura and countersigned by the
Warrant Agent and when payment of the purchase price for the Units has been
made, the Warrants will constitute valid and binding obligations of Dura
entitled to the benefits of the Warrant Agreement. The Warrants are not subject
to the preemptive rights of any stockholder of Dura. The Warrants conform as to
legal matters in all material respects to the description thereof contained in
the Registration Statement and the Prospectuses under the caption "Description
of the Warrants."
(ix) The shares of Dura Common Stock issuable upon exercise of the
Warrants have been duly and validly reserved for the issuance and, when and if
issued upon such exercise and upon payment of the exercise price, in accordance
with the terms of the Warrant Agreement, will be duly and validly authorized and
issued, will be fully paid and nonassessable, and will not be subject to any
preemptive or similar rights of any stockholder of Dura.
(x) The issuance of the SDC II Common Stock has been duly authorized
and, when issued and paid for as part of the Units as contemplated by the U.S.
Purchase Agreement and the International Purchase Agreement, will be validly
issued, fully paid and non-assessable. Such SDC II Common Stock is not subject
to the preemptive or similar rights of any stockholder of SDC II.
(xi) To our knowledge, the Subsidiaries, are Dura's sole subsidiaries.
Each Subsidiary has been duly incorporated and is validly existing as a
corporation in good standing under the laws of the jurisdiction of its
incorporation, has corporate power and authority to own or lease its properties
and to conduct its business as described in the Registration Statement and
Prospectuses and is duly qualified as a foreign corporation to transact business
and is in good standing in each jurisdiction in which such qualification is
required, whether by reason of the ownership or leasing of property or the
conduct of business, except where the failure so to qualify or to be in good
standing would not result in a Dura Material Adverse Effect; all of the issued
and outstanding capital stock of each Subsidiary and SDC has been duly and
validly authorized and issued, are fully paid and non-assessable and, to the
best of our knowledge and information is owned by Dura free and clear of any
security interest, mortgage, pledge, lien, encumbrance, claim or equity; and
none of the outstanding shares of capital stock of any Subsidiary was issued in
violation of the preemptive rights of any securityholder of such Subsidiary (the
opinion called for by the last sentence of this paragraph (xi) may be given by
the General Counsel of Dura).
(xii) Each of the U.S. Purchase Agreement and the International
Purchase Agreement has been duly authorized, executed and delivered by Dura and
SDC II.
(xiii) The Registration Statement, including any Rule 462(b)
Registration Statement, has become effective under the Act. Any required filing
of the Prospectuses pursuant to Rule 424(b) has been made in the manner and
within the time period required by Rule 424(b). To our knowledge, no stop order
proceedings suspending the effectiveness of the Registration Statement
A-2
<PAGE>
or any Rule 462(b) Registration Statement have been instituted or threatened or
are pending under the Act.
(xiv) All descriptions in the Prospectuses of agreements and other
instruments to which Dura, SDC II or the Subsidiaries are a party are accurate
in all material respects. We know of no agreements required to be filed or
described in the Prospectuses or the Registration Statements which are not so
filed or described. To our knowledge, no breach or default exists under any
agreement or instrument to which Dura, SDC II or any Subsidiary is a party and
which is filed as an Exhibit to the Registration Statement or incorporated by
reference therein (the opinion called for by the last two sentences of this
paragraph (xiv) may be given by the General Counsel of Dura and SDC II).
(xv) The form of certificate used to evidence the Units complies in
all material respects with all applicable statutory requirements, and the
requirements of the Nasdaq National Market.
(xvi) To our knowledge, there is no legal or governmental proceeding
pending or threatened to which Dura, any Subsidiary or SDC II is a party or to
which any of the properties of Dura, any Subsidiary or SDC II is subject that is
required to be described in the Registration Statement or the Prospectuses and
is not so described, or of any statute or regulation, contract or other document
that is required to be described in the Registration Statement or the
Prospectuses or to be filed as an exhibit to the Registration Statement that is
not described or filed as required.
(xvii) The statements in the Registration Statement under Item 14, to
the extent that such statements constitute matters of law, summaries of
documents contained therein or summaries of legal matters have been prepared by
or reviewed by us and are correct in all material respects.
(xviii) The September 30, 1997 offer and sale of 1,000 shares of SDC II
Common Stock with an aggregate value of $1,000 by SDC II to Dura was exempt from
the registration requirements of Section 5 of the 1933 Act by virtue of Section
4(2) and/or Regulation D promulgated thereunder.
(xix) None of Dura, any Subsidiary or SDC II is in violation of its
charter or by-laws and no default by Dura or any subsidiary exists in the due
performance or observance of any material obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, loan agreement, note,
lease or other agreement or instrument that is described or referred to in the
Registration Statement or the Prospectuses or filed or incorporated by reference
as an exhibit to the Registration Statement (which opinion as to Dura may be
given by the General Counsel of Dura).
(xx) No filing with, or authorization, approval, consent, license,
order, registration, qualification or decree of, any court or governmental
authority or agency, domestic or foreign,
A-3
<PAGE>
(other than under the Act and the 1933 Act Regulations, which have been
obtained, or as may be required under the securities or blue sky laws of the
various states or any foreign jurisdiction , as to which no opinion is requested
or given) is necessary or required in connection with the due authorization,
execution and delivery of the Purchase Agreements or the offering, issuance,
sale or delivery of the Units, the SDC II Common Stock, the Warrants, or the
Dura Common Stock issuable upon exercise of the Warrants.
(xxi) The execution, delivery by Dura of, and the performance by Dura
of its obligations under the U.S. Purchase Agreement or the International
Purchase Agreement and the Warrant Agreement and the issuance and sale of the
Units contemplated thereby will not contravene any provision of applicable law
or the certificate of incorporation or bylaws of Dura or any Subsidiaries, or,
to our knowledge, any judgment, order or decree of any governmental body, agency
or court having jurisdiction over Dura or any of its property or any
Subsidiaries or any of their property, or, to our knowledge, constitute a breach
or default or a Dura Repayment Event (as defined in section 1(a)(xi) of the U.S.
Purchase Agreement) under any agreement or other instrument binding upon Dura or
any of the Subsidiaries, to which Dura or any of the Subsidiaries is a party and
filed as an exhibit to the Registration Statement or an Incorporated Document.
(xxii) The execution, delivery by SDC II of, and the performance by SDC
II of its obligations under the U.S. Purchase Agreement and the International
Purchase Agreement and the issuance and sale of the Units contemplated thereby
will not contravene any provision of applicable law or the certificate of
incorporation or bylaws of SDC II, or, to our knowledge, any judgment, order or
decree of any governmental body, agency or court having jurisdiction over SDC II
or any of its property, or, to our knowledge, constitute a breach or default or
a SDC II Repayment Event (as defined in section 1(a)(xii) of the U.S. Purchase
Agreement) under any agreement or other instrument binding upon SDC II, to which
SDC II is a party and filed as an exhibit to the Registration Statement or an
Incorporated Document.
(xxiii) Each of the Major Agreements has been duly authorized, executed
and delivered by Dura, SDC, DDSI and SDC II as applicable.
(xxiv) No holders of securities of Dura have rights against Dura which
have not been waived to the registration of shares of Dura Common Stock or other
securities, because of the filing of the Registration Statement by Dura or the
offering contemplated thereby (which opinion may be given by the General Counsel
of Dura).
(xxv) The Units have been duly authorized for quotation on the Nasdaq
National Market, upon notice of official issuance.
(xxvi) The statements in the Registration Statement and Prospectuses
under the caption "United States Federal Income Tax Consequences" and "United
States Taxation of Non-U.S. Persons" to the extent they constitute matters of
law or legal conclusions with respect thereto, have been prepared or reviewed by
us and are correct in all material respects.
A-4
<PAGE>
(xxvii) Neither Dura nor SDC II is an "investment company" or an entity
"controlled" by an "investment company", as such terms are defined in the 1940
Act.
In addition to the foregoing, (i) we believe that each of the
Incorporated Documents (except for financial statements and schedules and other
financial data included therein or omitted therefrom, as to which no opinion is
requested or given), when they became effective or were filed with the
Commission, as the case may be, complied as to form when filed with the
Commission in all material respects with the requirements of the Act and the
1934 Act, as applicable, and the rules and regulations of the Commission
thereunder; (ii) we believe that the Registration Statement, the Prospectuses
and each amendment or supplement to the Registration Statement and Prospectuses
(except for financial statements and schedules and other financial data included
or incorporated by reference therein or omitted therefrom, as to which no
opinion is requested or given), as of their respective effective or issue dates,
complied as to form in all material respects with the requirements of the Act
and the applicable rules and regulations of the Commission thereunder; (iii) we
confirm that nothing has come to our attention that has caused us to conclude
that (except for financial statements and schedules and other financial data
included or incorporated by reference therein or omitted therefrom, as to which
we need make no statement) the Registration Statement or any amendment thereto,
including the Rule 430A Information and Rule 434 Information (if applicable), at
the time such Registration Statement or any such amendment became effective,
contained an untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein,
in the lights of the circumstances under which they were made, not misleading or
that (except for financial statements and schedules and other financial data
included or incorporated by reference therein or omitted therefrom, as to which
we need make no statement) the Prospectuses, on the date hereof, include an
untrue statement of a material fact or omits to state a material fact necessary
in order to make the statements therein, in light of the circumstances under
which they were made not misleading.
In rendering such opinion, such counsel may rely (A) upon the opinions
of Lyon & Lyon and Kleinfeld, Kaplan & Becker and Mitchell R. Woodbury, Esq.
(which opinion may rely, to the extent appropriate, on the opinions of Conyers
Dill & Pearman, Bermuda counsel for Dura (Bermuda) Trading Company Ltd., and
Chancery Chambers, Barbados counsel for Dura (Barbados) Holding Company Ltd. and
Dura (Barbados) Ltd.) with respect to the matters opined upon by each, and (B),
as to matters of fact (but not as to legal conclusions), to the extent they deem
proper, on certificates of responsible officers of Dura or SDC II and public
officials. Such opinion shall be subject to standard limitations, exclusions,
qualifications and assumptions. Such opinion shall not state that it is to be
governed or qualified by, or that it is otherwise subject to, any treatise,
written policy or other document relating to legal opinions, including, without
limitation, the Legal Opinion Accord of the ABA Section of Business Law (1991).
A-5
<PAGE>
EXHIBIT B
EXHIBIT B
FORM OF OPINION OF PATENT COUNSEL
FOR DURA AND SDC II DELIVERED PURSUANT TO SECTION 5(C)
(i) Dura owns U.S. patents and U.S. Foreign patent applications which
are directed to Spiros and to certain uses of the Spiros product necessary
to protect the business of Dura and Spiros Corp. II as described in the
Prospectuses. With regard to the business presently and as proposed to be
conducted by Dura and Spiros Corp. II relating to the Spiros product as
described in the Registration Statement and the Prospectuses, and, except
as described therein, we have not received any notice of infringement of or
conflict with, and does not otherwise know of any basis for notice of any
such infringement of or conflict with, asserted rights of others with
respect to any patents, trademarks, service marks, trade names, copyrights,
technology or know-how relating to the Spiros product.
(ii) To the extent that the statements relating to the Spiros product
contained in the Registration Statement and Prospectuses under the
subheadings "Risk Factors--Business Risks Related to Spiros Corp. II and
Dura--Uncertainty Regarding Patents and Proprietary Technology;
Unpredictability of Patent Protection - Spiros Corp. II," "Risk Factors -
Business Risks Related to Spiros Corp. II and Dura -- Uncertainty Regarding
Patents and Proprietary Technology; Unpredicability of Patent Protection -
Dura," and the first paragraph of "Business of Spiros Corp. II -- Patents"
refer to opinions of counsel or matters of law, patents or patent
applications or purport to summarize the status of litigation or the
provisions of statutes, regulations, contracts, agreements or other
documents, such statements (A) have been prepared or reviewed by us and
accurately reflect the status of any such patent applications, litigation,
the provisions purported to be summarized and any of our opinions and (B)
do not contain any untrue statements of a material fact or omit to state
any material fact required to be stated therein or necessary to make the
statements therein not misleading.
B-1
<PAGE>
EXHIBIT C
FORM OF OPINION OF REGULATORY COUNSEL
FOR DURA AND SDC II
TO BE DELIVERED PURSUANT
TO SECTION 5(d)
(i) The descriptions in the Registration Statement of the statutes,
regulations and legal or governmental proceedings or procedures relating to
the FDA and the approval process relating to the products of Dura and SDC
II are accurate in all material respects and are a fair summary of those
statutes, regulations, proceedings or procedures.
(ii) Nothing has come to our attention that leads us to believe that
the descriptions of federal laws, regulations or rules relating to the
manufacture or sale of Dura's products and the approval process relating
thereto contained in the Registration Statement and the Prospectuses,
including, without limitation, the portions of the Registration Statement
and Prospectuses entitled "Risk Factors - Business Risks Related to Spiros
Corp, II and Dura - Government Regulation; No Assurance of FDA Approval,"
and "Business of Dura - Government Regulation," contain an untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statement therein not misleading.
(iii) We have no reason to believe that Dura's current business is not
being conducted in material compliance with currently applicable
requirements under the Federal Food, Drug and Cosmetic Act or that the FDA
is currently considering taking action that would result in withdrawal from
marketing of any of Dura's currently marketed products.
C-1
<PAGE>
EXHIBIT D
October , 1997
MERRILL LYNCH & CO.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
as Representatives of the several
Underwriters to be named in the
within mentioned Purchase Agreement
c/o Merrill Lynch & Co.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
North Tower
World Financial Center
New York, New York 10281-1209
Re: Proposed Public Offering by Dura Pharmaceuticals, Inc. and Spiros
Development Corporation II
Ladies and Gentlemen:
The undersigned, a stockholder and/or officer and/or director of Dura
Pharmaceuticals, Inc. ("Dura") understands that Merrill Lynch & Co. ("Merrill
Lynch") and Donaldson, Lufkin & Jenrette ("DLJ") propose to enter into a
Purchase Agreement (the "Purchase Agreement") with Dura and Spiros Development
Corporation II ("SDC II") that will provide for the public offering of units
comprised of the common stock of SDC II and warrants to purchase Dura's common
stock (the "Securities"). In recognition of the benefit that such an offering
will confer upon the undersigned as a stockholder and/or officer and/or director
of Dura, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the undersigned agrees with each
underwriter to be named in the Purchase Agreement that, during a period of
ninety (90) days from the date of the Purchase Agreement, the undersigned will
not, without the prior written consent of Merrill Lynch, directly or indirectly,
(i) sell, offer to sell, pledge, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or
warrant for the sale of, or otherwise dispose of or transfer any shares of
Dura's common stock (the "Dura Common Stock"), or any securities convertible
into or exchangeable or exercisable for Dura Common Stock, whether now owned or
hereafter acquired by the undersigned, or with respect to which the undersigned
has or hereafter acquires the power of disposition, or file, participate in, or
request the filing of any registration statement under the Securities Act of
1933, as amended, with respect to any of the foregoing or (ii) enter into any
swap or any other agreement or any transaction that transfers, in whole or in
part,
D-1
<PAGE>
directly or indirectly, the economic consequence of ownership of Dura Common
Stock, whether any such swap or transaction is to be settled by delivery of Dura
Common Stock or other securities, in cash or otherwise.
Very truly yours,
Signature:
------------------------
Print Name:
-----------------------
D-2
<PAGE>
If the foregoing is in accordance with your understanding of our agreement,
please sign and return to each of Dura and SDC II a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding
agreement among the U.S. Underwriters, Dura and SDC II in accordance with its
terms.
Very truly yours,
DURA PHARMACEUTICALS, INC.
By:
----------------------------------
Title:
SPIROS DEVELOPMENT CORPORATION II, INC.
By:
----------------------------------
Title:
CONFIRMED AND ACCEPTED,
as of the date first above written:
MERRILL LYNCH & CO.
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
By: MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
By: /s/ James J. Jackson, Vice President
------------------------------------
Authorized Signatory
For themselves and as U.S. Representatives of the other U.S. Underwriters named
in Schedule A hereto.
<PAGE>
- - - - --------------------------------------------------------------------------------
- - - - --------------------------------------------------------------------------------
SPIROS DEVELOPMENT CORPORATION II, INC.
(a Delaware corporation)
DURA PHARMACEUTICALS, INC.
(a Delaware corporation)
1,100,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
INTERNATIONAL PURCHASE AGREEMENT
Dated: December 16, 1997
- - - - --------------------------------------------------------------------------------
- - - - --------------------------------------------------------------------------------
<PAGE>
TABLE OF CONTENTS
SECTION 1. Representations and Warranties . . . . . . . . . . . . . . . . 4
(a) Representations and Warranties by the Companies. . . . . . . . 4
(i) Compliance with Registration Requirements . . . . . . . . 5
(ii) Incorporated Documents. . . . . . . . . . . . . . . . . . 5
(iii) Independent Accountants . . . . . . . . . . . . . . . . . 6
(iv) Financial Statements. . . . . . . . . . . . . . . . . . . 6
(v) No Material Adverse Change in Business. . . . . . . . . . 7
(vi) Good Standing of the Companies. . . . . . . . . . . . . . 7
(vii) Good Standing of Subsidiaries . . . . . . . . . . . . . . 8
(viii) Capitalization. . . . . . . . . . . . . . . . . . . . . . 8
(ix) Authorization of Agreements . . . . . . . . . . . . . . . 9
(x) Authorization and Description of Units. . . . . . . . . . 10
(xi) Registration or Similar Rights Waived . . . . . . . . . . 11
(xii) Absence of Defaults and Conflicts . . . . . . . . . . . . 11
(xiii) Compliance with Laws. . . . . . . . . . . . . . . . . . . 12
(xiv) Absence of Labor Dispute. . . . . . . . . . . . . . . . . 12
(xv) Absence of Proceedings. . . . . . . . . . . . . . . . . . 12
(xvi) Accuracy of Exhibits. . . . . . . . . . . . . . . . . . . 13
(xvii) Possession of Intellectual Property . . . . . . . . . . . 13
(xviii) Absence of Further Requirements . . . . . . . . . . . . . 14
(xix) Possession of Licenses and Permits. . . . . . . . . . . . 14
(xx) Title to Property . . . . . . . . . . . . . . . . . . . . 14
(xxi) Compliance with Cuba Act. . . . . . . . . . . . . . . . . 15
(xxii) Investment Company Act. . . . . . . . . . . . . . . . . . 15
(xxiii) Environmental Laws. . . . . . . . . . . . . . . . . . . . 15
(xxiv) Taxes . . . . . . . . . . . . . . . . . . . . . . . . . . 15
(xxv) Insurance . . . . . . . . . . . . . . . . . . . . . . . . 16
(xxvi) Accounting Controls . . . . . . . . . . . . . . . . . . . 16
(xxvii) Lock-up Agreements. . . . . . . . . . . . . . . . . . . . 16
(xxviii) Affiliate Transactions. . . . . . . . . . . . . . . . . . 16
(xxix) Distribution of Prospectuses. . . . . . . . . . . . . . . 16
(b) Officer's Certificates . . . . . . . . . . . . . . . . . . . . 17
SECTION 2. Sale and Delivery to Managers; Closing . . . . . . . . . . . . 17
(a) Initial International Units. . . . . . . . . . . . . . . . . . 17
(b) International Option Units . . . . . . . . . . . . . . . . . . 17
(c) Payment. . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
(d) Denominations; Registration. . . . . . . . . . . . . . . . . . 18
SECTION 3. Covenants of the Companies . . . . . . . . . . . . . . . . . . 18
(a) Compliance with Securities Regulations and Commission
Requests . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
(b) Filing of Amendments . . . . . . . . . . . . . . . . . . . . . 19
i
<PAGE>
(c) Delivery of Registration Statement . . . . . . . . . . . . . . 19
(d) Delivery of Prospectuses . . . . . . . . . . . . . . . . . . . 19
(e) Continued Compliance with Securities Laws. . . . . . . . . . . 20
(f) Rule 158 . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
(g) Use of Proceeds. . . . . . . . . . . . . . . . . . . . . . . . 20
(h) Listing. . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
(i) Restriction on Sale of Dura Common Stock . . . . . . . . . . . 20
(j) Reporting Requirements . . . . . . . . . . . . . . . . . . . . 21
SECTION 4. Payment of Expenses. . . . . . . . . . . . . . . . . . . . . . 21
(a) Expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
(b) Termination of Agreement . . . . . . . . . . . . . . . . . . . 21
SECTION 5. Conditions of Managers' Obligations. . . . . . . . . . . . . . 22
(a) Effectiveness of Registration Statement. . . . . . . . . . . . 22
(b) Opinion of Counsel for the Companies . . . . . . . . . . . . . 22
(c) Opinion of Patent Counsel for the Companies. . . . . . . . . . 22
(d) Opinion of Regulatory Counsel for the Companies. . . . . . . . 22
(e) Opinion of Counsel for the Managers. . . . . . . . . . . . . . 22
(f) Officers' Certificate. . . . . . . . . . . . . . . . . . . . . 23
(g) Accountants' Comfort Letter. . . . . . . . . . . . . . . . . . 23
(h) Bring-down Comfort Letter. . . . . . . . . . . . . . . . . . . 23
(i) Approval of Listing. . . . . . . . . . . . . . . . . . . . . . 23
(j) No Objection . . . . . . . . . . . . . . . . . . . . . . . . . 23
(k) Lock-up Agreements . . . . . . . . . . . . . . . . . . . . . . 24
(l) Purchase of Initial U.S. Units . . . . . . . . . . . . . . . . 24
(m) Conditions to Purchase of International Option Units . . . . . 24
(i) Officers' Certificate . . . . . . . . . . . . . . . . . . 24
(ii) Opinions of Counsel for the Companies . . . . . . . . . . 24
(iii) Opinion of Counsel for the Managers . . . . . . . . . . . 24
(iv) Bring-down Comfort Letter . . . . . . . . . . . . . . . . 24
(n) Additional Documents . . . . . . . . . . . . . . . . . . . . . 24
(o) Termination of Agreement . . . . . . . . . . . . . . . . . . . 25
SECTION 6. Indemnification. . . . . . . . . . . . . . . . . . . . . . . . 25
(a) Indemnification of Managers. . . . . . . . . . . . . . . . . . 25
(b) Indemnification of the Companies and Directors and Officers. . 26
(c) Actions against Parties; Notification. . . . . . . . . . . . . 26
(d) Settlement without Consent if Failure to Reimburse . . . . . . 27
SECTION 7. Contribution . . . . . . . . . . . . . . . . . . . . . . . . . 27
SECTION 8. Representations, Warranties and Agreements to Survive
Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
SECTION 9. Termination of Agreement . . . . . . . . . . . . . . . . . . . 29
(a) Termination; General . . . . . . . . . . . . . . . . . . . . . 29
(b) Liabilities. . . . . . . . . . . . . . . . . . . . . . . . . . 29
SECTION 10. Default by One or More of the Managers . . . . . . . . . . . . 29
ii
<PAGE>
SECTION 11. Default by the Companies . . . . . . . . . . . . . . . . . . . 30
SECTION 12. Notices. . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
SECTION 13. Parties. . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
SECTION 14. Governing Law and Time . . . . . . . . . . . . . . . . . . . . 31
SECTION 15. Effect of Headings . . . . . . . . . . . . . . . . . . . . . . 31
SCHEDULES
Schedule A - List of Managers. . . . . . . . . . . . . . . . . . . Sch A-1
Schedule B - Pricing Information . . . . . . . . . . . . . . . . . Sch B-1
Schedule C - List of Persons and Entities Subject to Lock-up . . . Sch C-1
EXHIBITS
Exhibit A - Form of Opinion of Counsel for Dura . . . . . . . . . . . A-1
Exhibit B - Form of Opinion of Intellectual Property
Counsel for Dura. . . . . . . . . . . . . . . . . . . . . B-1
Exhibit C - Form of Opinion of U.S. Regulatory Counsel
for the Companies . . . . . . . . . . . . . . . . . . . . C-1
Exhibit D - Form of Lock-up Letter. . . . . . . . . . . . . . . . . . D-1
iii
<PAGE>
SPIROS DEVELOPMENT CORPORATION II, INC.
(a Delaware corporation)
DURA PHARMACEUTICALS, INC.
(a Delaware corporation)
1,100,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
INTERNATIONAL PURCHASE AGREEMENT
December 16, 1997
MERRILL LYNCH INTERNATIONAL
(as "Lead Manager")
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
(together, the "Managers")
c/o Merrill Lynch International
Ropemaker Place
25 Ropemaker Street
London EC2Y 9LY
England
Ladies and Gentlemen:
Spiros Development Corporation II, Inc., a Delaware corporation ("SDC II"),
and Dura Pharmaceuticals, Inc., a Delaware corporation ("Dura" and, together
with SDC II, the "Companies"), confirm their respective agreements with Merrill
Lynch International ("Merrill Lynch") and Donaldson, Lufkin & Jenrette
Securities Corporation (together, the "Managers," which term shall also include
any underwriter substituted as hereinafter provided in Section 10
<PAGE>
hereof), for whom Merrill Lynch is acting as representative (in such capacity,
the "Lead Manager"), with respect to the issue and sale by the Companies, and
the purchase by the Managers, acting severally and not jointly, of the
respective number of units set forth in said Schedule A, each unit composed of
one share of callable common stock, par value $.001 per share, of SDC II
("SDC II Common Stock") and one warrant (each a "Warrant") that will entitle the
registered owner thereof to purchase one-fourth of one share of common stock,
par value $.001 per share, of Dura ("Dura Common Stock") at a per share exercise
price as set forth in Schedule A hereto, pursuant to and subject to certain
adjustments as set forth in the Warrant certificate to be issued as part of the
Unit Certificate (as hereinafter defined), and with respect to the grant by SDC
II and Dura to the Managers, acting severally and not jointly, of the option
described in Section 2(b) hereof to purchase all or any part of 165,000
additional units to cover over-allotments, if any. The SDC II Common Stock and
the Warrants will be paired for sale as units by SDC II and Dura and then sold
to the Managers. The aforesaid 1,100,000 units (the "Initial International
Units") to be purchased by the Managers and all or any part of the 165,000 units
subject to the option described in Section 2(b) (the "International Option
Units") are hereinafter called, collectively, the "International Units."
It is understood that the Companies concurrently are entering into an
agreement dated the date hereof (the "U.S. Purchase Agreement") providing for
the offering by the Companies of an aggregate of 4,400,000 units composed of one
share of SDC II Common Stock and one Warrant (the "Initial U.S. Units") through
arrangements with certain underwriters in the United States and Canada (the
"U.S. Underwriters") for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated
and Donaldson, Lufkin & Jenrette Securities Corporation are acting as
representatives (the "U.S. Representatives") and the grant by the Companies to
the U.S. Underwriters, acting severally and not jointly, of an option to
purchase all or any part of the U.S. Underwriters' pro rata portion of up to
660,000 additional units composed of one share of SDC II Common Stock and one
Warrant solely to cover over-allotments, if any (the "U.S. Option Units" and,
together with the International Option Units, the "Option Units"). The Initial
U.S. Units and the U.S. Option Units are hereinafter called the "U.S. Units."
It is understood that the Companies are not obligated to sell and the Managers
are not obligated to purchase, any Initial International Units unless all of the
Initial U.S. Units are contemporaneously purchased by the U.S. Underwriters.
The Managers and the U.S. Underwriters are hereinafter collectively called
the "Underwriters", the Initial U.S. Units and the Initial International Units
are hereinafter collectively called the "Initial Units", and the U.S. Units and
the International Units are hereinafter collectively called the "Units."
The Underwriters concurrently will enter into an Intersyndicate Agreement
of even date herewith (the "Intersyndicate Agreement") providing for the
coordination of certain transactions among the Underwriters under the direction
of Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated (in
such capacity, the "Global Coordinator").
2
<PAGE>
The Companies understand that the Managers propose to make a public
offering of the International Units as soon as the Lead Manager deems advisable
after this Agreement has been executed and delivered.
Each Unit initially will be represented by a certificate representing one
or more Warrants and one or more shares of SDC II Common Stock (a "Unit
Certificate"). Each Unit will be transferable only as a whole and as described
in the Prospectuses (as hereinafter defined) through December 31, 1999 or such
earlier date on which the Purchase Option (as defined in the Prospectuses) is
exercised or expires unexercised, after which date the Warrants and the SDC II
Common Stock will trade separately; PROVIDED, HOWEVER, that such separation date
will be accelerated upon the occurrence of an Acceleration Event (as defined in
the Prospectuses) with respect to Dura. The SDC II Common Stock, the Warrants
and the U.S. Units are more fully described in the Registration Statement (as
hereinafter defined) and the Prospectuses.
The Companies have filed with the Securities and Exchange Commission (the
"Commission") a combined registration statement (Nos. 333-37673 and
333-37673-01) covering the registration of the U.S. Units under the Securities
Act of 1933, as amended (the "1933 Act"), including the related preliminary
prospectus or prospectuses, (a) with respect to SDC II, on Form S-1, relating to
the SDC II Common Stock comprising a portion of the U.S. Units, and (b) with
respect to Dura, on Form S-3, relating to the Warrants comprising a portion of
the U.S. Units, the Dura Common Stock underlying the Warrants and the Dura
Common Stock issuable upon exercise of the Purchase Option. Promptly after
execution and delivery of this Agreement, the Companies will either (i) prepare
and file a prospectus in accordance with the provisions of Rule 430A ("Rule
430A") of the rules and regulations of the Commission under the 1933 Act (the
"1933 Act Regulations") and paragraph (b) of Rule 424 ("Rule 424(b)") of the
1933 Act Regulations or (ii) if the Companies have elected to rely upon Rule 434
("Rule 434") of the 1933 Act Regulations, prepare and file a term sheet (a "Term
Sheet") in accordance with the provisions of Rule 434 and Rule 424(b). Two
forms of prospectus are to be used in connection with the offering and sale of
the Units: one relating to the International Units (the "Form of International
Prospectus") and one relating to the U.S. Units (the "Form of U.S. Prospectus").
The Form of International Prospectus is identical to the Form of U.S.
Prospectus, except for the front cover and back cover pages, the information
under the caption "Underwriting", the inclusion in the "Prospectus Summary"
section of the Form of International Prospectus of a paragraph under the caption
"United States Taxation of Non-U.S. Persons" and the exclusion in the Form of
International Prospectus of a section under the caption "United States Federal
Income Tax Consequences." The information included in any such prospectus or in
any such Term Sheet, as the case may be, that was omitted from such registration
statement at the time it became effective but that is deemed to be part of such
registration statement at the time it became effective (A) pursuant to paragraph
(b) of Rule 430A is referred to as "Rule 430A Information" or (B) pursuant to
paragraph (d) of Rule 434 is referred to as "Rule 434 Information." Each Form
of International Prospectus and Form of U.S. Prospectus used before such
registration statement became effective, and any prospectus that omitted, as
applicable, the Rule 430A Information or the Rule 434 Information, that was used
after such effectiveness and
3
<PAGE>
prior to the execution and delivery of this Agreement, is herein called a
"preliminary prospectus." Such registration statement, including the exhibits
thereto, schedules thereto, if any, and the documents incorporated by reference
therein pursuant to Item 12 of Form S-3 under the 1933 Act, at the time it
became effective and including the Rule 430A Information and the Rule 434
Information, as applicable, is herein called the "Registration Statement." Any
registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations
is herein referred to as the "Rule 462(b) Registration Statement," and after
such filing the term "Registration Statement" shall include the Rule 462(b)
Registration Statement. The final Form of International Prospectus and the
final Form of U.S. Prospectus, including the documents incorporated by reference
therein pursuant to Item 12 of Form S-3 under the 1933 Act, in the forms first
furnished to the Underwriters for use in connection with the offering of the
Units (the "Unit Offering") are herein called the "International Prospectus" and
the "U.S. Prospectus," respectively, and, collectively, the "Prospectuses." If
Rule 434 is relied on, the term "International Prospectus" and "U.S. Prospectus"
shall refer to the preliminary International Prospectus dated December 1, 1997
and the preliminary U.S. Prospectus dated December 1, 1997, respectively, each
together with the applicable Term Sheet and all references in this Agreement to
the date of such Prospectuses shall mean the date of the applicable Term Sheet.
For purposes of this Agreement, all references to the Registration Statement,
any preliminary prospectus, the International Prospectus, the U.S. Prospectus or
any Term Sheet or any amendment or supplement to any of the foregoing shall be
deemed to include the copy filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval system ("EDGAR").
Prior to the Closing Time (as defined), Dura intends to acquire all of the
outstanding capital stock of Spiros Development Corporation ("SDC") for an
aggregate purchase price of approximately $45.7 million, payable in cash, shares
of Dura Common Stock, or any combination thereof (the "SDC Purchase").
All references in this Agreement to financial statements and schedules and
other information which is "contained", "included" or "stated" in the
Registration Statement, any preliminary prospectus (including the Form of U.S.
Prospectus and the Form of International Prospectus) or the Prospectuses (or
other references of like import) shall be deemed to mean and include all such
financial statements and schedules and other information which is incorporated
by reference in the Registration Statement, any preliminary prospectus
(including the Form of U.S. Prospectus and the Form of International Prospectus)
or the Prospectuses, as the case may be; and all references in this Agreement to
amendments or supplements to the Registration Statement, any preliminary
prospectus or the Prospectuses shall be deemed to mean and include the filing of
any document under the Securities Exchange Act of 1934 (the "1934 Act") which is
incorporated by reference in the Registration Statement, such preliminary
prospectus or the Prospectuses, as the case may be.
4
<PAGE>
SECTION 1. REPRESENTATIONS AND WARRANTIES.
(a) REPRESENTATIONS AND WARRANTIES BY THE COMPANIES. The Companies
jointly and severally represent and warrant to each Manager as of the date
hereof, as of the Closing Time referred to in Section 2(c) hereof, and as of
each Date of Delivery (if any) referred to in Section 2(b) hereof, and agree
with each Manager, as follows:
(i) COMPLIANCE WITH REGISTRATION REQUIREMENTS. Dura meets the
requirements for use of Form S-3 under the 1933 Act. Each of the
Registration Statement and any Rule 462(b) Registration Statement has
become effective under the 1933 Act and no stop order suspending the
effectiveness of the Registration Statement or any Rule 462(b) Registration
Statement has been issued under the 1933 Act and no proceedings for that
purpose have been instituted or are pending or, to the knowledge of the
Companies, are contemplated by the Commission, and any request on the part
of the Commission for additional information has been complied with.
At the respective times the Registration Statement, any Rule 462(b)
Registration Statement and any post-effective amendments thereto become
effective and at the Closing Time (and, if any International Option Units
are purchased, at the Date of Delivery), the Registration Statement, the
Rule 462(b) Registration Statement and any amendments and supplements
thereto complied and will comply in all material respects with the
requirements of the 1933 Act and the 1933 Act Regulations and did not and
will not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the
statements therein not misleading. Neither of the Prospectuses nor any
amendments or supplements thereto, at the time the Prospectuses or any
amendments or supplements were issued and at the Closing Time (and, if any
International Option Units are purchased, at the Date of Delivery),
included or will include an untrue statement of a material fact or omitted
or will omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading. If Rule 434 is used, the Companies will comply with
the requirements of Rule 434. The representations and warranties in this
subsection shall not apply to statements in or omissions from the
Registration Statement or the International Prospectus made in reliance
upon and in conformity with information furnished to the Companies in
writing by any Manager through Merrill Lynch expressly for use in the
Registration Statement or the International Prospectus.
Each preliminary prospectus and the prospectuses filed as part of the
Registration Statement as originally filed or as part of any amendment
thereto, or filed pursuant to Rule 424 under the 1933 Act, complied when so
filed in all material respects with the 1933 Act Regulations and each
preliminary prospectus and the Prospectuses delivered to the Underwriters
for use in connection with this offering was identical to the
5
<PAGE>
electronically transmitted copies thereof filed with the Commission
pursuant to EDGAR, except to the extent permitted by Regulation S-T.
(ii) INCORPORATED DOCUMENTS. The documents incorporated or
deemed to be incorporated by reference in the Registration Statement and
the Prospectuses, when they became effective or at the time they were or
hereafter are filed with the Commission, complied and will comply in all
material respects with the requirements of the 1933 Act and the 1933 Act
Regulations or the Securities Exchange Act of 1934 (the "1934 Act") and the
rules and regulations of the Commission thereunder (the "1934 Act
Regulations"), as applicable, and, when read together with the other
information in the Prospectuses, at the time the Registration Statement
became effective, at the time the Prospectuses were issued and at the
Closing Time (and, if any U.S. Option Units are purchased, at the Date of
Delivery), did not and will not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.
(iii) INDEPENDENT ACCOUNTANTS. Deloitte & Touche LLP, which are
reporting upon the audited financial statements and supporting schedules
with respect to Dura, Spiros Development Corporation ("SDC") and SDC II
incorporated by reference or included in the Registration Statement, are
independent accountants as required by the 1933 Act and the 1933 Act
Regulations.
(iv) FINANCIAL STATEMENTS. (A) The financial statements of Dura
incorporated by reference or included in the Registration Statement and the
Prospectuses, together with the related schedules and notes, present fairly
the financial position of Dura (and, for relevant periods consistent with
the Commission's rules and regulations, Dura's Subsidiaries (as defined in
clause (vii) below)) at the dates indicated and the statements of
operations, shareholders' equity and cash flows of Dura (and, for relevant
periods consistent with the Commission's rules and regulations, each of the
Subsidiaries) for the periods specified; except as otherwise stated in the
Registration Statement, said financial statements have been prepared in
conformity with generally accepted accounting principles ("GAAP") applied
on a consistent basis throughout the periods involved. The supporting
schedules, if any, included in the Registration Statement present fairly in
accordance with GAAP the information required to be stated therein. The
selected financial data and summary financial information for Dura and the
Subsidiaries included in the Prospectuses present fairly in accordance with
GAAP the information shown therein and have been compiled on a basis
consistent with that of the audited financial statements of Dura and the
Subsidiaries included in the Registration Statement. Other than the
financial statements and schedules referred to in this paragraph (iv), no
other financial statements or schedules are required to be included in the
Registration Statement or incorporated therein by reference.
6
<PAGE>
(B) The financial statements of SDC included in the Registration
Statement and the Prospectuses, together with the related schedules and
notes, present fairly the financial position of SDC at the dates indicated
and the statements of operations, shareholders' equity and cash flows of
SDC for the periods specified; EXCEPT AS OTHERWISE STATED IN THE
REGISTRATION STATEMENT, said financial statements have been prepared in
conformity with GAAP applied on a consistent basis throughout the periods
involved.
(C) The financial statements of SDC II included in the Registration
Statement and the Prospectuses, together with the related schedules and
notes, present fairly the financial position of SDC II at the date
indicated; except as otherwise stated in the Registration Statement, said
financial statements have been prepared in conformity with GAAP.
(D) The pro forma financial statements and the related notes thereto
included in the Registration Statement and the Prospectuses or incorporated
therein by reference present fairly in accordance with GAAP the information
shown therein, have been prepared in accordance with the Commission's rules
and guidelines with respect to pro forma financial statements and have been
properly compiled on the bases described therein, and the assumptions used
in the preparation thereof are reasonable and the adjustments used therein
are appropriate to give effect to the transactions and circumstances
referred to therein.
(v) NO MATERIAL ADVERSE CHANGE IN BUSINESS. Since the
respective dates as of which information is given in the Registration
Statement and the Prospectuses, except as otherwise stated therein, (A)
there has been no material adverse change in the condition, financial or
otherwise, or in the earnings, business affairs or business prospects of
Dura and the Subsidiaries (as defined below), considered as one enterprise,
whether or not arising in the ordinary course of business (a "Dura Material
Adverse Effect"), (B) there has been no material adverse change in the
condition, financial or otherwise, or in the earnings, business affairs or
business prospects of SDC, whether or not arising in the ordinary course of
business (an "SDC Material Adverse Effect"), (C) there has been no material
adverse change in the condition, financial or otherwise, or in the
earnings, business affairs or business prospects of SDC II, whether or not
arising in the ordinary course of business (an "SDC II Material Adverse
Effect"), (D) there have been no transactions entered into by Dura or any
Subsidiary, SDC or SDC II, other than in the ordinary course of business,
which are material with respect to Dura and the Subsidiaries, considered as
one enterprise, SDC or SDC II, respectively, and (D) there has been no
dividend or distribution of any kind declared, paid or made by each of SDC,
SDC II or Dura, on any class of its respective capital stock. As used in
this Agreement on the date hereof, a "Material Adverse Effect" shall mean
both a Dura Material Adverse Effect and an SDC Material Adverse Effect.
7
<PAGE>
(vi) GOOD STANDING OF THE COMPANIES. (A) Dura has been duly
organized and is validly existing as a corporation in good standing under
the laws of the State of Delaware and has corporate power and authority to
own, lease and operate its properties and to conduct its business as
described in the Prospectuses and to enter into and perform its obligations
under this Agreement; and Dura is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction in
which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure to
so qualify or to be in good standing would not result in a Dura Material
Adverse Effect.
(B) SDC II has been duly organized and is validly existing as a
corporation in good standing under the laws of the State of Delaware and
has corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Prospectuses and to enter
into and perform its obligations under this Agreement; and SDC II is duly
qualified as a foreign corporation to transact business and is in good
standing in each jurisdiction in which such qualification is required,
whether by reason of the ownership or leasing of property or the conduct of
business, except where the failure to so qualify or to be in good standing
would not result in an SDC II Material Adverse Effect.
(vii) GOOD STANDING OF SUBSIDIARIES. Dura Delivery Systems,
Inc., a Delaware corporation ("DDSI"), Health Script Pharmacy Services,
Inc., a Colorado corporation ("Health Script"), Healthco Solutions, Inc., a
Colorado corporation ("Healthco"), HS Wholesaler, Inc., a Colorado
corporation ("HS Wholesaler"), Scandi Acquisition Corp., a Delaware
corporation ("Scandi"), DCI, Ltd., a corporation organized under the laws
of the Cayman Islands ("DCI"), Dura (Bermuda) Trading Company Ltd., a
corporation organized under the laws of Bermuda ("Dura (Bermuda)"), Dura
(Barbados) Ltd., a corporation organized under the laws of Barbados ("Dura
(Barbados)"), Dura (Barbados) Holding Company Ltd., a corporation organized
under the laws of Barbados ("Dura (Barbados) Holding"), Dura USA Holdings,
Inc., a Delaware corporation ("Dura USA") and SDC Acquisition Corp., a
Delaware corporation ("SDC Acquisition") are the only subsidiaries of Dura
(DDSI, Health Script, Healthco, HS Wholesaler, Scandi, DCI, Dura (Bermuda),
Dura (Barbados), Dura (Barbados) Holding, Dura USA, SDC Acquisition and,
unless otherwise indicated, SDC, are hereinafter referred to as the
"Subsidiaries"). Except for the Subsidiaries, neither Dura nor any
Subsidiary owns any shares of stock or any other equity securities of any
corporation or has any equity interests in any firm, partnership,
association or other entity other than 775,193 shares of Common Stock of
Trega Biosciences, Inc. and 754,799 shares of Common Stock of Cosmederm
Technologies, Inc., each held by Dura. Each Subsidiary has been duly
organized and is validly existing as a corporation in good standing under
the laws of the jurisdiction of its incorporation, has corporate power and
authority to own, lease and operate its properties and conduct its business
as described in the Prospectuses and is duly qualified as a foreign
corporation to transact business and is in good standing in each
jurisdiction
8
<PAGE>
in which such qualification is required, whether by reason of the ownership
or leasing of property or the conduct of business, except where the failure
so to qualify or to be in good standing would not result in a Material
Adverse Effect; all of the issued and outstanding capital stock of each
Subsidiary has been duly authorized and validly issued, is fully paid and
non-assessable and (other than with respect to SDC) is owned solely by Dura
or another Subsidiary free and clear of any security interest, mortgage,
pledge, lien, encumbrance, claim or equity; none of the outstanding shares
of capital stock of any Subsidiary was issued in violation of the
preemptive or similar rights of any securityholder of such Subsidiary
arising by operation of law, under the charter or by-laws of such
Subsidiary or under any agreement to which Dura or such Subsidiary is a
party.
(B) Upon the consummation of the SDC Purchase, all of the outstanding
shares of capital stock of SDC will be owned by Dura free and clear of any
security interest, mortgage, pledge, lien, encumbrance, claim or equity.
(viii) CAPITALIZATION. The authorized, issued and outstanding
capital stock of each of Dura and SDC II is as set forth in the
Prospectuses under the column "Actual" under the captions "Dura
Capitalization" and "Spiros Corp. II Capitalization", respectively (except,
in the case of Dura, for subsequent issuances, if any, pursuant to
reservations, agreements or employee benefit plans referred to in the
Prospectuses or incorporated by reference therein or pursuant to the
exercise of convertible securities, warrants or options referred to in the
Prospectuses or incorporated by reference therein). The shares of issued
and outstanding capital stock of each of Dura and SDC II have been duly
authorized and validly issued and are fully paid and non-assessable; none
of the outstanding shares of capital stock of Dura or SDC II was issued in
violation of the preemptive or other similar rights of any securityholder
of Dura or SDC II, respectively, arising by operation of law, under the
charter or by-laws of Dura or SDC II, as the case may be, or under any
agreement to which Dura or SDC II is a party. Except as disclosed in the
Prospectuses or incorporated by reference therein, there are no outstanding
options, warrants or other rights calling for the issuance of, and no
commitments, plans or arrangements to issue, any shares of capital stock of
Dura, SDC II or any Subsidiary or any security convertible into or
exchangeable for capital stock of Dura, SDC II or any Subsidiary.
(ix) AUTHORIZATION OF AGREEMENTS. (A) This Agreement and the
U.S. Purchase Agreement have been duly authorized, executed and delivered
by each of Dura and SDC II.
(B) The Warrant Agreement (as hereinafter defined) has been duly
authorized by Dura, and when executed and delivered by Dura and the Warrant
Agent thereunder, will constitute a valid and binding agreement of Dura,
enforceable against Dura in accordance with its terms, except as
enforcement thereof may be limited by bankruptcy,
9
<PAGE>
insolvency (including, without limitation, all laws relating to fraudulent
transfers), reorganization, moratorium or similar laws affecting
enforcement of creditors' rights generally and except as enforcement
thereof is subject to general principles of equity (regardless of whether
enforcement is considered in a proceeding in equity or at law).
(C) Each of the Development Agreement, the Technology Agreement, the
Albuterol and Product Option Agreement, the Manufacturing and Marketing
Agreement and the Services Agreement (each as defined in the Prospectuses,
and collectively referred to herein as the "Transaction Agreements") has
been duly authorized by Dura and SDC II and, in the case of the Technology
Agreement, Dura, SDC II, SDC and DDSI, and when executed and delivered by
Dura and SDC II, and, in the case of the Technology Agreement, Dura, SDC
II, SDC and DDSI, will constitute valid and binding agreements of each of
Dura, SDC II, SDC and DDSI, as the case may be, enforceable against Dura,
SDC II, SDC and DDSI in accordance with their terms, except as the
enforcement thereof may be limited by bankruptcy, insolvency (including,
without limitation, all laws relating to fraudulent transfers),
reorganization, moratorium or similar laws affecting enforcement of
creditors' rights generally and except as enforcement thereof is subject to
general principles of equity (regardless of whether enforcement is
considered in a proceeding in equity or at law).
(x) AUTHORIZATION AND DESCRIPTION OF UNITS. (A) The SDC II
Common Stock to be issued by SDC II as a component of the Units has been
duly authorized for issuance and sale to the Managers pursuant to this
Agreement and to the U.S. Underwriters pursuant to the U.S. Purchase
Agreement, respectively, and, when issued and delivered by SDC II against
payment of the purchase price therefor as provided in this Agreement and
the U.S. Purchase Agreement, respectively, will be validly issued, fully
paid and non-assessable; the SDC II Common Stock conforms in all material
respects to the statements relating thereto contained in the Prospectuses
and such description conforms to the rights set forth in the instruments
defining the same; no holder of SDC II Common Stock will be subject to
personal liability by reason of being such a holder; and the issuance of
the SDC II Common Stock is not subject to the preemptive or other similar
rights of any securityholder of SDC II.
(B) The Warrants to be issued as a component of the Units have been
duly authorized by Dura for issuance and sale to the Managers pursuant to
this Agreement and to the U.S. Underwriters pursuant to the U.S. Purchase
Agreement, respectively, and, when duly executed, issued and delivered by
Dura and duly countersigned by the Warrant Agent (as hereinafter defined)
in the manner provided for in the Warrant Agreement (the "Warrant
Agreement") to be entered into between Dura and ChaseMellon Shareholder
Services, as warrant agent (the "Warrant Agent"), and, when issued and
delivered by Dura against payment of the purchase price therefor as
provided in this Agreement and the U.S. Purchase Agreement, respectively,
will constitute valid and binding obligations of Dura, entitled to the
benefits of the Warrant Agreement, and will
10
<PAGE>
be enforceable in accordance with its terms, except as the enforcement
thereof may be limited by bankruptcy, insolvency (including, without
limitation, all laws relating to fraudulent transfers), reorganization,
moratorium or similar laws affecting enforcement of creditors' rights
generally and except as enforcement thereof is subject to general
principles of equity (regardless of whether enforcement is considered in a
proceeding in equity or at law); such Warrants are not subject to the
preemptive rights of any stockholder of Dura.
(C) Dura shall have available such number of shares of Dura Common
Stock deliverable upon exercise of the Warrants as is sufficient to permit
the exercise in full of the Warrants. All shares of Dura Common Stock
issued upon exercise of the Warrants, when issued and paid for in
accordance with the terms of the Warrant Agreement, will be duly
authorized, validly issued, fully paid and nonassessable; shares of Dura
Common Stock are not subject to the preemptive rights of any stockholder of
Dura; and all corporate action required to be taken for such authorization,
issue and sale of the Dura Common Stock will have been validly and
sufficiently taken upon the issuance of the Warrants; such shares of Dura
Common Stock conform in all material respects to the descriptions thereof
contained or incorporated by reference in the Prospectuses and all
corporate action required to be taken for the authorization, issue and sale
of such shares of Dura Common Stock has been validly and sufficiently
taken.
(xi) REGISTRATION OR SIMILAR RIGHTS WAIVED. Except as set forth
in the Prospectuses, there are no persons with registration or other
similar rights to have any securities registered pursuant to the
Registration Statement or otherwise registered by the Companies under the
1933 Act who have not waived such rights.
(xii) ABSENCE OF DEFAULTS AND CONFLICTS. (A) Neither Dura nor
any Subsidiary is in violation of its charter or by-laws or in default in
the performance or observance of any obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, deed of trust,
loan or credit agreement, note, lease or other agreement or instrument to
which Dura or any Subsidiary is a party or by which it or any of them may
be bound, or to which any of the property or assets of Dura or any
Subsidiary is subject (collectively, "Agreements and Instruments") except
for such defaults that would not result in a Material Adverse Effect; and
the execution, delivery and performance of each of this Agreement, the U.S.
Purchase Agreement, the Warrant Agreement and the Transaction Agreements by
Dura, SDC and DDSI, as the case may by, the issuance and delivery of the
Warrants and the issuance of shares of Dura Common Stock upon the exercise
of the Warrants and the consummation by Dura, SDC and DDSI, as the case may
be, of the transactions contemplated in this Agreement, the U.S. Purchase
Agreement, the Warrant Agreement and the Transaction Agreements and in the
Registration Statement (including the issuance and sale of the Warrants as
part of the Units) and compliance by Dura, SDC and DDSI, as the case may
be, with their respective obligations under this Agreement, the U.S.
Purchase Agreement, the Warrant
11
<PAGE>
Agreement and each of the Transaction Agreements to which they are a party
have been duly authorized by all necessary corporate action and do not and
will not, whether with or without the giving of notice or passage of time
or both, conflict with or constitute a breach of, or default or Repayment
Event (as defined below) under, or result in the creation or imposition of
any lien, charge or encumbrance upon any property or assets of Dura or any
Subsidiary pursuant to, the Agreements and Instruments (except for such
conflicts, breaches or defaults or liens, charges or encumbrances that
would not result in a Material Adverse Effect), nor will such action result
in any violation of the provisions of the charter or by-laws of Dura or any
Subsidiary or any applicable material law, statute, rule, regulation,
judgment, order, writ or decree of any government, government
instrumentality or court, domestic or foreign, having jurisdiction over
Dura or any Subsidiary or any of their assets, properties or operations.
As used herein, a "Repayment Event" means any event or condition which
gives the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder's behalf) the right to require the
repurchase, redemption or repayment of all or a portion of such
indebtedness by Dura or any Subsidiary.
(B) SDC II is not in violation of its charter or by-laws or in
default in the performance or observance of any obligation, agreement,
covenant or condition contained in any contract, indenture, mortgage, deed
of trust, loan or credit agreement, note, lease or other agreement or
instrument to which SDC II is a party or by which it may be bound, or to
which any of the property or assets of SDC II is subject (collectively,
"SDC II Agreements and Instruments") except for such defaults that would
not result in an SDC II Material Adverse Effect; and the execution,
delivery and performance of each of this Agreement, the U.S. Purchase
Agreement and the Transaction Agreements by SDC II and the consummation by
SDC II of the transactions contemplated herein, therein and in the
Registration Statement (including the issuance and sale of the SDC II
Common Stock as part of the Units and the use of the proceeds from the sale
of the Units as described in the Prospectuses under the caption "Use of
Proceeds") and compliance by SDC II with its obligations under this
Agreement, the U.S. Purchase Agreement and each of the Transaction
Agreements have been duly authorized by all necessary corporate action and
do not and will not, whether with or without the giving of notice or
passage of time or both, conflict with or constitute a breach of, or
default or SDC II Repayment Event (as defined below) under, or result in
the creation or imposition of any lien, charge or encumbrance upon any
property or assets of SDC II pursuant to, the SDC II Agreements and
Instruments (except for such conflicts, breaches or defaults or liens,
charges or encumbrances that would not result in an SDC II Material Adverse
Effect), nor will such action result in any violation of the provisions of
the charter or by-laws of SDC II or any applicable material law, statute,
rule, regulation, judgment, order, writ or decree of any government,
government instrumentality or court, domestic or foreign, having
jurisdiction over SDC II or any of its assets, properties or operations.
As used herein, an "SDC II Repayment Event" means any event or condition
which gives the holder of any note, debenture or other evidence of
indebtedness (or any person acting on
12
<PAGE>
such holder's behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by SDC II.
(xiii) COMPLIANCE WITH LAWS. Except as set forth in the
Prospectuses, Dura and the Subsidiaries and SDC II are in compliance in all
material respects with all applicable laws, statutes, ordinances, rules or
regulations, the enforcement of which, individually or in the aggregate,
would be reasonably expected to have a Material Adverse Effect or an SDC II
Material Adverse Effect, as the case may be.
(xiv) ABSENCE OF LABOR DISPUTE. No labor dispute with the
employees of Dura or any Subsidiary exists or, to the knowledge of Dura, is
imminent, and Dura is not aware of any existing or imminent labor
disturbance by the employees of any of its or any Subsidiary's principal
suppliers, manufacturers, customers or contractors, which, in either case,
may reasonably be expected to result in a Dura Material Adverse Effect or
an SDC II Material Adverse Effect.
(xv) ABSENCE OF PROCEEDINGS. There is no action, suit,
proceeding, inquiry or investigation (except applications for regulatory
approval for marketing of pharmaceutical products) before or brought by any
court or governmental agency or body, domestic or foreign, now pending or,
to the knowledge of either Dura or SDC II, threatened against or affecting
Dura or any Subsidiary or SDC II that is required to be disclosed in the
Registration Statement or that might reasonably be expected to have a
Material Adverse Effect, or an SDC II Material Adverse Effect, or which
might reasonably be expected to materially and adversely affect the
properties or assets of either Dura and the Subsidiaries (other than SDC),
considered as one enterprise, or SDC II or SDC, as the case may be, or the
consummation of the transactions contemplated in this Agreement, the U.S.
Purchase Agreement, the Warrant Agreement and the Transaction Agreements or
the performance by Dura or SDC II of its obligations hereunder or
thereunder; the aggregate of all pending legal or governmental proceedings
to which Dura or any Subsidiary or SDC II, as the case may be, is a party
or which affect any of their respective property or assets is subject which
are not described in the Registration Statement, including ordinary routine
litigation incidental to its business, could not reasonably be expected to
result in a Material Adverse Effect or an SDC II Material Adverse Effect,
as the case may be.
(xvi) ACCURACY OF EXHIBITS. There are no contracts or documents
which are required to be described in the Registration Statement, the
Prospectuses or the documents incorporated by reference therein or to be
filed as exhibits thereto which have not been described and filed as
required.
(xvii) POSSESSION OF INTELLECTUAL PROPERTY. (A) Except as set
forth in the Prospectuses, each of Dura and the Subsidiaries owns or
possesses adequate licenses or other rights to use the patents, patent
rights, licenses, inventions, copyrights, know how
13
<PAGE>
(including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), which are
necessary for the operation of their businesses as presently conducted
except where the failure to so own or have the right to use would not have
a Material Adverse Effect. Except as disclosed in the Prospectuses,
nothing has come to the attention of Dura or the Subsidiaries to the effect
that (1) any product, process, method, substance, part or other material
presently contemplated to be sold by or employed by Dura or any of the
Subsidiaries in connection with Dura's or such Subsidiary's business may
infringe any patent, trademark, service mark, trade name, copyright,
license or other right owned by others, (2) there is pending or threatened
any claim or litigation against or affecting Dura and the Subsidiaries
contesting their right to sell or use any such product, process, method,
substance, part or other material or (3) there is, or there is pending, any
patent, invention, device, application or any applicable statute, law,
rule, regulation, standard or code, in the case of each of clause (1), (2)
or (3) above, which could have Material Adverse Effect.
(B) SDC II will, to the extent provided for in the Technology
Agreement, have the right to use all patents, patent rights, licenses,
inventions, copyrights, know how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information,
systems or procedures) owned or controlled by Dura or the Subsidiaries,
which are necessary for the operation of its business as described in the
Prospectuses. SDC II has not received any notice of proceedings relating
to revocation or modification of any such licenses, permits, certificates,
consents, orders, approvals or authorizations which singularly or in the
aggregate, if the subject of an unfavorable ruling or finding, could have a
SDC II Material Adverse Effect.
(xviii) ABSENCE OF FURTHER REQUIREMENTS. (A) No filing with, or
authorization, approval, consent, license, order, registration,
qualification or decree of, any court or governmental authority or agency
is necessary or required for the performance by the Companies of their
obligations under this Agreement, the U.S. Purchase Agreement, the Warrant
Agreement and the Transaction Agreements, in connection with the offering,
issuance, sale and delivery of the shares of SDC II Common Stock, the
Warrants or the shares of Dura Common Stock deliverable upon exercise of
the Warrants or the consummation of the transactions contemplated by this
Agreement, the U.S. Purchase Agreement, the Warrant Agreement and the
Transaction Agreements, except such as have been already obtained or as may
be required under the 1933 Act or the 1933 Act Regulations and foreign or
state securities or blue sky laws.
(B) No filing with, or authorization, approval, consent, license,
order, registration, qualification or decree of, any court or governmental
authority or agency is necessary or required for the consummation by SDC
and DDSI of the transactions contemplated by this Agreement, except such as
have already been obtained.
14
<PAGE>
(xix) POSSESSION OF LICENSES AND PERMITS. Dura and the
Subsidiaries and SDC II possess such permits, licenses, approvals, consents
and other authorizations (collectively, "Governmental Licenses") issued by
the appropriate federal, state, local or foreign regulatory agencies or
bodies material to the conduct of the business now operated by Dura, the
Subsidiaries and SDC II, respectively; Dura and the Subsidiaries and SDC II
are in compliance with the terms and conditions of all such Governmental
Licenses, except where the failure so to comply would not, singly or in the
aggregate, have a Material Adverse Effect or a SDC II Material Adverse
Effect, as the case may be; all of the Governmental Licenses are valid and
in full force and effect, except when the invalidity of such Governmental
Licenses or the failure of such Governmental Licenses to be in full force
and effect would not have a Material Adverse Effect or a SDC II Material
Adverse Effect, as the case may be; and neither Dura nor any Subsidiary nor
SDC II has received any notice of proceedings relating to the revocation or
modification of any such Governmental Licenses which, singly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding,
would result in a Material Adverse Effect or an SDC II Material Adverse
Effect; provided, however, that no FDA approval has been received with
respect to products that Dura, the Subsidiaries or SDC II currently are not
permitted to market.
(xx) TITLE TO PROPERTY. Dura and the Subsidiaries have good and
marketable title to all material properties and assets owned by Dura and
the Subsidiaries, in each case, free and clear of all mortgages, pledges,
liens, security interests, claims, restrictions or encumbrances of any kind
except such as (a) are described or incorporated by reference in the
Prospectuses or (b) do not, singly or in the aggregate, materially affect
the value of such property and do not interfere with the use made and
proposed to be made of such property by Dura or the affected Subsidiaries,
as the case may be; and all properties held under lease by Dura or any
Subsidiary are held under valid, subsisting and enforceable leases.
(B) SDC II has good and marketable title to all material properties
and assets described in the Prospectuses as owned by it, free and clear of
all mortgages, pledges, liens, security interests, claims, restrictions or
encumbrances of any kind except such as (a) are described in the
Prospectuses or (b) do not, singly or in the aggregate, materially affect
the value of such property and do not interfere with the use made and
proposed to be made of such property by SDC II.
(xxi) COMPLIANCE WITH CUBA ACT. Dura has complied with, and is
and will be in compliance with, the provisions of that certain Florida act
relating to disclosure of doing business with Cuba, codified as Section
517.075 of the Florida statutes, and the rules and regulations thereunder
(collectively, the "Cuba Act") or is exempt therefrom.
(xxii) INVESTMENT COMPANY ACT. Neither of the Companies is and,
upon the issuance and sale of the Units as herein contemplated and the
application of the net
15
<PAGE>
proceeds therefrom as described in the Prospectuses, will not be an
"investment company" or an entity "controlled" by an "investment company"
as such terms are defined in the Investment Company Act of 1940, as amended
(the "1940 Act").
(xxiii) ENVIRONMENTAL LAWS. Except as described in the Registration
Statement and except as would not, singly or in the aggregate, result in a
Dura Material Adverse Effect, (A) neither Dura nor any Subsidiary is in
material violation of any federal, state, local or foreign law, rule,
regulation, ordinance or any judicial or administrative interpretation
thereof, including any judicial or administrative order, consent, decree or
judgment, relating to pollution or protection of human health, the
environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including,
without limitation, laws and regulations relating to the release or
threatened release of chemicals, pollutants, contaminants, wastes, toxic
substances, hazardous substances, petroleum or petroleum products
(collectively, "Hazardous Materials") or to the manufacture, processing,
distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials (collectively, "Environmental Laws"), (B) Dura and the
Subsidiaries have all permits, authorizations and approvals required under
any applicable Environmental Laws and are each in compliance with their
requirements, (C) there are no pending or, to the best knowledge of Dura,
threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against Dura
or any of the Subsidiaries and (iv) to the best knowledge of Dura, there
are no events or circumstances that could form the basis of an order for
clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting Dura or any
Subsidiary relating to Hazardous Materials or any Environmental Laws.
(xxiv) TAXES. Dura and the Subsidiaries have filed all federal,
state, local and foreign tax returns that are required to be filed or have
duly requested extensions thereof and have paid all taxes required to be
paid by any of them and any related assessments, fines or penalties, except
for any such tax, assessment, fine or penalty that is being contested in
good faith and by appropriate proceedings; and adequate charges, accruals
and reserves have been provided for in the financial statements referred to
in Section 1(a)(iv)(A) above in respect of all federal, state, local and
foreign taxes for all periods as to which the tax liability of Dura or any
Subsidiary has not been finally determined or remains open to examination
by applicable taxing authorities.
(xxv) INSURANCE. Dura and the Subsidiaries carry or are entitled
to the benefits of insurance in such amounts and covering such risks as is
generally maintained by companies of established repute engaged in the same
or similar business and all such insurance is in full force and effect.
16
<PAGE>
(xxvi) ACCOUNTING CONTROLS. Dura and the Subsidiaries maintain a
system of internal accounting controls sufficient to provide reasonable
assurance that (A) transactions are executed in accordance with
management's general and specific authorizations; (B) transactions are
recorded as necessary to permit preparations of financial statements in
conformity with GAAP and to maintain accountability for assets; (C) access
to assets is permitted only in accordance with management's general or
specific authorizations; and (D) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.
(xxvii) LOCK-UP AGREEMENTS. The Companies have obtained and
delivered to the Managers the agreements, in the form of Exhibit D hereto,
of the persons and entities named in Schedule C annexed hereto to the
effect that each such person will not, for a period of 90 days from the
date of this Agreement and except as otherwise provided in their respective
agreement, without the prior written consent of Merrill Lynch, directly or
indirectly, offer to sell, grant any option for the sale of, or otherwise
dispose of any shares of Dura Common Stock or any securities convertible
into or exercisable for shares of Dura Common Stock owned by such person or
entity or with respect to which such person has the power of disposition.
(xxviii) AFFILIATE TRANSACTIONS. No relationship, direct or
indirect, exists between or among any of Dura or any affiliate of Dura, on
the one hand, and any director, officer, shareholder, customer or supplier
of any of them, on the other hand, which is required by the 1933 Act or by
the 1933 Act Regulations to be described in the Registration Statement or
the Prospectuses and which is not so described or is not described as
required or is not incorporated by reference therein.
(xxix) DISTRIBUTION OF PROSPECTUSES. The Companies have not
distributed and, prior to the later to occur of (A) Closing Time and (B)
completion of the distribution of the Units, will not distribute any
prospectus (as such term is defined in the 1933 Act and the 1933 Act
Regulations) in connection with the offering and sale of the Units other
than the Registration Statement, any preliminary prospectus, the
Prospectuses or other materials, if any, permitted by the 1933 Act or by
the 1933 Act Regulations and approved by the Lead Manager.
(b) OFFICER'S CERTIFICATES. Any certificate signed by any officer of Dura
or any Subsidiary or SDC II, delivered to the Global Coordinator, the Lead
Manager or to counsel for the Managers shall be deemed a representation and
warranty by Dura or SDC II, as the case may be, to each Manager as to the
matters covered thereby.
17
<PAGE>
SECTION 2. SALE AND DELIVERY TO MANAGERS; CLOSING.
(a) INITIAL INTERNATIONAL UNITS. On the basis of the representations and
warranties herein contained and subject to the terms and conditions herein set
forth, the Companies, severally and not jointly, agree to sell to each Manager,
and each Manager, severally and not jointly, agrees to purchase from the
Companies, at the price per Unit set forth in Schedule B, the number of Initial
International Units set forth in Schedule A opposite the name of such Manager,
plus any additional number of Initial International Units that such Manager may
become obligated to purchase pursuant to the provisions of Section 10 hereof.
(b) INTERNATIONAL OPTION UNITS. In addition, on the basis of the
representations and warranties herein contained and subject to the terms and
conditions herein set forth, the Companies, acting severally and not jointly,
hereby grant an option to the Managers, severally and not jointly, to purchase
up to an additional 165,000 Units at the same price per Unit set forth in
Schedule B for the Initial International Units. The option hereby granted will
expire 30 days after the date hereof and may be exercised in whole or in part
from time to time only for the purpose of covering over-allotments which may be
made in connection with the offering and distribution of the Initial
International Units upon notice by the Global Coordinator to the Companies
setting forth the number of International Option Units as to which the several
Managers are then exercising the option and the time and date of payment and
delivery for such International Option Units. Any such time and date of
delivery (a "Date of Delivery") shall be determined by the Global Coordinator,
but shall not be later than seven full business days after the exercise of said
option, nor in any event prior to the Closing Time, as hereinafter defined. If
the option is exercised as to all or any portion of the International Option
Units, each of the Managers, acting severally and not jointly, will purchase
that proportion of the total number of International Option Units then being
purchased which the number of Initial International Units set forth in
Schedule A opposite the name of such Manager bears to the total number of
Initial International Units, subject in each case to such adjustments as the
Global Coordinator in its discretion shall make to eliminate any sales or
purchases of fractional Units.
(c) PAYMENT. Payment of the purchase price for, and delivery of
certificates for, the Initial U.S. Units shall be made at the offices of
Brobeck, Phleger & Harrison LLP, 550 West C Street, Suite 1300, San Diego,
California 92101, or at such other place as shall be agreed upon by the Global
Coordinator and the Companies, at 7:00 A.M. (California time) on the third
(fourth, if the pricing occurs after 4:30 P.M. (Eastern time) on any given day)
business day after the date hereof (unless postponed in accordance with the
provisions of Section 10), or such other time not later than ten business days
after such date as shall be agreed upon by the Global Coordinator and the
Companies (such time and date of payment and delivery being herein called
"Closing Time").
In addition, in the event that any or all of the International Option Units
are purchased by the Managers, payment of the purchase price for, and delivery
of certificates for, such International Option Units shall be made at the
above-mentioned offices, or at such other place
18
<PAGE>
as shall be agreed upon by the Global Coordinator and the Companies, on each
Date of Delivery as specified in the notice from the Global Coordinator to the
Companies.
Payment shall be made to the Companies by wire transfer of immediately
available funds to a bank account designated by the Companies, against delivery
to the Lead Manager of certificates for the respective accounts of the Managers
of certificates for the International Units to be purchased by them. It is
understood that each Manager has authorized the Lead Manager, for its account,
to accept delivery of, receipt for, and make payment of the purchase price for,
the Initial International Units and the International Option Units, if any, that
it has agreed to purchase. Merrill Lynch, individually and not as
representative of the Managers, may (but shall not be obligated to) make payment
of the purchase price for the Initial International Units or the International
Option Units, if any, to be purchased by any Manager whose funds have not been
received by the Closing Time or the relevant Date of Delivery, as the case may
be, but such payment shall not relieve such Manager from its obligations
hereunder.
(d) DENOMINATIONS; REGISTRATION. Certificates for the Initial
International Units and the International Option Units, if any, shall be in such
denominations and registered in such names as the Lead Manager may request in
writing at least one full business day before the Closing Time or the relevant
Date of Delivery, as the case may be. The certificates for the Initial
International Units and the International Option Units, if any, will be made
available for examination and packaging by the Managers in The City of New York
not later than 10:00 A.M. (Eastern time) on the business day prior to the
Closing Time or the relevant Date of Delivery, as the case may be.
SECTION 3. COVENANTS OF THE COMPANIES. Each of the Companies covenants
with each Manager as follows:
(a) COMPLIANCE WITH SECURITIES REGULATIONS AND COMMISSION REQUESTS.
The Companies, subject to Section 3(b), will comply with the requirements
of Rule 430A or Rule 434, as applicable, and will notify the Global
Coordinator immediately, and confirm the notice in writing, (i) when any
post-effective amendment to the Registration Statement shall become
effective, or any supplement to the Prospectuses or any amended
Prospectuses shall have been filed, (ii) of the receipt of any comments
from the Commission, (iii) of any request by the Commission for any
amendment to the Registration Statement or any amendment or supplement to
the Prospectuses or for additional information and (iv) of the issuance by
the Commission of any stop order suspending the effectiveness of the
Registration Statement or of any order preventing or suspending the use of
any preliminary prospectus, or of the suspension of the qualification of
the Units for offering or sale in any jurisdiction, or of the initiation or
threatening of any proceedings for any of such purposes. The Companies
will promptly effect the filings necessary pursuant to Rule 424(b) and will
take such steps as they deem necessary to ascertain promptly whether the
form of prospectus transmitted for filing under Rule 424(b) was received
for filing by the Commission and, in the event that it
19
<PAGE>
was not, will promptly file such prospectus. The Companies will make every
reasonable effort to prevent the issuance of any stop order and, if any
stop order is issued, to obtain the lifting thereof at the earliest
possible moment.
(b) FILING OF AMENDMENTS. The Companies will give the Global
Coordinator notice of their intention to file or prepare any amendment to
the Registration Statement (including any filing under Rule 462(b)), any
Term Sheet or any amendment, supplement or revision to either the
prospectus included in the Registration Statement at the time it became
effective or to the Prospectuses, whether pursuant to the 1933 Act, the
1934 Act or otherwise, will furnish the Global Coordinator with copies of
any such documents a reasonable amount of time prior to such proposed
filing or use, as the case may be, and will not file or use any such
document to which the Global Coordinator or counsel for the Managers shall
object.
(c) DELIVERY OF REGISTRATION STATEMENT. The Companies have furnished
or will deliver to the Lead Manager and counsel for the Managers, without
charge, signed copies of the Registration Statement as originally filed and
of each amendment thereto (including exhibits filed therewith or
incorporated by reference therein and documents incorporated or deemed to
be incorporated by reference therein) and signed copies of all consents and
certificates of experts, and will also deliver to the Lead Manager, without
charge, a conformed copy of the Registration Statement as originally filed
and of each amendment thereto (without exhibits) for each of the Managers.
The copies of the Registration Statement and each amendment thereto
furnished to the Managers will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.
(d) DELIVERY OF PROSPECTUSES. The Companies have delivered to each
Manager, without charge, as many copies of each preliminary prospectus as
such Manager reasonably requested, and the Companies hereby consent to the
use of such copies for purposes permitted by the 1933 Act. The Companies
will furnish to each Manager, without charge, during the period when the
International Prospectus is required to be delivered under the 1933 Act or
the 1934 Act, such number of copies of the International Prospectus (as
amended or supplemented) as such Manager may reasonably request. The
International Prospectus and any amendments or supplements thereto
furnished to the Managers will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR,
except to the extent permitted by Regulation S-T.
(e) CONTINUED COMPLIANCE WITH SECURITIES LAWS. The Companies will
comply with the 1933 Act and the 1933 Act Regulations and the 1934 Act and
the 1934 Act Regulations so as to permit the completion of the distribution
of the Units as contemplated in this Agreement, the U.S. Purchase Agreement
and in the Prospectuses. If at any time when a prospectus is required by
the 1933 Act to be delivered in
20
<PAGE>
connection with sales of the Units, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel
for the Managers or for the Companies, to amend the Registration Statement
or amend or supplement any Prospectus in order that the Prospectuses will
not include any untrue statements of a material fact or omit to state a
material fact necessary in order to make the statements therein not
misleading in the light of the circumstances existing at the time any such
Prospectus is delivered to a purchaser, or if it shall be necessary, in the
opinion of such counsel, at any such time to amend the Registration
Statement or amend or supplement any Prospectus in order to comply with the
requirements of the 1933 Act or the 1933 Act Regulations, the Companies
will promptly prepare and file with the Commission, subject to Section
3(b), such amendment or supplement as may be necessary to correct such
statement or omission or to make the Registration Statement or the
Prospectuses comply with such requirements, and the Companies will furnish
to the Managers such number of copies of such amendment or supplement as
the Managers may reasonably request.
(f) RULE 158. The Companies will timely file such reports pursuant
to the 1934 Act as are necessary in order to make generally available to
their securityholders as soon as practicable an earnings statement for the
purposes of, and to provide the benefits contemplated by, the last
paragraph of Section 11(a) of the 1933 Act.
(g) USE OF PROCEEDS. SDC II will use the net proceeds received by it
from the sale of the Units in the manner specified in the Prospectuses
under "Use of Proceeds."
(h) LISTING. The Companies will use their best efforts to effect and
maintain the quotation of the Units on the Nasdaq National Market and will
file with the Nasdaq National Market all documents and notices required by
the Nasdaq National Market of companies that have securities that are
traded in the over-the-counter market and quotations for which are reported
by the Nasdaq National Market.
(i) RESTRICTION ON SALE OF DURA COMMON STOCK. During a period of 90
days from the date of the Prospectuses, Dura will not, without the prior
written consent of the Global Coordinator, (i) directly or indirectly,
offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right
or warrant to purchase or otherwise transfer or dispose of any shares of
Dura Common Stock or any securities convertible into or exercisable or
exchangeable for shares of Dura Common Stock or file any registration
statement under the 1933 Act with respect to any of the foregoing or
(ii) enter into any swap or any other agreement or any transaction that
transfers, in whole or in part, directly or indirectly, the economic
consequence of ownership of Dura Common Stock whether any such swap or
transaction described in clause (i) or (ii) above is to be settled by
delivery of shares of Dura Common Stock or such other securities, in cash
or otherwise. The foregoing sentence shall not apply to (A) the Units to
be sold hereunder or under the U.S. Purchase Agreement, (B) any shares of
Dura Common Stock issued by Dura upon the exercise of
21
<PAGE>
an option or warrant or the conversion of a security outstanding on the
date hereof and referred to in, or incorporated by reference into, the
Prospectuses, (C) any shares of Dura Common Stock issued or options to
purchase Dura Common Stock granted pursuant to existing employee benefit
plans of Dura referred to in, or incorporated by reference into, the
Prospectuses or (D) any shares of Dura Common Stock issued to stockholders
of SDC in connection with the acquisition of all of the outstanding stock
of SDC pursuant to a registration statement on Form S-3 filed with the
Commission on October 15, 1997, as amended (No. 333-37955).
(j) REPORTING REQUIREMENTS. The Companies, during the period when the
Prospectuses are required to be delivered under the 1933 Act or the 1934
Act, will file all documents required to be filed with the Commission
pursuant to the 1934 Act within the time periods required by the 1934 Act
and the 1934 Act Regulations.
(k) LOCK-UP AGREEMENTS. SDC II will cause each person that becomes a
director or officer within 90 days of the date hereof to deliver an
agreement substantially in the form of Exhibit D hereto.
SECTION 4. PAYMENT OF EXPENSES.
(a) EXPENSES. SDC II will pay or cause to be paid all expenses incident
to the performance of the Companies' obligations under this Agreement, including
(i) the preparation, printing and filing of the Registration Statement
(including financial statements and exhibits) as originally filed and of each
amendment thereto, (ii) the preparation, printing and delivery to the
Underwriters of this Agreement, any Agreement among Underwriters, the Warrant
Agreement and such other documents as may be required in connection with the
offering, purchase, sale, issuance or delivery of the Units, (iii) the
preparation, issuance and delivery of the certificates for the Units to the
Underwriters, including any stock or other transfer taxes and any stamp or other
duties payable upon the sale, issuance or delivery of the Units to the
Underwriters and the transfer of the Units between the Managers and the U.S.
Underwriters, (iv) the fees and disbursements of the Companies' counsel,
accountants and other advisors, (v) the fees and disbursements of SDC's counsel,
accountants and other advisors, (vi) the printing and delivery to the
Underwriters of copies of each preliminary prospectus, any Term Sheets and of
the Prospectuses and any amendments or supplements thereto, (vii) the
preparation, printing and delivery to the Underwriters of copies of the Blue Sky
Survey and any supplement thereto, (viii) the fees and expenses of any transfer
agent or registrar for the Units, (ix) all charges of the Warrant Agent, (x) the
filing fees incident to, and the reasonable fees and disbursements of counsel to
the Underwriters in connection with, the review by the National Association of
Securities Dealers, Inc. (the "NASD") of the terms of the sale of the Units, and
(xi) the fees and expenses incurred in connection with the listing of the Units,
the SDC II Common Stock and the Warrants on the Nasdaq National Market; PROVIDED
that the Underwriters will reimburse SDC II for up to $1,140,000 of expenses
incurred in connection with the Offerings.
22
<PAGE>
(b) TERMINATION OF AGREEMENT. If this Agreement is terminated by the Lead
Manager in accordance with the provisions of Section 5, Section 9(a)(i) or
Section 11, the Companies shall reimburse the Managers for all of their
out-of-pocket expenses, including the reasonable fees and disbursements of
counsel for the Managers.
SECTION 5. CONDITIONS OF MANAGERS' OBLIGATIONS. The obligations of the
several Managers hereunder are subject to the accuracy of the representations
and warranties of the Companies contained in Section 1 hereof or in certificates
of any officer of the Companies or any Subsidiary delivered pursuant to the
provisions hereof, to the performance by the Companies of their covenants and
other obligations hereunder, and to the following further conditions:
(a) EFFECTIVENESS OF REGISTRATION STATEMENT. The Registration
Statement, including any Rule 462(b) Registration Statement has become
effective and at Closing Time no stop order suspending the effectiveness of
the Registration Statement shall have been issued under the 1933 Act or
proceedings therefor initiated or threatened by the Commission, and any
request on the part of the Commission for additional information shall have
been complied with to the reasonable satisfaction of counsel to the
Managers. A prospectus containing the Rule 430A Information shall have
been filed with the Commission in accordance with Rule 424(b) (or a
post-effective amendment providing such information shall have been filed
and declared effective in accordance with the requirements of Rule 430A)
or, if the Companies have elected to rely upon Rule 434, a Term Sheet shall
have been filed with the Commission in accordance with Rule 424(b).
(b) OPINION OF COUNSEL FOR THE COMPANIES. At Closing Time, the Lead
Manager shall have received the favorable opinion, dated as of Closing
Time, of Brobeck, Phleger & Harrison LLP, counsel for Dura and SDC II, in
form and substance satisfactory to counsel for the Managers, and, to the
extent provided in Exhibit A hereto, Mitchell R. Woodbury, General Counsel
for Dura, together with signed or reproduced copies of such letters for the
other Manager, to the effect set forth in Exhibit A hereto.
(c) OPINION OF PATENT COUNSEL FOR THE COMPANIES. At Closing Time,
the Lead Manager shall have received the favorable opinion, dated as of
Closing Time, of Lyon & Lyon LLP (solely with respect to patents concerning
the Spiros products), patent counsel for the Companies, in form and
substance satisfactory to counsel for the Managers, together with signed or
reproduced copies of such letter for the other Manager, to the effect set
forth in Exhibit B hereto.
(d) OPINION OF REGULATORY COUNSEL FOR THE COMPANIES. At Closing
Time, the Lead Manager shall have received the favorable opinion, dated as
of Closing Time, of Kleinfeld, Kaplan and Becker, regulatory counsel for
the Companies, in form and substance satisfactory to counsel for the
Managers, together with signed or reproduced copies of such letter for the
other Manager, to the effect set forth in Exhibit C hereto.
23
<PAGE>
(e) OPINION OF COUNSEL FOR THE MANAGERS. At Closing Time, the Lead
Manager shall have received the favorable opinion, dated as of Closing
Time, of Shearman & Sterling, counsel for the Managers, together with
signed or reproduced copies of such letter for the other Manager, with
respect to such matters as the Managers may reasonably request. In giving
such opinion, such counsel may rely, as to all matters governed by the laws
of jurisdictions other than the law of the State of New York and the
federal law of the United States upon the opinions of counsel satisfactory
to the Lead Manager. Such counsel may also state that, insofar as such
opinion involves factual matters, they have relied, to the extent they deem
proper, upon certificates of officers of the Companies and the Subsidiaries
and certificates of public officials.
(f) OFFICERS' CERTIFICATE. At Closing Time, there shall not have
been, since the date hereof or since the respective dates as of which
information is given in the Prospectuses, any Dura Material Adverse Effect,
SDC Material Adverse Effect or SDC II Material Adverse Effect, whether or
not arising in the ordinary course of business, and the Lead Manager shall
have received a certificate of the President or a Vice President of Dura
and of the chief financial or chief accounting officer of Dura, and the
President or a Vice President of SDC II and of the chief financial or chief
accounting officer of SDC II, dated as of the Closing Time, to the effect
that (i) there has been no such material adverse effect, (ii) the
representations and warranties of Dura and SDC II set forth in Section 1(a)
hereof are true and correct with the same force and effect as though
expressly made at and as of the Closing Time, (iii) each of Dura and SDC II
shall have complied with all agreements and satisfied all conditions on its
part to be performed or satisfied at or prior to Closing Time, and (iv) no
stop order suspending the effectiveness of the Registration Statement has
been issued and no proceedings for that purpose have been instituted or are
pending or are contemplated by the Commission.
(g) ACCOUNTANTS' COMFORT LETTER. At the time of the execution of
this Agreement, the Lead Manager shall have received from Deloitte & Touche
LLP a letter, dated such date, in form and substance satisfactory to the
Lead Manager, together with signed or reproduced copies of such letter for
the other Manager, containing statements and information of the type
ordinarily included in accountants' "comfort letters" to underwriters with
respect to the financial statements and certain financial information
contained in the Registration Statement and the Prospectuses.
(h) BRING-DOWN COMFORT LETTER. At Closing Time, the Lead Manager
shall have received from Deloitte & Touche LLP a letter, dated as of
Closing Time, to the effect that they reaffirm the statements made in the
letter furnished pursuant to subsection (g) of this Section 5, except that
the specified date referred to shall be a date not more than three business
days prior to Closing Time.
(i) APPROVAL OF LISTING. At Closing Time, the Units shall have been
approved for inclusion in the Nasdaq National Market, subject only to
official notice of issuance.
24
<PAGE>
(j) NO OBJECTION. The NASD has confirmed that it has not raised any
objection with respect to the fairness and reasonableness of the
underwriting terms and arrangements.
(k) LOCK-UP AGREEMENTS. At the date of this Agreement, the Managers
shall have received an agreement substantially in the form of Exhibit D
hereto signed by the persons listed on Schedule C hereto.
(l) PURCHASE OF INITIAL U.S. UNITS. Contemporaneously with the
purchase by the Managers of the Initial International Units under this
Agreement, the U.S. Underwriters shall have purchased the Initial U.S.
Units under the U.S. Purchase Agreement.
(m) CONDITIONS TO PURCHASE OF INTERNATIONAL OPTION UNITS. In the
event that the Managers exercise their option provided in Section 2(b)
hereof to purchase all or any portion of the International Option Units,
the representations and warranties of the Companies contained herein and
the statements in any certificates furnished by the Companies and any
Subsidiary hereunder shall be true and correct as of each Date of Delivery
and, at the relevant Date of Delivery, the Lead Manager shall have
received:
(i) OFFICERS' CERTIFICATE. A certificate, dated such Date
of Delivery, of the President or a Vice President of each of the
Companies and of the chief financial or chief accounting officer of
each of the Companies confirming that the certificate delivered at the
Closing Time pursuant to Section 5(f) remains true and correct as of
such Date of Delivery.
(ii) OPINIONS OF COUNSEL FOR THE COMPANIES. The favorable
opinions of Brobeck, Phleger & Harrison LLP, counsel for the
Companies, Lyon & Lyon, patent counsel for the Companies, and
Kleinfeld, Kaplan and Becker, regulatory counsel for the Companies,
each in form and substance satisfactory to counsel for the Managers,
dated such Date of Delivery, relating to the International Option
Units to be purchased on such Date of Delivery and otherwise to the
same effect as the opinions required by Sections 5(b), 5(c) and 5(d).
(iii) OPINION OF COUNSEL FOR THE MANAGERS. The favorable
opinion of Shearman & Sterling, counsel for the Managers, dated such
Date of Delivery, relating to the International Option Units to be
purchased on such Date of Delivery and otherwise to the same effect as
the opinion required by Section 5(e).
(iv) BRING-DOWN COMFORT LETTER. A letter from Deloitte &
Touche LLP, in form and substance satisfactory to the Lead Manager and
dated such Date of Delivery, substantially in the same form and
substance as the letter furnished to the Lead Manager pursuant to
Section 5(h), except that the "specified date" in the
25
<PAGE>
letter furnished pursuant to this paragraph shall be a date not more
than five days prior to such Date of Delivery.
(n) ADDITIONAL DOCUMENTS. At Closing Time and at each Date of
Delivery, counsel for the Managers shall have been furnished with such
documents and opinions as they may require for the purpose of enabling them
to pass upon the issuance and sale of the Units as herein contemplated, or
in order to evidence the accuracy of any of the representations or
warranties, or the fulfillment of any of the conditions, herein contained;
and all proceedings taken by the Companies in connection with the issuance
and sale of the Units as herein contemplated shall be reasonably
satisfactory in form and substance to the Managers and counsel for the
Managers.
(o) TERMINATION OF AGREEMENT. If any condition specified in this
Section 5 shall not have been fulfilled when and as required to be
fulfilled, this Agreement, or, in the case of any condition to the purchase
of International Option Units, on a Date of Delivery which is after the
Closing Time, the obligations of the Managers to purchase the relevant
International Option Units, may be terminated by the Lead Manager by notice
to the Companies at any time at or prior to Closing Time or such Date of
Delivery, as the case may be, and such termination shall be without
liability of any party to any other party except as provided in Section 4
and except that Sections 1, 6, 7 and 8 shall survive any such termination
and remain in full force and effect.
SECTION 6. INDEMNIFICATION.
(a) INDEMNIFICATION OF MANAGERS. The Companies, jointly and severally,
agree to indemnify and hold harmless each Manager and each person, if any, who
controls any Manager within the meaning of Section 15 of the 1933 Act or Section
20 of the 1934 Act as follows:
(i) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, arising out of any untrue statement or
alleged untrue statement of a material fact contained in the Registration
Statement (or any amendment thereto), including the Rule 430A Information
and the Rule 434 Information, if applicable, or the omission or alleged
omission therefrom of a material fact required to be stated therein or
necessary to make the statements therein not misleading or arising out of
any untrue statement or alleged untrue statement of a material fact
included in any preliminary prospectus or the Prospectuses (or any
amendment or supplement thereto), or the omission or alleged omission
therefrom of a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not
misleading;
(ii) against any and all loss, liability, claim, damage and
expense whatsoever, as incurred, to the extent of the aggregate amount paid
in settlement of any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or of any claim
whatsoever based upon any such untrue statement or
26
<PAGE>
omission, or any such alleged untrue statement or omission; provided that
(subject to Section 6(d) below) any such settlement is effected with the
written consent of the Companies; and
(iii) against any and all expense whatsoever, as incurred
(including the fees and disbursements of counsel chosen by Merrill Lynch),
reasonably incurred in investigating, preparing or defending against any
litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or any claim whatsoever based upon any
such untrue statement or omission, or any such alleged untrue statement or
omission, to the extent that any such expense is not paid under (i) or (ii)
above;
PROVIDED, HOWEVER, that this indemnity agreement shall not apply to any loss,
liability, claim, damage or expense to the extent arising out of any untrue
statement or omission or alleged untrue statement or omission made in reliance
upon and in conformity with written information furnished to the Companies by
any Manager through the Lead Manager expressly for use in the Registration
Statement (or any amendment thereto), including the Rule 430A Information and
the Rule 434 Information, if applicable, or any preliminary prospectus or the
International Prospectus (or any amendment or supplement thereto).
(b) INDEMNIFICATION OF THE COMPANIES, DIRECTORS AND OFFICERS. Each
Manager severally agrees to indemnify and hold harmless the Companies, their
directors, each of their officers who signed the Registration Statement, and
each person, if any, who controls either of the Companies within the meaning of
Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all
loss, liability, claim, damage and expense described in the indemnity contained
in subsection (a) of this Section 6, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions, made
in the Registration Statement (or any amendment thereto), including the Rule
430A Information and the Rule 434 Information, if applicable, or any preliminary
international prospectus or the International Prospectus (or any amendment or
supplement thereto) in reliance upon and in conformity with written information
furnished to the Companies by such Manager through the Lead Manager expressly
for use in the Registration Statement (or any amendment thereto) or such
preliminary prospectus or the International Prospectus (or any amendment or
supplement thereto).
(c) ACTIONS AGAINST PARTIES; NOTIFICATION. Each indemnified party shall
give notice as promptly as reasonably practicable to each indemnifying party of
any action commenced against it in respect of which indemnity may be sought
hereunder, but failure to so notify an indemnifying party shall not relieve such
indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it
from any liability which it may have otherwise than on account of this indemnity
agreement. In the case of parties indemnified pursuant to Section 6(a) above,
counsel to the indemnified parties shall be selected by Merrill Lynch, and, in
the case of parties indemnified pursuant to Section 6(b) above, counsel to the
indemnified parties shall be selected by the Companies. An indemnifying party
may participate at its own expense in the defense of any such action;
27
<PAGE>
PROVIDED, HOWEVER, that counsel to the indemnifying party shall not (except with
the consent of the indemnified party) also be counsel to the indemnified party.
In no event shall the indemnifying parties be liable for fees and expenses of
more than one counsel (in addition to any local counsel) separate from their own
counsel for all indemnified parties in connection with any one action or
separate but similar or related actions in the same jurisdiction arising out of
the same general allegations or circumstances. No indemnifying party shall,
without the prior written consent of the indemnified parties, settle or
compromise or consent to the entry of any judgment with respect to any
litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever in respect of which
indemnification or contribution could be sought under this Section 6 or Section
7 hereof (whether or not the indemnified parties are actual or potential parties
thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party from all liability arising out
of such litigation, investigation, proceeding or claim and (ii) does not include
a statement as to or an admission of fault, culpability or a failure to act by
or on behalf of any indemnified party.
(d) SETTLEMENT WITHOUT CONSENT IF FAILURE TO REIMBURSE. If at any time an
indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel, such indemnifying party
agrees that it shall be liable for any settlement of the nature contemplated by
Section 6(a) effected without its written consent if (i) such settlement is
entered into more than 45 days after receipt by such indemnifying party of the
aforesaid request, (ii) such indemnifying party shall have received notice of
the terms of such settlement at least 30 days prior to such settlement being
entered into and (iii) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such
settlement.
SECTION 7. CONTRIBUTION. If the indemnification provided for in
Section 6 hereof is for any reason unavailable to or insufficient to hold
harmless an indemnified party in respect of any losses, liabilities, claims,
damages or expenses referred to therein, then each indemnifying party shall
contribute to the aggregate amount of such losses, liabilities, claims, damages
and expenses incurred by such indemnified party, as incurred, (i) in such
proportion as is appropriate to reflect the relative benefits received by the
Companies on the one hand and the Managers on the other hand from the offering
of the Units pursuant to this Agreement or (ii) if the allocation provided by
clause (i) is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i)
above but also the relative fault of the Companies on the one hand and of the
Managers on the other hand in connection with the statements or omissions that
resulted in such losses, liabilities, claims, damages or expenses, as well as
any other relevant equitable considerations.
The relative benefits received by the Companies on the one hand and the
Managers on the other hand in connection with the offering of the Units pursuant
to this Agreement shall be deemed to be in the same respective proportions as
the total net proceeds from the offering of the Units pursuant to this Agreement
(before deducting expenses) received by the Companies and
28
<PAGE>
the total underwriting discount received by the Managers, in each case as set
forth on the cover of the International Prospectus, or, if Rule 434 is used, the
corresponding location on the Term Sheet, bear to the aggregate initial public
offering price of the Units as set forth on such cover.
The relative fault of the Companies on the one hand and the Managers on the
other hand shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact relates to information supplied by the
Companies or by the Managers and the parties' relative intent, knowledge, access
to information and opportunity to correct or prevent such statement or omission.
The Companies and the Managers agree that it would not be just and
equitable if contribution pursuant to this Section 7 were determined by pro rata
allocation (even if the Managers were treated as one entity for such purpose) or
by any other method of allocation which does not take account of the equitable
considerations referred to above in this Section 7. The aggregate amount of
losses, liabilities, claims, damages and expenses incurred by an indemnified
party and referred to above in this Section 7 shall be deemed to include any
legal or other expenses reasonably incurred by such indemnified party in
investigating, preparing or defending against any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, no U.S. Underwriter shall
be required to contribute any amount in excess of the amount by which the total
price at which the Units underwritten by it and distributed to the public were
offered to the public exceeds the amount of any damages which such Manager has
otherwise been required to pay by reason of any such untrue or alleged untrue
statement or omission or alleged omission.
No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the 1933 Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.
For purposes of this Section 7, each person, if any, who controls a Manager
within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act
shall have the same rights to contribution as such Manager, and each director of
each of the Companies, each officer of each of the Companies who signed the
Registration Statement, and each person, if any, who controls the Companies
within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act
shall have the same rights to contribution as the Companies. The Managers'
respective obligations to contribute pursuant to this Section are several in
proportion to the number of Initial International Units set forth opposite their
respective names in Schedule A hereto and not joint.
29
<PAGE>
SECTION 8. REPRESENTATIONS, WARRANTIES AND AGREEMENTS TO SURVIVE
DELIVERY. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Companies or any Subsidiary
submitted pursuant hereto, shall remain operative and in full force and effect,
regardless of any investigation made by or on behalf of any Manager or
controlling person, or by or on behalf of the Companies, and shall survive
delivery of the Units to the Managers.
SECTION 9. TERMINATION OF AGREEMENT.
(a) TERMINATION; GENERAL. The Lead Manager may terminate this Agreement,
by notice to the Companies, at any time at or prior to Closing Time (i) if there
has been, since the time of execution of this Agreement or since the respective
dates as of which information is given in the International Prospectus, any Dura
Material Adverse Effect or SDC II Material Adverse Effect, whether or not
arising in the ordinary course of business, or (ii) if there has occurred any
material adverse change in the financial markets in the United States or the
international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a
prospective change in national or international political, financial or economic
conditions, in each case the effect of which is such as to make it, in the
judgment of the Lead Manager, impracticable to market the Units or to enforce
contracts for the sale of the Units, or (iii) if trading in any securities of
the Companies has been suspended or materially limited by the Commission or the
Nasdaq National Market, or if trading generally on the American Stock Exchange
or the New York Stock Exchange or in the Nasdaq National Market has been
suspended or materially limited, or minimum or maximum prices for trading have
been fixed, or maximum ranges for prices have been required, by any of said
exchanges or by such system or by order of the Commission, the NASD or any other
governmental authority, or (iv) if a banking moratorium has been declared by
either Federal or New York or California authorities.
(b) LIABILITIES. If this Agreement is terminated pursuant to this Section
9, such termination shall be without liability of any party to any other party
except as provided in Section 4 hereof, and provided further that Sections 1, 6,
7 and 8 shall survive such termination and remain in full force and effect.
SECTION 10. DEFAULT BY ONE OR MORE OF THE MANAGERS. If one or more of the
Managers shall fail at Closing Time or a Date of Delivery to purchase the Units
which it or they are obligated to purchase under this Agreement (the "Defaulted
Units"), the Lead Manager shall have the right, within 24 hours thereafter, to
make arrangements for one or more of the non-defaulting Managers, or any other
underwriters, to purchase all, but not less than all, of the Defaulted Units in
such amounts as may be agreed upon and upon the terms herein set forth; if,
however, the Lead Manager shall not have completed such arrangements within such
24-hour period, then:
30
<PAGE>
(a) if the number of Defaulted Units does not exceed 10% of the
number of Units to be purchased on such date, the non-defaulting Managers
shall be obligated, each severally and not jointly, to purchase the full
amount thereof in the proportions that their respective underwriting
obligations hereunder bear to the underwriting obligations of all
non-defaulting Managers, or
(b) if the number of Defaulted Units exceeds 10% of the number of
Units to be purchased on such date, this Agreement or, with respect to any
Date of Delivery which occurs after Closing Time, the obligation of the
Managers to purchase and of the Companies to sell the International Option
Units to be purchased and sold on such Date of Delivery shall terminate
without liability on the part of any non-defaulting Manager.
No action taken pursuant to this Section 10 shall relieve any defaulting
Manager from liability in respect of its default.
In the event of any such default which does not result in a termination of
this Agreement or, in the case of a Date of Delivery which is after Closing
Time, which does not result in a termination of the obligation of the Managers
to purchase and the Companies to sell the relevant International Option Units,
as the case may be, either the Managers or the Companies shall have the right to
postpone Closing Time or the relevant Date of Delivery, as the case may be, for
a period not exceeding seven days in order to effect any required changes in the
Registration Statement or Prospectuses or in any other documents or
arrangements. As used herein, the term "Manager" includes any person
substituted for a Manager under this Section.
SECTION 11. DEFAULT BY THE COMPANIES. If the Companies shall fail at
Closing Time or at the Date of Delivery to sell the number of Units that they
are obligated to sell hereunder, then this Agreement shall terminate without any
liability on the part of any nondefaulting party; PROVIDED, HOWEVER, that the
provisions of Sections 1, 4, 6, 7 and 8 shall remain in full force and effect.
No action taken pursuant to this Section 11 shall relieve the Companies from
liability, if any, in respect of such default.
SECTION 12. NOTICES. All notices and other communications hereunder shall
be in writing and shall be deemed to have been duly given if mailed or
transmitted by any standard form of telecommunication. Notices to the Managers
shall be directed to the Lead Manager at Ropemaker Place, 25 Ropemaker Street,
London, EC2Y 92Y, England attention of Debs Yates; notices to either of the
Companies shall be directed to them at:
Dura Pharmaceuticals, Inc.
7475 Lusk Boulevard
San Diego, California 92121- 4204
Attn: Mitchell R. Woodbury
31
<PAGE>
with a copy to:
Brobeck, Phleger & Harrison LLP
550 West "C" Street, Suite 1300
San Diego, California 92101
Attn: Faye H. Russell
SECTION 13. PARTIES. This Agreement shall inure to the benefit of and be
binding upon the Managers and the Companies and their respective successors.
Nothing expressed or mentioned in this Agreement is intended or shall be
construed to give any person, firm or corporation, other than the Managers and
the Companies and their respective successors and the controlling persons and
officers and directors referred to in Sections 6 and 7 and their heirs and legal
representatives, any legal or equitable right, remedy or claim under or in
respect of this Agreement or any provision herein contained. This Agreement and
all conditions and provisions hereof are intended to be for the sole and
exclusive benefit of the Managers and the Companies and their respective
successors, and said controlling persons and officers and directors and their
heirs and legal representatives, and for the benefit of no other person, firm or
corporation. No purchaser of Units from any Manager shall be deemed to be a
successor by reason merely of such purchase.
SECTION 14. GOVERNING LAW AND TIME. THIS AGREEMENT SHALL BE GOVERNED BY
AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. EXCEPT AS
OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 15. EFFECT OF HEADINGS. The Article and Section headings herein
and the Table of Contents are for convenience only and shall not affect the
construction hereof.
32
<PAGE>
If the foregoing is in accordance with your understanding of our agreement,
please sign and return to each of Dura and SDC II a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding
agreement among the Managers, Dura and SDC II in accordance with its terms.
Very truly yours,
DURA PHARMACEUTICALS, INC.
By: /s/ Cam L. Garner
--------------------------------
Title: Chairman, President & CEO
SPIROS DEVELOPMENT CORPORATION II, INC.
By: /s/ David S. Kabakoff
--------------------------------
Title: Chairman, President & CEO
CONFIRMED AND ACCEPTED,
as of the date first above written:
MERRILL LYNCH INTERNATIONAL
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
By: MERRILL LYNCH INTERNATIONAL
By: /s/ James G. Jackson, Vice President
------------------------------------
Authorized Signatory
33
<PAGE>
SCHEDULE A
Number
of Initial
International
Name of Manager Units
--------------- -----
Merrill Lynch International. . . . . . . . . . . . . . . . . . . . . 550,000
Donaldson, Lufkin & Jenrette Securities Corporation. . . . . . . . . 550,000
---------
Total. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,100,000
---------
---------
Sch A - 1
<PAGE>
SCHEDULE B
SPIROS DEVELOPMENT CORPORATION II, INC.
DURA PHARMACEUTICALS, INC.
1,100,000 Units
Each Unit Consisting of
One Share of Callable Common Stock of Spiros Development Corporation II, Inc.
and One Warrant to Purchase
One-Fourth of One Share of Common Stock of Dura Pharmaceuticals, Inc.
1. The initial public offering price per International Unit, determined
as provided in Section 2, shall be $16.00.
2. The purchase price per International Unit to be paid by the Managers
shall be $14.88, being an amount equal to the initial public offering price set
forth above less $1.12 per International Unit.
3. The exercise price of the Warrants shall be $54.84 per share of Dura
Common Stock.
Sch B - 1
<PAGE>
SCHEDULE C
James C. Blair
Julia Brown
Herbert J. Conrad
Joseph C. Cook, Jr.
Chester Damecki
Cam L. Garner
David F. Hale
Malcolm Hill
David S. Kabakoff
Robert W. Keith
Erle T. Mast
James W. Newman
Charles W. Prettyman
Gordon V. Ramseier
Robert K. Schultz
Charles G. Smith
Walter F. Spath
David Sudolsky
Clyde Witham
Mitchell R. Woodbury
Sch C - 1
<PAGE>
EXHIBIT A
FORM OF OPINION OF COUNSEL FOR DURA, SDC II and SDC
TO BE DELIVERED PURSUANT TO
SECTION 5(b)
[For purposes of this opinion, to be delivered at the Closing Time, the
term "Subsidiaries" includes SDC.]
(i) Each of Dura and SDC II has been duly incorporated and is validly
existing as a corporation in good standing under the laws of the State of
Delaware.
(ii) Each of Dura and SDC II has full corporate power and authority to
own or lease its properties and conduct its business as described in the
Registration Statement and Prospectuses and, to enter into and perform its
obligations under the U.S. Purchase Agreement and the International Purchase
Agreement.
(iii) Each of Dura and SDC II is duly qualified as a foreign
corporation to transact business and is in good standing in each jurisdiction in
which such qualification is required, whether by reason of the ownership or
leasing of property or the conduct of business, except where the failure so to
qualify or to be in good standing would not result in a Dura Material Adverse
Effect or a SDC II Material Adverse Effect, as the case may be (which opinion as
to Dura may be given by the General Counsel of Dura).
(iv) The authorized capital stock of Dura conforms as to legal matters
in all material respects to the description thereof contained in the
Registration Statement and Prospectuses. The authorized and outstanding shares
of capital stock of Dura are as set forth under the caption "Capitalization" and
have been duly and validly authorized and issued, are fully paid and
non-assessable, and are not subject to any preemptive rights (the opinion called
for by the last sentence of this paragraph (iv) may be given by the General
Counsel of Dura).
(v) The authorized, capital stock of SDC II conforms as to legal
matters in all material respects to the descriptions thereof contained in the
Registration Statement and Prospectuses under the caption "Spiros Corp. II
Capital Stock".
(vi) The outstanding shares of Special Common Stock of SDC II are as
set forth under the caption "Capitalization" have been duly and validly
authorized and issued, are, to our knowledge, fully paid and nonassessable, and
are not subject to any preemptive rights.
(vii) The Warrant Agreement has been duly authorized, executed and
delivered by Dura and constitutes a legal, valid and binding obligation of Dura,
enforceable against Dura in accordance to its terms.
A-1
<PAGE>
(viii) The issuance of the Warrants has been duly authorized by Dura
and, when duly executed, issued and delivered by Dura and countersigned by the
Warrant Agent and when payment of the purchase price for the Units has been
made, the Warrants will constitute valid and binding obligations of Dura
entitled to the benefits of the Warrant Agreement. The Warrants are not subject
to the preemptive rights of any stockholder of Dura. The Warrants conform as to
legal matters in all material respects to the description thereof contained in
the Registration Statement and the Prospectuses under the caption "Description
of the Warrants."
(ix) The shares of Dura Common Stock issuable upon exercise of the
Warrants have been duly and validly reserved for the issuance and, when and if
issued upon such exercise and upon payment of the exercise price, in accordance
with the terms of the Warrant Agreement, will be duly and validly authorized and
issued, will be fully paid and nonassessable, and will not be subject to any
preemptive or similar rights of any stockholder of Dura.
(x) The issuance of the SDC II Common Stock has been duly authorized
and, when issued and paid for as part of the Units as contemplated by the U.S.
Purchase Agreement and the International Purchase Agreement, will be validly
issued, fully paid and non-assessable. Such SDC II Common Stock is not subject
to the preemptive or similar rights of any stockholder of SDC II.
(xi) To our knowledge, the Subsidiaries, are Dura's sole subsidiaries.
Each Subsidiary has been duly incorporated and is validly existing as a
corporation in good standing under the laws of the jurisdiction of its
incorporation, has corporate power and authority to own or lease its properties
and to conduct its business as described in the Registration Statement and
Prospectuses and is duly qualified as a foreign corporation to transact business
and is in good standing in each jurisdiction in which such qualification is
required, whether by reason of the ownership or leasing of property or the
conduct of business, except where the failure so to qualify or to be in good
standing would not result in a Dura Material Adverse Effect; all of the issued
and outstanding capital stock of each Subsidiary and SDC has been duly and
validly authorized and issued, are fully paid and non-assessable and, to the
best of our knowledge and information is owned by Dura free and clear of any
security interest, mortgage, pledge, lien, encumbrance, claim or equity; and
none of the outstanding shares of capital stock of any Subsidiary was issued in
violation of the preemptive rights of any securityholder of such Subsidiary (the
opinion called for by the last sentence of this paragraph (xi) may be given by
the General Counsel of Dura).
(xii) Each of the U.S. Purchase Agreement and the International
Purchase Agreement has been duly authorized, executed and delivered by Dura and
SDC II.
(xiii) The Registration Statement, including any Rule 462(b)
Registration Statement, has become effective under the Act. Any required filing
of the Prospectuses pursuant to Rule 424(b) has been made in the manner and
within the time period required by Rule 424(b). To our knowledge, no stop order
proceedings suspending the effectiveness of the Registration Statement
A-2
<PAGE>
or any Rule 462(b) Registration Statement have been instituted or threatened or
are pending under the Act.
(xiv) All descriptions in the Prospectuses of agreements and other
instruments to which Dura, SDC II or the Subsidiaries are a party are accurate
in all material respects. We know of no agreements required to be filed or
described in the Prospectuses or the Registration Statements which are not so
filed or described. To our knowledge, no breach or default exists under any
agreement or instrument to which Dura, SDC II or any Subsidiary is a party and
which is filed as an Exhibit to the Registration Statement or incorporated by
reference therein (the opinion called for by the last two sentences of this
paragraph (xiv) may be given by the General Counsel of Dura and SDC II).
(xv) The form of certificate used to evidence the Units complies in
all material respects with all applicable statutory requirements, and the
requirements of the Nasdaq National Market.
(xvi) To our knowledge, there is no legal or governmental proceeding
pending or threatened to which Dura, any Subsidiary or SDC II is a party or to
which any of the properties of Dura, any Subsidiary or SDC II is subject that is
required to be described in the Registration Statement or the Prospectuses and
is not so described, or of any statute or regulation, contract or other document
that is required to be described in the Registration Statement or the
Prospectuses or to be filed as an exhibit to the Registration Statement that is
not described or filed as required.
(xvii) The statements in the Registration Statement under Item 14, to
the extent that such statements constitute matters of law, summaries of
documents contained therein or summaries of legal matters have been prepared by
or reviewed by us and are correct in all material respects.
(xviii) The September 30, 1997 offer and sale of 1,000 shares of SDC II
Common Stock with an aggregate value of $1,000 by SDC II to Dura was exempt from
the registration requirements of Section 5 of the 1933 Act by virtue of Section
4(2) and/or Regulation D promulgated thereunder.
(xix) None of Dura, any Subsidiary or SDC II is in violation of its
charter or by-laws and no default by Dura or any subsidiary exists in the due
performance or observance of any material obligation, agreement, covenant or
condition contained in any contract, indenture, mortgage, loan agreement, note,
lease or other agreement or instrument that is described or referred to in the
Registration Statement or the Prospectuses or filed or incorporated by reference
as an exhibit to the Registration Statement (which opinion as to Dura may be
given by the General Counsel of Dura).
A-3
<PAGE>
(xx) No filing with, or authorization, approval, consent, license,
order, registration, qualification or decree of, any court or governmental
authority or agency, domestic or foreign, (other than under the Act and the 1933
Act Regulations, which have been obtained, or as may be required under the
securities or blue sky laws of the various states or any foreign jurisdiction,
as to which no opinion is requested or given) is necessary or required in
connection with the due authorization, execution and delivery of the Purchase
Agreements or the offering, issuance, sale or delivery of the Units, the SDC II
Common Stock, the Warrants, or the Dura Common Stock issuable upon exercise of
the Warrants.
(xxi) The execution, delivery by Dura of, and the performance by Dura
of its obligations under the U.S. Purchase Agreement or the International
Purchase Agreement and the Warrant Agreement and the issuance and sale of the
Units contemplated thereby will not contravene any provision of applicable law
or the certificate of incorporation or bylaws of Dura or any Subsidiaries, or,
to our knowledge, any judgment, order or decree of any governmental body, agency
or court having jurisdiction over Dura or any of its property or any
Subsidiaries or any of their property, or, to our knowledge, constitute a breach
or default or a Dura Repayment Event (as defined in section 1(a)(xi) of the U.S.
Purchase Agreement) under any agreement or other instrument binding upon Dura or
any of the Subsidiaries, to which Dura or any of the Subsidiaries is a party and
filed as an exhibit to the Registration Statement or an Incorporated Document.
(xxii) The execution, delivery by SDC II of, and the performance by SDC
II of its obligations under the U.S. Purchase Agreement and the International
Purchase Agreement and the issuance and sale of the Units contemplated thereby
will not contravene any provision of applicable law or the certificate of
incorporation or bylaws of SDC II, or, to our knowledge, any judgment, order or
decree of any governmental body, agency or court having jurisdiction over SDC II
or any of its property, or, to our knowledge, constitute a breach or default or
a SDC II Repayment Event (as defined in section 1(a)(xii) of the U.S. Purchase
Agreement) under any agreement or other instrument binding upon SDC II, to which
SDC II is a party and filed as an exhibit to the Registration Statement or an
Incorporated Document.
(xxiii) Each of the Major Agreements has been duly authorized, executed
and delivered by Dura, SDC, DDSI and SDC II as applicable.
(xxiv) No holders of securities of Dura have rights against Dura which
have not been waived to the registration of shares of Dura Common Stock or other
securities, because of the filing of the Registration Statement by Dura or the
offering contemplated thereby (which opinion may be given by the General Counsel
of Dura).
(xxv) The Units have been duly authorized for quotation on the Nasdaq
National Market, upon notice of official issuance.
A-4
<PAGE>
(xxvi) The statements in the Registration Statement and Prospectuses
under the caption "United States Federal Income Tax Consequences" and "United
States Taxation of Non-U.S. Persons" to the extent they constitute matters of
law or legal conclusions with respect thereto, have been prepared or reviewed by
us and are correct in all material respects.
(xxvii) Neither Dura nor SDC II is an "investment company" or an entity
"controlled" by an "investment company", as such terms are defined in the 1940
Act.
In addition to the foregoing, (i) we believe that each of the
Incorporated Documents (except for financial statements and schedules and other
financial data included therein or omitted therefrom, as to which no opinion is
requested or given), when they became effective or were filed with the
Commission, as the case may be, complied as to form when filed with the
Commission in all material respects with the requirements of the Act and the
1934 Act, as applicable, and the rules and regulations of the Commission
thereunder; (ii) we believe that the Registration Statement, the Prospectuses
and each amendment or supplement to the Registration Statement and Prospectuses
(except for financial statements and schedules and other financial data included
or incorporated by reference therein or omitted therefrom, as to which no
opinion is requested or given), as of their respective effective or issue dates,
complied as to form in all material respects with the requirements of the Act
and the applicable rules and regulations of the Commission thereunder; (iii) we
confirm that nothing has come to our attention that has caused us to conclude
that (except for financial statements and schedules and other financial data
included or incorporated by reference therein or omitted therefrom, as to which
we need make no statement) the Registration Statement or any amendment thereto,
including the Rule 430A Information and Rule 434 Information (if applicable), at
the time such Registration Statement or any such amendment became effective,
contained an untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein,
in the lights of the circumstances under which they were made, not misleading or
that (except for financial statements and schedules and other financial data
included or incorporated by reference therein or omitted therefrom, as to which
we need make no statement) the Prospectuses, on the date hereof, include an
untrue statement of a material fact or omits to state a material fact necessary
in order to make the statements therein, in light of the circumstances under
which they were made not misleading.
In rendering such opinion, such counsel may rely (A) upon the opinions
of Lyon & Lyon and Kleinfeld, Kaplan & Becker and Mitchell R. Woodbury, Esq.
(which opinion may rely, to the extent appropriate, on the opinions of Conyers
Dill & Pearman, Bermuda counsel for Dura (Bermuda) Trading Company Ltd., and
Chancery Chambers, Barbados counsel for Dura (Barbados) Holding Company Ltd. and
Dura (Barbados) Ltd.) with respect to the matters opined upon by each, and (B),
as to matters of fact (but not as to legal conclusions), to the extent they deem
proper, on certificates of responsible officers of Dura or SDC II and public
officials. Such opinion shall be subject to standard limitations, exclusions,
qualifications and assumptions. Such opinion shall not state that it is to be
governed or qualified by, or that it is otherwise subject to, any treatise,
written policy or other document relating to legal opinions, including, without
limitation, the Legal Opinion Accord of the ABA Section of Business Law (1991).
A-5
<PAGE>
EXHIBIT B
FORM OF OPINION OF PATENT COUNSEL
FOR DURA AND SDC II DELIVERED PURSUANT TO SECTION 5(C)
(i) Dura owns U.S. patents and U.S. Foreign patent applications which
are directed to Spiros and to certain uses of the Spiros product necessary
to protect the business of Dura and Spiros Corp. II as described in the
Prospectuses. With regard to the business presently and as proposed to be
conducted by Dura and Spiros Corp. II relating to the Spiros product as
described in the Registration Statement and the Prospectuses, and, except
as described therein, we have not received any notice of infringement of or
conflict with, and does not otherwise know of any basis for notice of any
such infringement of or conflict with, asserted rights of others with
respect to any patents, trademarks, service marks, trade names, copyrights,
technology or know-how relating to the Spiros product.
(ii) To the extent that the statements relating to the Spiros product
contained in the Registration Statement and Prospectuses under the
subheadings "Risk Factors--Business Risks Related to Spiros Corp. II and
Dura--Uncertainty Regarding Patents and Proprietary Technology;
Unpredictability of Patent Protection - Spiros Corp. II," "Risk Factors -
Business Risks Related to Spiros Corp. II and Dura -- Uncertainty Regarding
Patents and Proprietary Technology; Unpredicability of Patent Protection -
Dura," and the first paragraph of "Business of Spiros Corp. II -- Patents"
refer to opinions of counsel or matters of law, patents or patent
applications or purport to summarize the status of litigation or the
provisions of statutes, regulations, contracts, agreements or other
documents, such statements (A) have been prepared or reviewed by us and
accurately reflect the status of any such patent applications, litigation,
the provisions purported to be summarized and any of our opinions and (B)
do not contain any untrue statements of a material fact or omit to state
any material fact required to be stated therein or necessary to make the
statements therein not misleading.
B-1
<PAGE>
EXHIBIT C
FORM OF OPINION OF REGULATORY COUNSEL
FOR DURA AND SDC II
TO BE DELIVERED PURSUANT
TO SECTION 5(d)
(i) The descriptions in the Registration Statement of the
statutes, regulations and legal or governmental proceedings or procedures
relating to the FDA and the approval process relating to the products of
Dura and SDC II are accurate in all material respects and are a fair
summary of those statutes, regulations, proceedings or procedures.
(ii) Nothing has come to our attention that leads us to believe
that the descriptions of federal laws, regulations or rules relating to the
manufacture or sale of Dura's products and the approval process relating
thereto contained in the Registration Statement and the Prospectuses,
including, without limitation, the portions of the Registration Statement
and Prospectuses entitled "Risk Factors - Business Risks Related to Spiros
Corp, II and Dura - Government Regulation; No Assurance of FDA Approval,"
and "Business of Dura - Government Regulation," contain an untrue statement
of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statement therein not misleading.
(iii) We have no reason to believe that Dura's current business is
not being conducted in material compliance with currently applicable
requirements under the Federal Food, Drug and Cosmetic Act or that the FDA
is currently considering taking action that would result in withdrawal from
marketing of any of Dura's currently marketed products.
C-1
<PAGE>
EXHIBIT D
October , 1997
MERRILL LYNCH & CO.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
DONALDSON, LUFKIN & JENRETTE SECURITIES CORPORATION
as Representatives of the several
Underwriters to be named in the
within mentioned Purchase Agreement
c/o Merrill Lynch & Co.
Merrill Lynch, Pierce, Fenner & Smith
Incorporated
North Tower
World Financial Center
New York, New York 10281-1209
Re: Proposed Public Offering by Dura Pharmaceuticals, Inc. and Spiros
Development Corporation II
Ladies and Gentlemen:
The undersigned, a stockholder and/or officer and/or director of Dura
Pharmaceuticals, Inc. ("Dura") understands that Merrill Lynch & Co. ("Merrill
Lynch") and Donaldson, Lufkin & Jenrette ("DLJ") propose to enter into a
Purchase Agreement (the "Purchase Agreement") with Dura and Spiros Development
Corporation II ("SDC II") that will provide for the public offering of units
comprised of the common stock of SDC II and warrants to purchase Dura's common
stock (the "Securities"). In recognition of the benefit that such an offering
will confer upon the undersigned as a stockholder and/or officer and/or director
of Dura, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the undersigned agrees with each
underwriter to be named in the Purchase Agreement that, during a period of
ninety (90) days from the date of the Purchase Agreement, the undersigned will
not, without the prior written consent of Merrill Lynch, directly or indirectly,
(i) sell, offer to sell, pledge, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or
warrant for the sale of, or otherwise dispose of or transfer any shares of
Dura's common stock (the "Dura Common Stock"), or any securities convertible
into or exchangeable or exercisable for Dura Common Stock, whether now owned or
hereafter acquired by the undersigned, or with respect to which the undersigned
has or hereafter acquires the power of disposition, or file, participate in, or
request the filing of any registration statement under the Securities Act of
1933, as amended, with respect to any of the foregoing or (ii) enter into any
swap or any other agreement or any transaction that transfers, in whole or in
part,
D-1
<PAGE>
directly or indirectly, the economic consequence of ownership of Dura Common
Stock, whether any such swap or transaction is to be settled by delivery of Dura
Common Stock or other securities, in cash or otherwise.
Very truly yours,
Signature:
------------------------
Print Name:
-----------------------
D-2
